Search Result
Results for "
norepinephrine
" in MedChemExpress (MCE) Product Catalog:
64
Isotope-Labeled Compounds
| Cat. No. |
상품명 |
Target |
연구분야 |
Chemical Structure |
-
- HY-13715
-
-
-
- HY-13715A
-
-
-
- HY-122272
-
|
BRL29060
|
Serotonin Transporter
Adrenergic Receptor
P2X Receptor
Apoptosis
|
Neurological Disease
Cancer
|
|
Paroxetine is an oral inhibitor that falls under the category of selective serotonin reuptake inhibitors (SSRIs). Paroxetine is also a very weak norepinephrine (NE) reuptake inhibitor, capable of inducing cell apoptosis and having anti-tumor activity. Paroxetine has antidepressant, anti-anxiety, and pain-relieving effects, and it can help improve conditions like obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual anxiety, and chronic headaches .
|
-
-
- HY-B0193A
-
|
|
Adrenergic Receptor
Autophagy
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Prazosin hydrochloride is a well-tolerated, CNS-active α1-adrenergic receptor antagonist for the research of high blood pressure and alcohol use disorders . Prazosin hydrochloride potently inhibits Norepinephrine (NE)-stimulated 45Ca efflux with an IC50 of 0.15 nM .Prazosin hydrochloride inhibits organic cation transporters OCT-1 and OCT-3 with IC50s of 1.8, and 13 μM, respectively .
|
-
-
- HY-13715B
-
-
-
- HY-B0196
-
-
-
- HY-14472
-
|
NS-2330
|
Dopamine Transporter
Serotonin Transporter
|
Metabolic Disease
|
|
Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent . Tesofensine is a CNS acting anti-obesity agent .
|
-
-
- HY-N7142S
-
|
|
Adrenergic Receptor
|
Neurological Disease
Metabolic Disease
|
|
DL-Norepinephrine-d6 hydrochloride is the deuterium labeled DL-Norepinephrine hydrochloride. DL-Norepinephrine hydrochloride is an external racemic catecholamine neurotransmitter, which is an equal mixture of the left-handed (L-, with activity) and right-handed (D-, with very low or no activity) stereoisomers. DL-Norepinephrine hydrochloride after being labeled with tritium can be used as a tracer for the research on Parkinson's disease .
|
-
-
- HY-13715C
-
-
-
- HY-B0196A
-
|
Wy 45030 hydrochloride
|
Serotonin Transporter
|
Neurological Disease
Cancer
|
|
Venlafaxine hydrochloride (Wy 45030 hydrochloride) is an orally active, potent serotonin (5-HT)/norepinephrine (NE) reuptake dual inhibitor. Venlafaxine is an antidepressant .
|
-
-
- HY-100637
-
|
|
Drug Metabolite
Adrenergic Receptor
nAChR
|
Neurological Disease
|
|
Hydroxybupropion is the major active metabolite of Bupropion. Hydroxybupropion is metabolized by CYP2B6. Bupropion is an atypical antidepressant and smoking-cessation agent. Hydroxybupropion inhibits norepinephrine uptake with an IC50 value of 1.7 μM. Hydroxybupropion is also a nACh receptor antagonist .
|
-
-
- HY-113323
-
|
HMPG; MHPG; MOPEG
|
Endogenous Metabolite
|
Neurological Disease
|
|
3-Methoxy-4-hydroxyphenylglycol (HMPG) is a metabolite of norepinephrine degradation in the brain. 3-Methoxy-4-hydroxyphenylglycol is an indicators of central nervous system noradrenergic activity. 3-Methoxy-4-hydroxyphenylglycol can be used for research of depression, chronic schizophrenia, etc .
|
-
-
- HY-108256
-
|
|
5-HT Receptor
|
Neurological Disease
|
|
Melitracen hydrochloride is an orally active biphasic antidepressant and antianxiety agent. Melitracen hydrochloride can inhibit the uptake of Norepinephrine and 5-HT (serotonin) through the presynaptic membrane inducing the increase of monoamine transmitters in synaptic space .
|
-
-
- HY-12798B
-
|
AR-13324 hydrochloride
|
ROCK
|
Cardiovascular Disease
Neurological Disease
|
|
Netarsudil (AR-13324) hydrochloride is a competitive inhibitor of Rho-associated protein kinases (ROCK I and ROCK II) and a reversible inhibitor of the norepinephrine transporter (NET). Netarsudil hydrochloride reduces intraocular pressure by inhibiting ROCK, causing relaxation of trabecular meshwork cells and dilation of episcleral veins, thereby increasing the ease of aqueous humor outflow, while inhibiting NET to reduce aqueous humor production. Netarsudil hydrochloride is mainly used in the study of ocular hypertension and primary open-angle glaucoma .
|
-
-
- HY-N7142
-
|
|
Adrenergic Receptor
|
Neurological Disease
|
|
DL-Norepinephrine hydrochloride is an external racemic catecholamine neurotransmitter, which is an equal mixture of the left-handed (L-, with activity) and right-handed (D-, with very low or no activity) stereoisomers. DL-Norepinephrine hydrochloride after being labeled with tritium can be used as a tracer for the research on Parkinson's disease .
|
-
-
- HY-135026
-
|
|
Adrenergic Receptor
|
Neurological Disease
|
|
DL-Norepinephrine tartrate is an external racemic catecholamine neurotransmitter, which is an equal mixture of the left-handed (L-, with activity) and right-handed (D-, with very low or no activity) stereoisomers. DL-Norepinephrine tartrate after being labeled with tritium can be used as a tracer for the research on Parkinson's disease .
|
-
-
- HY-B0952
-
|
Tuaminoheptane
|
Adrenergic Receptor
|
Neurological Disease
|
|
2-Aminoheptane (Tuaminoheptane) is a norepinephrine transporter inhibitor. 2-Aminoheptane binds to norepinephrine transporter via ionic and hydrophobic interactions to block norepinephrine uptake. 2-Aminoheptane deactivates ω-TAmla enzyme, reduces recombinant whole cell stability, and acts as an amino group donor substrate for ω-TA and ω-TAmla enzymes. 2-Aminoheptane can be used in research on depression and Alzheimer's disease .
|
-
-
- HY-B1435
-
|
Thymoxamine hydrochloride
|
Adrenergic Receptor
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
|
|
Moxisylyte (Thymoxamine) hydrochloride is a selective α1A-adrenergic receptor antagonist. Moxisylyte hydrochloride competitively antagonizes the activation mediated by norepinephrine. Moxisylyte hydrochloride relaxes penile cavernous smooth muscle and aids erectile function. Moxisylyte hydrochloride is applicable to research related to erectile dysfunction and multiple system atrophy .
|
-
-
- HY-19907
-
|
BMS-820836
|
Dopamine Transporter
Monoamine Transporter
Serotonin Transporter
|
Neurological Disease
|
|
Liafensine (BMS-820836) is an orally active, blood-brain barrier-permeable monoamine reuptake inhibitor, with an IC50 of 5.67 nM against DAT, 1.08 nM against SERT, and 7.99 nM against NET. Liafensine binds to DAT to block dopamine reuptake. Liafensine binds to SERT to block serotonin reuptake. Liafensine binds to NET to block norepinephrine reuptake. Liafensine can be used in studies related to depression .
|
-
-
- HY-B1237
-
|
|
Calcium Channel
Fungal
|
Cardiovascular Disease
Infection
|
|
Suloctidil is an orally active calcium channel blocker and antifungal agent. Suloctidil antagonizes vasoconstriction induced by norepinephrine, angiotensin and serotonin. Suloctidil inhibits platelet function and exhibits neuroprotective effects. Suloctidil exerts inhibitory effects on Candida albicans biofilm and virulence. Suloctidil can be used in research on vasospasm relief, antithrombosis and superficial candidiasis .
|
-
-
- HY-113474
-
-
-
- HY-13715R
-
-
-
- HY-W008794
-
|
(±)-Normetanephrine hydrochloride; DL-Normetanephrine hydrochloride; (Rac)-Normetanephrine hydrochloride
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Normetanephrine ((±)-Normetanephrine) hydrochloride is the O-methylated metabolite of norepinephrine (NE) .
|
-
-
- HY-N7142S3
-
|
|
Isotope-Labeled Compounds
Adrenergic Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
DL-Norepinephrine-d6 is the deuterium labeled DL-Norepinephrine. DL-Norepinephrine is an external racemic catecholamine neurotransmitter, which is an equal mixture of the left-handed (L-, with activity) and right-handed (D-, with very low or no activity) stereoisomers. DL-Norepinephrine after being labeled with tritium can be used as a tracer for the research on Parkinson's disease .
|
-
-
- HY-B0196R
-
|
Wy 45030 (Standard)
|
Serotonin Transporter
Reference Standards
|
Neurological Disease
Cancer
|
|
Venlafaxine (Standard) is the analytical standard of Venlafaxine. This product is intended for research and analytical applications. Venlafaxine (Wy 45030) is an orally active, potent serotonin (5-HT)/norepinephrine (NE) reuptake dual inhibitor. Venlafaxine is an antidepressant .
|
-
-
- HY-15413A
-
|
LY 2216684 hydrochloride
|
Serotonin Transporter
|
Neurological Disease
|
|
Edivoxetine (LY 2216684) hydrochloride is a potent and selective norepinephrine reuptake inhibitor. Edivoxetine hydrochloride can be used for the study of major depressive disorder (MDD) and attention-deficit/hyperactivity disorder (ADHD) .
|
-
-
- HY-110019
-
|
Lu 19-005
|
Serotonin Transporter
Dopamine Transporter
|
Neurological Disease
|
|
Indatraline hydrochloride (Lu 19-005) is a non-selective monoamine transporter inhibitor that blocks the reuptake of neurotransmitters (dopamine, serotonin, and norepinephrine). Indatraline hydrochloride can be used for the research of antidepressive. Indatraline hydrochloride induces autophagy while simultaneously inhibiting cell proliferation. Indatraline hydrochloride may also serve to direct the development of new agents for autophagy-related diseases such as atherosclerosis or restenosis .
|
-
-
- HY-B1272A
-
-
-
- HY-P4641
-
|
Trp-Phe
|
Angiotensin-converting Enzyme (ACE)
Endothelin Receptor
|
Cardiovascular Disease
|
|
H-Trp-Phe-OH (Trp-Phe) is an ACE inhibitor and endothelial function regulator, with an ACE IC50 of 0.318 mg/mL. H-Trp-Phe-OH increases nitric oxide concentration, reduces endothelin-1 (ET-1) levels, and reverses norepinephrine-mediated endothelial cell dysfunction. H-Trp-Phe-OH exhibits antihypertensive activity. H-Trp-Phe-OH can be used in studies related to hypertension and atherosclerosis .
|
-
-
- HY-N7506
-
|
Delta3,2-Hydroxylbakuchiol
|
Monoamine Transporter
Dopamine Transporter
|
Neurological Disease
|
|
13-Hydroxyisobakuchiol (Delta3,2-Hydroxylbakuchiol), an analog of Bakuchiol (HY-N0235) that can be isolated from Psoralea corylifolia (L.), is a potent selective monoamine transporter inhibitor. 13-Hydroxyisobakuchiol is more selective for the dopamine transporter (DAT) (IC50 = 0.58 μM) and norepinephrine transporter (NET) (IC50 = 0.69 μM) than for the serotonin transporter (SERT) (IC50 = 312.02 μM). 13-Hydroxyisobakuchiol increases the activity of intact mice and improves the decreased activity of reserpinized mice in vivo. 13-Hydroxyisobakuchiol can be used for the research of disorders such as Parkinson's disease and depression .
|
-
-
- HY-B1105A
-
-
-
- HY-B1202
-
|
AY-22284
|
Aldose Reductase
|
Metabolic Disease
|
|
Alrestatin (AY-22284) is an aldose reductase inhibitor. Alrestatin reduces fructose levels in the uterine fluid of mice. Alrestatin interferes with sperm capacitation and impairs fertilization function in mice. Alrestatin decreases basal and tyramine-induced norepinephrine release in rat pancreatic specimens in vitro. Alrestatin enhances glucose- and arginine-stimulated insulin secretion in vivo. Alrestatin can be used in studies related to diabetes and reproductive diseases .
|
-
-
- HY-13715AR
-
-
-
- HY-116211
-
|
WIN-25978
|
Biochemical Assay Reagents
|
Neurological Disease
|
|
Amfonelic acid (WIN-25978) is a highly selective dopamine reuptake inhibitor. Amfonelic acid interferes with the in vitro neuronal uptake of norepinephrine in the iris of rats, but does not alter the concentrations of norepinephrine or dopamine in the whole mouse brain. Amfonelic acid can be used as a pharmacological tool to study the brain reward system, dopamine pathway and dopamine transporter .
|
-
-
- HY-18332A
-
-
-
- HY-12766
-
|
|
Dopamine Transporter
nAChR
|
Neurological Disease
|
|
Bupropion morpholinol (Hydroxy Bupropion) is a major metabolite of Bupropion. Bupropion morpholinol inhibits Dopamine, Norepinephrine transporters and the α4β2 nicotinic receptor in vitro. Bupropion morpholinol contributes to antidepressant and smoking cessation activities .
|
-
-
- HY-113323A
-
|
HMPG sulfate; MHPG sulfate; MOPEG sulfate
|
Endogenous Metabolite
|
Neurological Disease
|
|
3-Methoxy-4-hydroxyphenylglycol sulfate (HMPG sulfate) is a metabolite of norepinephrine degradation in the brain. 3-Methoxy-4-hydroxyphenylglycol sulfate is an indicators of central nervous system noradrenergic activity. 3-Methoxy-4-hydroxyphenylglycol sulfate can be used for research of depression, chronic schizophrenia, etc .
|
-
-
- HY-122272R
-
|
BRL29060 (Standard)
|
Serotonin Transporter
Adrenergic Receptor
P2X Receptor
Apoptosis
Reference Standards
|
Neurological Disease
Cancer
|
|
Paroxetine (Standard) is the analytical standard of Paroxetine. This product is intended for research and analytical applications. Paroxetine is an oral inhibitor that falls under the category of selective serotonin reuptake inhibitors (SSRIs). Paroxetine is also a very weak norepinephrine (NE) reuptake inhibitor, capable of inducing cell apoptosis and having anti-tumor activity. Paroxetine has antidepressant, anti-anxiety, and pain-relieving effects, and it can help improve conditions like obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual anxiety, and chronic headaches .
|
-
-
- HY-W685943
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Heptaminol is a fatty amine with pressor properties and a potential antihypotension agent. Heptaminol is also a competitive inhibitor of norepinephrine uptake and an inhibitor of nicotine-induced catecholamine release (IC50: 650 μM). Heptaminol does not inhibit norepinephrine release induced by 59 mM K + but rather inhibits high-affinity Na +-dependent norepinephrine uptake .
|
-
-
- HY-118796
-
|
4-HO-MET; 4-Hydroxy-N-methyl-N-ethyltryptamine
|
5-HT Receptor
Serotonin Transporter
|
Neurological Disease
|
|
4-Hydroxy MET (4-HO-MET; 4-Hydroxy-N-methyl-N-ethyltryptamine) is a synthetic tryptamine psychoactive substance. 4-Hydroxy MET is a partial 5-HT2A receptor agonist, a serotonin transporter inhibitor and weak norepinephrine transporter inhibitor. 4-Hydroxy MET affects emotional, motoric, and cognitive functions via serotonergic hallucinogenic activity .
|
-
-
- HY-131007
-
|
|
Adrenergic Receptor
|
Metabolic Disease
|
|
FFN270 hydrochloride, a fluorescent tracer of norepinephrine, is a fluorescent substrate of the norepinephrine and vesicular monoamine transporters. FFN270 hydrochloride exhibits two resolved absorption/excitation maxima depending on solvent pH (FFN270 ex: 320 nm or 365 nm, em: 475 nm) and can function as ratiometric fluorescent pH-sensors .
|
-
-
- HY-N3198A
-
|
(-)-Sophoramine
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Sophoramine ((-)-Sophoramine) is a prejunctional α2-adrenoceptor inhibitor that can be found in the seeds of Sophora alopecuroides. Sophoramine inhibits prejunctional α2-adrenoceptors to facilitate norepinephrine release from adrenergic nerves. Sophoramine shows cytotoxic activity against human cancer cells, positive inotropic activity, and activity in rodent arrhythmia models. Sophoramine can be used for the research of arrhythmias .
|
-
-
- HY-N7142S1
-
|
|
Adrenergic Receptor
|
Neurological Disease
|
|
DL-Norepinephrine-d3 hydrochloride is the deuterium labeled DL-Norepinephrine hydrochloride. DL-Norepinephrine hydrochloride is an external racemic catecholamine neurotransmitter, which is an equal mixture of the left-handed (L-, with activity) and right-handed (D-, with very low or no activity) stereoisomers. DL-Norepinephrine hydrochloride after being labeled with tritium can be used as a tracer for the research on Parkinson's disease.
|
-
-
- HY-13715S
-
-
-
- HY-13715BR
-
|
Levarterenol bitartrate monohydrate (Standard); L-Noradrenaline bitartrate monohydrate (Standard)
|
Reference Standards
Adrenergic Receptor
Autophagy
Endogenous Metabolite
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Norepinephrine (bitartrate monohydrate) (Standard) is the analytical standard of Norepinephrine (bitartrate monohydrate). This product is intended for research and analytical applications. Norepinephrine (Levarterenol; L-Noradrenaline) bitartrate monohydrate is a potent adrenergic receptor (AR) agonist. Norepinephrine activates α1, α2, β1 receptors .
|
-
-
- HY-14472R
-
|
NS-2330 (Standard)
|
Dopamine Transporter
Serotonin Transporter
Reference Standards
|
Metabolic Disease
|
|
Tesofensine (Standard) is the analytical standard of Tesofensine. This product is intended for research and analytical applications. Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent . Tesofensine is a CNS acting anti-obesity agent .
|
-
-
- HY-18332C
-
|
|
Serotonin Transporter
Dopamine Transporter
|
Neurological Disease
|
|
DOV-216,303 (Free Base) is a potent triple serotonin, norepinephrine, and dopamine reuptake inhibitor, with IC50 values of 14 nM, 20 nM and 78 nM for hSERT, hNET and hDAT, respectively. Has antidepressant-like effects and increases monoamine release in the prefrontal cortex of olfactory bulbectomized (OBX) rats .
|
-
-
- HY-16094
-
|
BW 467C60
|
Adrenergic Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Bethanidine sulfate (BW 467C60) is an orally active antihypertensive agent and adrenergic neuron blocker. Bethanidine sulfate exerts its antihypertensive effect by inhibiting the release of norepinephrine from sympathetic nerve terminals. Bethanidine sulfate exhibits anti-ventricular arrhythmic activity. Bethanidine sulfate can be used in research related to hypertension, ventricular tachycardia, and ventricular fibrillation .
|
-
-
- HY-18610A
-
|
Ro 8-4650
|
Dopamine Transporter
Adrenergic Receptor
5-HT Receptor
|
Neurological Disease
|
|
Diclofensine (Ro 8-46500) is an orally active neuronal monoamine uptake inhibitor. Diclofensine blocks the uptake of dopamine, noradrenaline, and serotonin by rat brain synaptosomes with IC50 values of 0.74, 2.3 and 3.7 nM, respectively. Diclofensine potentiates norepinephrine-induced hypertension and attenuates Tyramine (HY-W007606)-induced hypertension. Diclofensine produces psychostimulant and mood-elevating effects without causing sudden disappearance or withdrawal reactions. Diclofensine can be used in the research of moderate to severe depression .
|
-
-
- HY-U00096A
-
|
Toludesvenlafaxine; LY03005 free base; LPM570065 free base
|
Serotonin Transporter
|
Neurological Disease
|
|
Ansofaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) used for the research of depression .
|
-
- HY-G0005
-
|
Para-Naphthol duloxetine
|
Drug Metabolite
|
Neurological Disease
|
|
Para-Naphthol Duloxetine is a metabolite of Duloxetine, which is a serotonin-norepinephrine reuptake inhibitor (SNRI).
|
-
- HY-B0773
-
|
BRL29060 mesylate
|
Serotonin Transporter
Adrenergic Receptor
|
Neurological Disease
|
|
Paroxetine mesylate, a phenylpiperidine derivative, is a potent and selective serotonin reuptake inhibitor (SSRI). Paroxetine mesylate is a very weak inhibitor of norepinephrine (NE) uptake but it is still more potent at this site than the other SSRIs .
|
-
- HY-W423643
-
|
|
Drug Derivative
|
Neurological Disease
|
|
Benzedrone is a synthetic drug derivative. Benzedrone can increase the levels of neurotransmitters such as dopamine, serotonin and norepinephrine in the brain, thus producing a stimulant effect. Benzedrone can be used in the research of new psychoactive substances (NPS) .
|
-
- HY-107128
-
|
TD-9855 hydrochloride
|
Serotonin Transporter
|
Neurological Disease
|
|
Ampreloxetine (TD-9855) hydrochloride is an orally active and CNS-penetrant inhibitor of Norepinephrine transporter (NET) and Serotonin 5-HT uptake transporter (SERT), but not Dopamine transporter (DAT). Ampreloxetine hydrochloride binds norepinephrine transporters (NET) and serotonin transporters (SERT) with EC50 values of 11.7 ng/mL and 50.8 ng/mL, respectively, in plasma .
|
-
- HY-129040
-
|
MIBG; Iobenguane
|
Monoamine Transporter
|
Neurological Disease
Endocrinology
Cancer
|
|
m-Iodobenzylguanidine (Iobenguane) is a ligand with high affinity against norepinephrine transporter (NET). m-Iodobenzylguanidine is used as an imaging agent in the diagnostic imaging and radionuclide studies of neuroendocrine tumors, such as neuroblastoma, pheochromocytoma and carcinoid tumor .
|
-
- HY-178249
-
|
|
Adrenergic Receptor
Dopamine Receptor
|
Neurological Disease
|
|
(1R,2S)-Dihydrobupropion is a norepinephrine-dopamine reuptake inhibitor. (1R,2S)-Dihydrobupropion is one of the active metabolites of Bupropion (HY-B0403). (1R,2S)-Dihydrobupropion can be used for the researches of neurological disease and inflammation .
|
-
- HY-18332B
-
|
|
Dopamine Transporter
Adrenergic Receptor
5-HT Receptor
|
Neurological Disease
|
|
DOV-102,677 is an orally sctive triple monoamine neurotransmitter reuptake inhibitor that simultaneously inhibits the dopamine (DAT) (IC50 = 129 nM; Ki = 222 nM), norepinephrine (NET) (IC50 = 103 nM; Ki = 1030 nM), and serotonin (SERT) (IC50 = 133 nM; Ki = 740 nM) transporters. DOV-102,677 demonstrated significant antidepressant-like activity and sensory-motor gating regulatory effects in mouse experiments. DOV-102,677 can be used for research on depression .
|
-
- HY-148863
-
|
|
Calcium Channel
Monoamine Transporter
|
Inflammation/Immunology
|
|
Cavα2δ1&NET-IN-2 (Compound 45CS) is a dual inhibitor of the α2δ‑1 subunit of voltage-gated calcium channels (Cavα2δ-1) and the norepinephrine transporter (NET). Cavα2δ1&NET-IN-2 inhibits Cavα2δ-1 with a Ki of 454 nM. Cavα2δ1&NET-IN-2 inhibits NET with a Ki of 59 nM and IC50 of 7 nM. Cavα2δ1&NET-IN-2 can be used for research of pain .
|
-
- HY-101554
-
|
Guancidine
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Guancydine (Guancidine) is an orally active antihypertensive agent and vasodilator. Guancydine antagonizes the pressor effects of Angiotensin and Norepinephrine (HY-13715). Guancydine induces vasodilation in renal, mesenteric and cranial vascular beds, reduces peripheral resistance, increases cardiac output and lowers arterial blood pressure. Guancydine increases renal and forearm blood flow, reduces renal and forearm vascular resistance, alters cardiac systolic time, and reverses myocardial hypertrophy in hypertensive rats. Guancydine is applicable for research related to hypertension .
|
-
- HY-103218
-
|
|
Adrenergic Receptor
|
Neurological Disease
|
|
Talsupram (hydrochloride) is a selective norepinephrine inhibitor with high affinity for norepinephrine transporter (NET) and can be used in the study of neuropathic pain .
|
-
- HY-106504
-
-
- HY-12389
-
|
8-OHAMX
|
GlyT
|
Neurological Disease
|
|
8-Hydroxyamoxapine is an orally active antidepressant, which inhibits the reuptake of norepinephrine and serotonin at synapses .
|
-
- HY-105132
-
-
- HY-10427A
-
|
iso-NRI-022
|
Serotonin Transporter
Dopamine Transporter
|
Cardiovascular Disease
|
|
iso-WAY-260022 (Compound 13R) is an orally active, brain-penetrant and selective norepinephrine transporter (hNET) inhibitor with an IC50 value of 140 nM. iso-WAY-260022 also shows inhibitory effects on human serotonin (hSERT) and dopamine transporters (hDAT). iso-WAY-260022 inhibits norepinephrine reuptake and increases hypothalamic norepinephrine levels to regulate thermoregulatory center function. iso-WAY-260022 is promising for research of vasomotor symptoms, such as menopausal hot flushes, night sweats .
|
-
- HY-123398
-
-
- HY-17032A
-
|
(rac)-AS1069562 hydrochloride; YM-08054
|
5-HT Receptor
|
Neurological Disease
|
|
Indeloxazine hydrochloride is a 5-HT receptor and norepinephrine (NE) reuptake inhibitor. Indeloxazine hydrochloride is an antidepressant and cerebral activator .
|
-
- HY-118064A
-
|
LY-368975 hydrochloride
|
Monoamine Transporter
|
Neurological Disease
|
|
(R)-Thionisoxetine hydrochloride (LY-368975 hydrochloride) is a potent and selective central and peripheral norepinephrine (NE) uptake inhibitor. (R)-Thionisoxetine hydrochloride prevents 6-hydroxydopamine-induced hypothalamic NE depletion with an ED50 of 0.21 mg/kg. (R)-Thionisoxetine hydrochloride can be used in the study of a variety of diseases, including depression and urinary incontinence .
|
-
- HY-118064
-
|
LY-368975
|
Dopamine Receptor
|
Neurological Disease
|
|
(R)-Thionisoxetine is a potent and selective inhibitor of central and peripheral norepinephrine (NE) uptake. (R)-thionisoxetine prevented hypothalamic NE depletion by 6-hydroxydopamine with an ED50 of 0.21 mg/kg. (R)-Thionisoxetine can be used for the research of a variety of diseases including depression and urinary incontinence .
|
-
- HY-129985
-
|
DU23811
|
Serotonin Transporter
5-HT Receptor
|
Neurological Disease
|
|
Clovoxamine (DU23811) (Compound 35) has binding affinity for serotonin transporter (SERT) (Ki: 61 nM). Clovoxamine is a 5-HT and norepinephrine reuptake (NE) re-uptake inhibitor. Clovoxamine is an antidepressant .
|
-
- HY-B0602B
-
|
O-Desmethylvenlafaxine fumarate
|
5-HT Receptor
Adrenergic Receptor
Drug Metabolite
|
Neurological Disease
|
|
Desvenlafaxine (O-Desmethylvenlafaxine) fumarate is a selective serotonin and norepinephrine reuptake inhibitor. Desvenlafaxine (O-Desmethylvenlafaxine) fumarate is the major metabolite of the antidepressant venlafaxine. Desvenlafaxine (O-Desmethylvenlafaxine) fumarate has the potential for the research of depression and related disorders and diseases (extracted from patent WO2009049354A1) .
|
-
- HY-B0602C
-
|
O-Desmethylvenlafaxine hydrochloride
|
5-HT Receptor
Adrenergic Receptor
Drug Metabolite
|
Neurological Disease
|
|
Desvenlafaxine (O-Desmethylvenlafaxine) hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor. Desvenlafaxine (O-Desmethylvenlafaxine) hydrochloride is the major metabolite of the antidepressant venlafaxine. Desvenlafaxine (O-Desmethylvenlafaxine) hydrochloride has the potential for the research of depression and related disorders and diseases (extracted from patent WO2009049354A1) .
|
-
- HY-18332
-
-
- HY-P3064
-
|
Leiurotoxin I
|
Potassium Channel
|
Neurological Disease
|
|
Scyllatoxin (Leiurotoxin I) is a peptide toxin, it can be isolated from the venom of the scorpion (Leiurus quinquestriatus hebraeus). Scyllatoxin is a blocker of small-conductance KCa (SK) channel. Scyllatoxin enhances both norepinephrine (NE) and epinephrine (Epi) release in vivo .
|
-
- HY-W061043
-
|
|
Serotonin Transporter
Dopamine Transporter
|
Neurological Disease
|
|
DOV-216,303 is an antidepressant compound. DOV-216,303 inhibits the reuptake of norepinephrine (NE), serotonin (5‐HT), and dopamine (DA), with IC50 values of 14 nM, 20 nM and 78 nM for hSERT, hNET and hDAT, respectively. DOV-216,303 increases monoamine release in the prefrontal cortex of olfactory bulbectomized (OBX) rats .
|
-
- HY-15413
-
|
LY 2216684
|
Adrenergic Receptor
|
Neurological Disease
|
|
Edivoxetine (LY 2216684) is a potent and selective norepinephrine reuptake inhibitor. Edivoxetine can be used for the study of major depressive disorder (MDD) and attention-deficit/hyperactivity disorder (ADHD) .
|
-
- HY-126907
-
-
- HY-105297
-
|
|
5-HT Receptor
|
Neurological Disease
|
|
BMS-505130 fumarate is a potent, selective and orally active serotonin transport inhibitor with a Ki for binding to the serotonin transporter of 0.18 nM (Ki for norepinephrine and dopamine transporters of 4.6 and 2.1 μM, respectively). BMS-505130 fumarate can be used for the research of neurological disease, such as depression .
|
-
- HY-108256R
-
|
|
5-HT Receptor
Reference Standards
|
Neurological Disease
|
|
Melitracen (hydrochloride) (Standard) is the analytical standard of Melitracen (hydrochloride). This product is intended for research and analytical applications. Melitracen hydrochloride is an orally active biphasic antidepressant and antianxiety agent. Melitracen hydrochloride can inhibit the uptake of Norepinephrine and 5-HT (serotonin) through the presynaptic membrane inducing the increase of monoamine transmitters in synaptic space .
|
-
- HY-108985
-
|
EGYT-3615
|
Others
|
Neurological Disease
|
|
Trazium esilate (EGYT-3615) is an antidepressant, which influences the central dopaminergic system. Trazium esilate synergizes amphetamine, potentiates stereotypy and hypermotility. Trazium esilate blocks Apomorphine (HY-12723)-induced hypothermic and the stereotypy, and Bulbocapnine (HY-W436270)-induced cataleptic state. Trazium esilate enhances the effect of Norepinephrine (HY-13715) on isolated vas deferens of the rat .
|
-
- HY-B1435A
-
|
Thymoxamine
|
Adrenergic Receptor
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
|
|
Moxisylyte (Thymoxamine) is a selective α1A-adrenergic receptor antagonist. Moxisylyte competitively antagonizes the activation mediated by norepinephrine. Moxisylyte relaxes penile cavernous smooth muscle and aids erectile function. Moxisylyte is applicable to research related to erectile dysfunction and multiple system atrophy .
|
-
- HY-148862
-
|
|
Calcium Channel
Monoamine Transporter
|
Inflammation/Immunology
|
|
Cavα2δ1&NET-IN-1 (Compound 59S) is a dual inhibitor of the α2δ‑1 subunit of voltage-gated calcium channels (Cavα2δ-1) and the norepinephrine transporter (NET). Cavα2δ1&NET-IN-1 inhibits Cavα2δ-1 with a Ki of 112 nM. Cavα2δ1&NET-IN-1 inhibits NET with a Ki of 383 nM and IC50 of 67 nM. Cavα2δ1&NET-IN-1 can be used for research of pain .
|
-
- HY-W297421
-
|
(+)-Tomoxetine hydrochloride; LY-139602
|
Serotonin Transporter
|
Others
|
|
(S)-Tomoxetine hydrochloride (LY-139602) is an isomer of the norepinephrine reuptake inhibitor LY 139603 (HY-17385) with an inhibition constant (Ki) of 16.8 nM for norepinephrine reuptake .
|
-
- HY-B1202A
-
|
AY-22284A
|
Aldose Reductase
|
Metabolic Disease
|
|
Alrestatin (AY-22284) sodium is an aldose reductase inhibitor. Alrestatin sodium reduces fructose levels in the uterine fluid of mice. Alrestatin sodium interferes with sperm capacitation and impairs fertilization function in mice. Alrestatin sodium decreases basal and tyramine-induced norepinephrine release in rat pancreatic specimens in vitro. Alrestatin sodium enhances glucose- and arginine-stimulated insulin secretion in vivo. Alrestatin sodium can be used in studies related to diabetes and reproductive diseases .
|
-
- HY-101612
-
-
- HY-P1544
-
|
|
Endogenous Metabolite
Adenylate Cyclase
PKA
Calcium Channel
|
Neurological Disease
Metabolic Disease
|
|
Cerebellin is a neuromodulatory hexadecapeptide that serves as a marker for Purkinje cell maturation. Cerebellin stimulates norepinephrine release via the adenylate cyclase/PKA-dependent signaling pathway. Cerebellin reduces insulin secretion from pancreatic islets under high-glucose conditions. Cerebellin also regulates synaptic structure formation and controls catecholamine secretion in peripheral tissues. Cerebellin can be used in neurological research .
|
-
- HY-136625
-
|
|
N-myristoyltransferase
|
Cardiovascular Disease
|
|
LY134046 is an inhibitor of norepinephrine N-methyltransferase (NMT) with cardiovascular activity. LY134046 causes sustained reductions in mean arterial blood pressure and heart rate, but no significant reductions in norepinephrine concentrations in the rat brain. LY134046 does not interact with adrenergic or cholinergic receptors, and its hypotensive and bradycardic effects do not require neurogenic tension. LY134046 (40 mg/kg/day) causes sustained and significant inhibition of hypothalamic and brainstem NMT activity, resulting in central norepinephrine depletion.
|
-
- HY-10427
-
|
NRI-022
|
Histone Methyltransferase
|
Neurological Disease
|
|
WAY-260022 is a selective norepinephrine reuptake inhibitor with potent inhibitory activity on norepinephrine reuptake. WAY-260022 exhibits excellent selectivity in inhibiting serotonin and dopamine transporters. WAY-260022 also showed oral efficacy in a rat model of thermoregulatory dysfunction .
|
-
- HY-B1708
-
-
- HY-122300C
-
|
(Rac)-Levoprotiline hydrochloride
|
Adrenergic Receptor
|
Neurological Disease
|
|
Oxaprotiline hydrochloride is a potent norepinephrine (NA) uptake inhibitor. Oxaprotiline hydrochloride has antidepressant activity .
|
-
- HY-103217
-
-
- HY-101684A
-
|
CIBA 2330Go hydrochloride
|
Serotonin Transporter
|
Neurological Disease
|
|
Nitroxazepine hydrochloride is a tricyclic antidepressant (TCA) for the study of depression. Nitroxazepine acts as a serotonin-norepinephrine reuptake inhibitor.
|
-
- HY-W009184
-
|
|
Drug Intermediate
|
Others
|
|
Norepinephrine tartrate impurity 33 is an impurity of Norepinephrine tartrate (HY-13715C).
|
-
- HY-186093
-
|
|
Drug Intermediate
|
Others
|
|
(S,S)-Reboxetine-OH is a phenol compound. (S,S)-Reboxetine-OH can be used to synthesize norepinephrine transporter ligand .
|
-
- HY-U00069
-
|
|
Monoamine Transporter
|
Neurological Disease
Inflammation/Immunology
|
|
Thionisoxetine is a norepinephrine transporter inhibitor with a Ki value of 0.2 nM in rats, and exhibits anti-hyperalgesic and analgesic activities. Thionisoxetine reverses thermal hyperalgesia and mechanical allodynia in rats. Thionisoxetine can be used in studies related to persistent inflammatory pain .
|
-
- HY-107128R
-
|
TD-9855 hydrochloride (Standard)
|
Reference Standards
Serotonin Transporter
|
Neurological Disease
|
|
Ampreloxetine hydrochloride (Standard) (TD-9855 hydrochloride (Standard)) is the analytical standard of Ampreloxetine (hydrochloride) (HY-107128). This product is intended for research and analytical applications. Ampreloxetine (TD-9855) hydrochloride is an orally active and CNS-penetrant inhibitor of Norepinephrine transporter (NET) and Serotonin 5-HT uptake transporter (SERT), but not Dopamine transporter (DAT). Ampreloxetine hydrochloride binds norepinephrine transporters (NET) and serotonin transporters (SERT) with EC50 values of 11.7 ng/mL and 50.8 ng/mL, respectively, in plasma .
|
-
- HY-186094
-
|
|
Drug Derivative
Drug Intermediate
|
Neurological Disease
|
|
(S,S)-Demethyl-reboxetine is a key phenolic precursor for the preparation of the PET tracer (S,S)-[ 11C]-MeNER. (S,S)-Demethyl-reboxetine is also the demethylated derivative of Reboxetine (HY-14560). Efficient synthesis of the norepinephrine transporter (NET)-targeted tracer is achieved through 11C methylation of (S,S)-Demethyl-reboxetine. (S,S)-Demethyl-reboxetine serves as a core raw material for the synthesis of radiopharmaceuticals related to NET imaging .
|
-
- HY-182485
-
|
|
Dopamine β-hydroxylase
|
Others
|
|
U-11634 is an orally active dopamine β-hydroxylase noncompetitive inhibitor, with rat LD50 values of 1197 mg/kg (subcutaneous) and 524 mg/kg (oral). U-11634 blocks conversion of dopamine to norepinephrine and reduces norepinephrine levels in brain. U-11634 decreases food intake and spontaneous motor activity via dietary inclusion. U-11634 induces thyroid toxicity and inhibits pregnancy. U-11634 inhibits deciduomata formation in intact and steroid-treated rats, with no reversal by progesterone or oestradiol. U-11634 can be used for pregnancy .
|
-
- HY-182247
-
|
|
Serotonin Transporter
Dopamine Transporter
|
Neurological Disease
|
|
D-473 is an orally active, blood-brain barrier penetrant and serotonin-preferring reuptake inhibitor. D-473 inhibits serotonin, dopamine and norepinephrine transporters, and significantly elevates the extracellular levels of these three neurotransmitters in rat brain regions. D-473 exhibits definite antidepressant-like activity without inducing motor activation. D-473 is widely used in studies related to major depressive disorder .
|
-
- HY-106604
-
|
LM 1404
|
Monoamine Transporter
|
Neurological Disease
Metabolic Disease
|
|
Lortalamine (LM 1404) is a selective norepinephrine transporter inhibitor with an IC50 of <1 nM. Lortalamine is a non-tricyclic antidepressant. Lortalamine antagonises Reserpine (HY-N0480)-induced ptosis and hypothermia. Lortalamine inhibits norepinephrine uptake .
|
-
- HY-182244
-
|
|
Serotonin Transporter
5-HT Receptor
|
Endocrinology
|
|
SERT/NET-IN-1 is a blood-brain barrier-permeable SERT and NET inhibitor, with an IC50 of 11.2 nM against human SERT and an IC50 of 32.0 nM against human NET. SERT/NET-IN-1 blocks 5-HT reuptake to enhance serotonergic signaling. SERT/NET-IN-1 also blocks norepinephrine reuptake to enhance central noradrenergic transmission and inhibits the ejaculatory reflex. SERT/NET-IN-1 prolongs ejaculatory latency, reduces ejaculation frequency and preserves sexual function. SERT/NET-IN-1 exhibits cross-species microsomal metabolic stability, shows acceptable oral brain exposure in rats, and has favorable safety profiles. SERT/NET-IN-1 can be used in studies related to premature ejaculation .
|
-
- HY-101684
-
|
CIBA 2330Go
|
Serotonin Transporter
|
Neurological Disease
|
|
Nitroxazepine is a tricyclic antidepressant (TCA) for the research of depression. Nitroxazepine acts as a serotonin-norepinephrine reuptake inhibitor.
|
-
- HY-115762
-
-
- HY-W653777
-
|
|
Tau Protein
|
Neurological Disease
|
|
Dopegal is a metabolite od Norepinephrine. Dopegal activates asparagine endopeptidase and pathological Tau aggregation in locus coeruleus.
|
-
- HY-106493
-
-
- HY-158552
-
-
- HY-14607
-
|
HP 749
|
Potassium Channel
|
Neurological Disease
|
Besipirdine (hydrochloride) is a potassium channel blocker with cholinergic and adrenergic activity. The cholinergic activity of Besipirdine (hydrochloride) involves stimulating phosphatidylinositol turnover and reducing potassium currents. The adrenergic activity of Besipirdine (hydrochloride) involves stimulating norepinephrine release, which is attributed to the inhibition of presynaptic α2-adrenergic receptors and the inhibition of norepinephrine uptake. Besipirdine (hydrochloride) may be used in research for Alzheimer's disease .
|
-
- HY-122300A
-
|
(Rac)-Levoprotiline
|
Adrenergic Receptor
|
Neurological Disease
|
|
Oxaprotiline ((Rac)-Levoprotiline) is a potent Norepinephrine (NE)/Noradrenaline (NA) uptake inhibitor. Oxaprotiline has antidepressant activity .
|
-
- HY-12850
-
-
- HY-120325
-
-
- HY-W008794S
-
|
(±)-Normetanephrine-d3 hydrochloride; DL-Normetanephrine-d3 hydrochloride; (Rac)-Normetanephrine-d3 hydrochloride
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Normetanephrine-d3 (hydrochloride) is the deuterium labeled Normetanephrine hydrochloride. Normetanephrine ((±)-Normetanephrine) hydrochloride is the O-methylated metabolite of norepinephrine (NE) .
|
-
- HY-105856
-
-
- HY-172421
-
-
- HY-N9628
-
|
|
Adrenergic Receptor
|
Neurological Disease
|
|
Polygalatenoside A is a noradrenaline reuptake inhibitor with an IC50 of 30.0 μM against human noradrenaline transporter. Polygalatenoside A can be used in the research of mental disorders .
|
-
- HY-17590
-
|
(S,S)-Hydroxybupropion hydrochloride; GW-353162A; BW-306U
|
Monoamine Transporter
|
Neurological Disease
|
|
Radafaxine hydrochloride (GW-353162A) is a DAT (dopamine transporter) and NET(norepinephrine transporter) transporters inhibitor, and nAChR family modulator.
|
-
- HY-129668
-
|
|
Adrenergic Receptor
|
Neurological Disease
|
|
Bremazocine is a potent opioid kappa receptor agonist with analgesic activity. Bremazocine induces peripheral analgesia by releasing endogenous norepinephrine. The analgesic effect of bremazocine is associated with interaction with adenosine receptors. Bremazocine produces a dose-dependent peripheral analgesia after topical application. The effect of bremazocine is affected by nonselective α(2) adrenaline receptor antagonists, suggesting that it acts through a norepinephrine pathway .
|
-
- HY-17018A
-
|
ABT 200; A-75200 mesylate
|
Adrenergic Receptor
|
Neurological Disease
|
|
Napitane mesylate (ABT 200 mesylate) is an inhibitor for norepinephrine reuptake and an antagonist for presynaptic α2 receptor. Napitane mesylate exhibits antidepressant activity .
|
-
- HY-19346
-
|
|
ROCK
|
Others
|
|
AR-13324 analog mesylate is an analog of AR-13324. AR-13324 is an ROCK and norepinephrine transporter (NET) inhibitor .
|
-
- HY-E70970
-
-
- HY-12850A
-
-
- HY-B0161
-
-
- HY-14560C
-
|
FCE20124 mesylate; PNU155950E mesylate
|
Adrenergic Receptor
|
Neurological Disease
|
|
Reboxetine mesylate (FCE20124 mesylate) is a potent, selective, and specific noradrenaline reuptake inhibitor (NARI) for the research of depression. Reboxetine mesylate inhibits the uptake of norepinephrine, with a Ki of 8 nM .
|
-
- HY-W008794R
-
|
(±)-Normetanephrine hydrochloride (Standard); DL-Normetanephrine hydrochloride (Standard); (Rac)-Normetanephrine hydrochloride (Standard)
|
Reference Standards
Endogenous Metabolite
|
Metabolic Disease
|
|
Normetanephrine (hydrochloride) (Standard) is the analytical standard of Normetanephrine (hydrochloride). This product is intended for research and analytical applications. Normetanephrine ((±)-Normetanephrine) hydrochloride is the O-methylated metabolite of norepinephrine (NE) .
|
-
- HY-14790
-
|
(S,S)-(+)-Reboxetine
|
Adrenergic Receptor
|
Neurological Disease
|
|
Esreboxetine ((S,S)-Reboxetine) is a selective norepinephrine reuptake inhibitor with activity in increasing urethral resistance. Esreboxetine has been reported to be effective in patients with stress urinary incontinence in a Phase IIa clinical study, achieving this effect by increasing urethral closure. The mechanism of action of esreboxetine involves inhibition of norepinephrine transporters in the central and peripheral nervous systems. The peripheral selectivity of esreboxetine helps it significantly increase urethral resistance without penetrating the brain .
|
-
- HY-U00096
-
-
- HY-W344115
-
-
- HY-145577
-
|
|
Monoamine Oxidase
|
Neurological Disease
|
|
Lafadofensine is the monoamines reuptake inhibitor. Lafadofensine has th sufficient effects after short-term administration (extracted from patent WO2006121218A1, compound 1) .
|
-
- HY-B1225R
-
|
Romtiazin hydrochloride (Standard); Ampazine hydrochloride (Standard); Berophen hydrochloride (Standard)
|
Reference Standards
Dopamine Receptor
|
Neurological Disease
|
|
Promazine (hydrochloride) (Standard) is the analytical standard of Promazine (hydrochloride). This product is intended for research and analytical applications. Promazine (Romtiazin) hydrochloride is an antipsychotic and a dopamine receptor D2 antagonist. Promazine hydrochloride inhibits dopaminergic neurotransmission .
|
-
- HY-145577A
-
|
|
Monoamine Transporter
|
Neurological Disease
|
|
Lafadofensine D-(-)-Mandelic acid is the monoamines reuptake inhibitor. Lafadofensine D-(-)-Mandelic acid has sufficient effects after short-term administration .
|
-
- HY-163905
-
-
- HY-B1225A
-
|
Romtiazin; Ampazine; Berophen
|
Dopamine Receptor
|
Neurological Disease
|
|
Promazine (Romtiazin) is an antipsychotic and a dopamine receptor D2 antagonist. Promazine inhibits dopaminergic neurotransmission .
|
-
- HY-B1225
-
|
Romtiazin hydrochloride; Ampazine hydrochloride; Berophen hydrochloride
|
Dopamine Receptor
|
Neurological Disease
|
|
Promazine (Romtiazin) hydrochloride is an antipsychotic and a dopamine receptor D2 antagonist. Promazine hydrochloride inhibits dopaminergic neurotransmission .
|
-
- HY-167646
-
|
071031B
|
5-HT Receptor
|
Neurological Disease
|
|
Ammuxetine (071031B), a chiral compound, is a 5-HT and norepinephrine reuptake inhibitor (SSRI) with antidepressant activity and can be used in studies related to depression .
|
-
- HY-E70910
-
|
|
Biochemical Assay Reagents
|
Neurological Disease
|
|
Dopamine β-monooxygenase, Human (EC 1.14.17.1) is a copper-containing monooxygenase that converts dopamine into norepinephrine in noradrenergic neurons, adrenergic neurons, and adrenacentrocytes.
|
-
- HY-Y0123
-
|
|
Drug Derivative
|
Infection
Neurological Disease
|
|
DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine) .
|
-
- HY-172029
-
|
|
Monoamine Transporter
|
Neurological Disease
|
|
3,4-Methylenedioxy pyrovalerone metabolite 2 hydrochloride is an analog of Pyrovalerone. Pyrovalerone inhibits the dopamine transporter (DAT),serotonin transporter (SERT),and the norepinephrine transporter (NET) .
|
-
- HY-B0161A
-
|
(S)-Duloxetine hydrochloride; LY-248686 hydrochloride
|
Serotonin Transporter
|
Neurological Disease
Cancer
|
|
Duloxetine hydrochloride ((S)-Duloxetine hydrochloride) is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .
|
-
- HY-B0161E
-
|
(Rac)-Duloxetine hydrochloride
|
Serotonin Transporter
|
Neurological Disease
|
|
(±)-Duloxetine ((Rac)-Duloxetine) hydrochloride is the racemate of Duloxetine hydrochloride. Duloxetine hydrochloride, a serotonin-norepinephrine reuptake inhibitor, can be used for diabetic neuropathic pain and fibromyalgia as well as major depressive disorder research .
|
-
- HY-B0196B
-
|
|
Serotonin Transporter
|
Cancer
|
|
(S)-Venlafaxine is the (S)-configuration of Venlafaxine. Venlafaxine is an orally active, potent serotonin (5-HT)/norepinephrine (NE) reuptake dual inhibitor. Venlafaxine is an antidepressant agent .
|
-
- HY-113474R
-
-
- HY-W653885
-
-
- HY-167689
-
|
|
Adrenergic Receptor
|
Neurological Disease
|
|
Parethoxycaine hydrochloride is an anesthetic with nerve conduction blocking activity. Parethoxycaine hydrochloride exhibits non-selective inhibitory effects on responses to various stimulants in rat vas deferens and guinea pig ileum muscles. Parethoxycaine hydrochloride has an enhanced effect on the action of norepinephrine, and its methyl bromide derivative also exhibits the same properties on the action of norepinephrine and potassium ions. Derivatives of parethoxycaine hydrochloride have significant effects on calcium dose-response curves, displaying different tissue and stimulant selectivities. The mechanism of action of Parethoxycaine hydrochloride involves the regulation of calcium transport processes .
|
-
- HY-14794A
-
|
(1S,2R)-Milnacipran; F2695
|
Serotonin Transporter
Trk Receptor
PI3K
mTOR
P-glycoprotein
Akt
|
Neurological Disease
Inflammation/Immunology
|
|
Levomilnacipran ((1S,2R)-Milnacipran) is the enantiomer of Milnacipran (HY-B0168) and a strong substrate of P-gp that can cross the blood-brain barrier. Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor, with IC50 values of 10.5 nM and 19.0 nM, and Ki values of 92.2 nM and 1.2 nM for human norepinephrine transporter (NET) and serotonin transporter (SERT), respectively. Levomilnacipran has antidepressant and anxiolytic activities. Levomilnacipran hydrochloride can be used for the research of depression .
|
-
- HY-B0168B
-
|
(1S,2R)-Milnacipran hydrochloride; F-2695 hydrochloride
|
Serotonin Transporter
Trk Receptor
PI3K
Akt
mTOR
P-glycoprotein
|
Neurological Disease
Inflammation/Immunology
|
|
Levomilnacipran ((1S,2R)-Milnacipran) hydrochloride is the enantiomer of Milnacipran (HY-B0168) and a strong substrate of P-gp that can cross the blood-brain barrier. Levomilnacipran hydrochloride is a serotonin and norepinephrine reuptake inhibitor, with IC50 values of 10.5 nM and 19.0 nM, and Ki values of 92.2 nM and 1.2 nM for human norepinephrine transporter (NET) and serotonin transporter (SERT), respectively. Levomilnacipran hydrochloride has antidepressant and anxiolytic activities. Levomilnacipran hydrochloride can be used for the research of depression .
|
-
- HY-119541
-
-
- HY-16736
-
-
- HY-16736A
-
-
- HY-B1396R
-
|
BMY-13754 (Standard); MJ-13754-1 (Standard)
|
Reference Standards
5-HT Receptor
Adrenergic Receptor
|
Neurological Disease
Endocrinology
|
|
Nefazodone (hydrochloride) (Standard) is the analytical standard of Nefazodone (hydrochloride). This product is intended for research and analytical applications. Nefazodone hydrochloride (BMY-13754) is a potent and selective 5HT2A (Ki=5.8 nM) antagonist with moderate inhibition of 5-HT and noradrenaline uptake (IC50 of 290 and 300 nM, respectively). Nefazodone hydrochloride is a phenylpiperazine antidepressant with less alpha-adrenergic blocking activity .
|
-
- HY-59132R
-
|
|
Reference Standards
Drug Intermediate
|
Others
|
|
2-Amino-1-phenylethanol (Standard) is the analytical standard of 2-Amino-1-phenylethanol. This product is intended for research and analytical applications. 2-Amino-1-phenylethanol is a pharmaceutical intermediate that can be used for the synthesis of antimalarial agents and β2-adrenergic receptor agonists.
|
-
- HY-B1396
-
|
BMY-13754; MJ-13754-1
|
5-HT Receptor
Adrenergic Receptor
|
Neurological Disease
Endocrinology
|
|
Nefazodone hydrochloride (BMY-13754) is a potent and selective 5HT2A (Ki=5.8 nM) antagonist with moderate inhibition of 5-HT and noradrenaline uptake (IC50 of 290 and 300 nM, respectively). Nefazodone hydrochloride is a phenylpiperazine antidepressant with less alpha-adrenergic blocking activity .
|
-
- HY-U00050
-
|
E-10-OH-NT
|
Drug Metabolite
Adrenergic Receptor
mAChR
|
Neurological Disease
|
|
(E)-10-Hydroxynortriptyline (E-10-OH-NT) is a blood-brain barrier-permeable norepinephrine uptake inhibitor. (E)-10-Hydroxynortriptyline effectively promotes central norepinephrine neuronal transmission, with little interindividual variation in in vivo potency. (E)-10-Hydroxynortriptyline has low affinity for muscarinic receptors, exhibits only extremely weak anticholinergic activity, and does not inhibit salivary secretion. (E)-10-Hydroxynortriptyline can be used in studies related to depression .
|
-
- HY-131527
-
|
N-Desmethyl Venlafaxine hydrochloride; Wy 45494
|
Serotonin Transporter
|
Metabolic Disease
|
|
Wy-45494 hydrochloride (N-Desmethyl Venlafaxine hydrochloride; Wy 45494) is a minor active metabolite of the selective norepinephrine and serotonin reuptake inhibitor (SNRI) venlafaxine. It is formed from venlafaxine via the cytochrome P450 (CYP) isomer CYP3A4.2. Wy-45494 hydrochloride inhibits norepinephrine and serotonin reuptake in rat synaptosomal preparations (IC50s of 4.7 and 1.6 μM, respectively). In vivo, Wy-45494 hydrochloride reversed reserpine-induced hypothermia in mice at a minimum effective dose (MED) of 10 mg/kg.
|
-
- HY-B0457AS
-
-
- HY-B0196S
-
-
- HY-119541A
-
-
- HY-113121
-
|
|
Drug Metabolite
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Vanillylmandelic acid is the endproduct of epinephrine and norepinephrine metabolism. Vanillylmandelic acid can be used as an indication of the disorder in neurotransmitter metabolism as well. Vanillylmandelic acid has antioxidant activity towards DPPH radical with an IC50 value of 33 μM .
|
-
- HY-B0457S
-
|
Chlorimipramine-d3 hydrochloride; G-34586-d3 hydrochloride; NSC-169865-d3 hydrochloride
|
Serotonin Transporter
Dopamine Receptor
|
Neurological Disease
|
|
Clomipramine-d3 (hydrochloride) is a deuterium labeled Clomipramine hydrochloride. Clomipramine hydrochloride is a serotonin transporter (SERT), norepinephrine transporter (NET) dopamine transporter (DAT) blocker with Ki of 0.14, 54 and 3 nM, respectively .
|
-
- HY-B0196AS1
-
|
Wy 45030-d6 hydrochloride
|
Serotonin Transporter
|
Neurological Disease
|
|
Venlafaxine-d6 (hydrochloride) is the deuterium labeled Venlafaxine hydrochloride. Venlafaxine hydrochloride (Wy 45030 hydrochloride) is an orally active, potent serotonin (5-HT)/norepinephrine (NE) reuptake dual inhibitor. Venlafaxine is an antidepressant .
|
-
- HY-135615A
-
|
N-Desmethylsibutramine hydrochloride
|
Serotonin Transporter
|
Neurological Disease
Metabolic Disease
|
|
Desmethyl Sibutramine hydrochloride, the secondary metabolite of Sibutramine, is an orally active norepinephrine transporter (NET) and serotonin transporter (SERT) inhibitor. Desmethyl Sibutramine hydrochloride can be used in the research of obesity and appetite suppressant .
|
-
- HY-B1308
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Adrenalone hydrochloride is an adrenergic agonist used as a topical vasoconstrictor and hemostatic. Adrenalone hydrochloride is an inhibitor of dopamine β oxidase. Adrenalone hydrochloride is chemically similar to known norepinephrine transporter (NET) ligands with an IC50 of 36.9 μM .
|
-
- HY-B0161D
-
|
LY248686 hydrochloride
|
Serotonin Transporter
|
Others
|
|
(R)-Duloxetine (LY248686) Hydrochloride is a napthalenyloxy-substituted amine utilized in binding studies with human serum albumin, and unlike its enantiomer (S)-Duloxetine, it exhibits limited efficacy as a dual serotonin and norepinephrine reuptake inhibitor (SNRI).
|
-
- HY-131284
-
|
|
Drug Metabolite
|
Others
|
|
(S)-Dehydro Venlafaxine is an inactive S-enantiomer of Dehydro Venlafaxine. Dehydro Venlafaxine is an impurity of Venlafaxine hydrochloride. Venlafaxine hydrochloride (Wy 45030 hydrochloride) is a potent serotonin (5-HT) / norepinephrine (NE) reuptake dual inhibitor .
|
-
- HY-B0196S1
-
-
- HY-137447
-
-
- HY-B0161AS
-
|
(S)-Duloxetine D3 hydrochloride; LY248686 D3 hydrochloride
|
Serotonin Transporter
|
Neurological Disease
|
|
Duloxetine-d3 (hydrochloride) is a deuterium labeled Duloxetine hydrochloride. Duloxetine hydrochloride is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .
|
-
- HY-135615
-
|
N-Desmethylsibutramine
|
Serotonin Transporter
|
Neurological Disease
Metabolic Disease
|
|
Desmethyl Sibutramine, the secondary metabolite of Sibutramine, is an orally active norepinephrine transporter (NET) and serotonin transporter (SERT) inhibitor. Desmethyl Sibutramine can be used in the research of obesity and appetite suppressant .
|
-
- HY-B1308A
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Adrenalone is an adrenergic agonist used as a topical vasoconstrictor and hemostatic. Adrenalone is an inhibitor of dopamine β oxidase. Adrenalone is chemically similar to known norepinephrine transporter (NET) ligands with an IC50 of 36.9 μM .
|
-
- HY-B0196AS
-
-
- HY-W708023
-
|
|
5-HT Receptor
|
Neurological Disease
|
|
5-APDI hydrochloride is an indane with an amphetamine-like aminopropane group. 5-APDI hydrochloride inhibits the uptake of serotonin, dopamine, and norepinephrine by crude synaptosomes (IC50 values of 82 nM, 1,847 nM, and 849 nM, respectively) .
|
-
- HY-B0168A
-
|
|
Serotonin Transporter
PERK
|
Neurological Disease
|
|
Milnacipran hydrochloride is an orally active Serotonin (HY-B1473A) and Norepinephrine (HY-13715) reuptake inhibitor. Milnacipran hydrochloride inhibits monoamine transporters, especially the norepinephrine transporter and the serotonin transporter (Ki values of 31 and 8.5 nM, respectively). Milnacipran hydrochloride inhibits pERK1/2 activation. Milnacipran hydrochloride has antidepressant, anxiolytic and analgesic properties. Milnacipran hydrochloride inhibits biting behavior in mice. Milnacipran hydrochloride can be used in the study of major depressive disorder, anxiety disorders, and neuropathic pain (e.g., fibromyalgia) .
|
-
- HY-B0168
-
|
|
Serotonin Transporter
PERK
|
Neurological Disease
|
|
Milnacipran is an orally active Serotonin (HY-B1473A) and Norepinephrine (HY-13715) reuptake inhibitor. Milnacipran inhibits monoamine transporters, especially the norepinephrine transporter and the serotonin transporter (Ki values of 31 and 8.5 nM, respectively). Milnacipran inhibits pERK1/2 activation. Milnacipran has antidepressant, anxiolytic and analgesic properties. Milnacipran inhibits biting behavior in mice. Milnacipran can be used in the study of major depressive disorder, anxiety disorders, and neuropathic pain (e.g., fibromyalgia) .
|
-
- HY-B1272
-
-
- HY-136860
-
|
(R)-Wy 45030
|
5-HT Receptor
|
Neurological Disease
|
|
(R)-Venlafaxine is the R-enantiomer of venlafaxine (HY-B0196), an orally active and potent dual inhibitor of serotonin (5-HT) and norepinephrine (NE) reuptake. (R)-Venlafaxine can be utilized in antidepressant research .
|
-
- HY-A0175
-
|
Butriptylene
|
5-HT Receptor
|
Neurological Disease
|
|
Butriptyline (Butriptylene) is an orally active tricyclic antidepressant that slightly enhances central 5-HT effects. Butriptyline does not inhibit brain norepinephrine uptake. Butriptyline can be used for depression research .
|
-
- HY-W342779
-
|
|
Dopamine Receptor
|
Neurological Disease
|
|
4-Bromoamphetamine hydrochloride is an amphetamine derivative which acts as a serotonin-norepinephrine-dopamine releasing agent (SNDRA) and produces stimulant effects. 4-Bromoamphetamine hydrochloride is highly neurotoxic, producing long-term depletion of serotonin .
|
-
- HY-A0175A
-
|
Butriptylene hydrochloride
|
5-HT Receptor
|
Neurological Disease
|
|
Butriptyline (Butriptylene) hydrochloride is an orally active tricyclic antidepressant that slightly enhances central 5-HT effects. Butriptyline hydrochloride does not inhibit brain norepinephrine uptake. Butriptyline hydrochloride can be used for depression research .
|
-
- HY-B0196AR
-
|
Wy 45030 hydrochloride (Standard)
|
Reference Standards
Serotonin Transporter
|
Neurological Disease
Cancer
|
|
Venlafaxine (hydrochloride) (Standard) is the analytical standard of Venlafaxine (hydrochloride). This product is intended for research and analytical applications. Venlafaxine hydrochloride (Wy 45030 hydrochloride) is an orally active, potent serotonin (5-HT)/norepinephrine (NE) reuptake dual inhibitor. Venlafaxine is an antidepressant .
|
-
- HY-W016443
-
-
- HY-14560CR
-
|
FCE20124 mesylate (Standard); PNU155950E mesylate (Standard)
|
Reference Standards
Adrenergic Receptor
|
Neurological Disease
|
|
Reboxetine (mesylate) (Standard) is the analytical standard of Reboxetine (mesylate). This product is intended for research and analytical applications. Reboxetine mesylate (FCE20124 mesylate) is a potent, selective, and specific noradrenaline reuptake inhibitor (NARI) for the research of depression. Reboxetine mesylate inhibits the uptake of norepinephrine, with a Ki of 8 nM .
|
-
- HY-105856R
-
|
|
Reference Standards
Dopamine Receptor
|
Neurological Disease
|
|
Thozalinone (Standard) is the analytical standard of Thozalinone (HY-105856). This product is intended for research and analytical applications. Thozalinone is an orally active antidepressant agent. Thozalinone induces the release of Norepinephrine (HY-13715) and dopamine .
|
-
- HY-138818
-
|
NODVFX
|
Drug Metabolite
|
Neurological Disease
Cancer
|
|
N,O-Didesmethylvenlafaxine (NODVFX) is a metabolite of Venlafaxine (VFX; HY-B0196). Venlafaxine (Wy 45030) is an orally active, potent serotonin (5-HT)/norepinephrine (NE) reuptake dual inhibitor .
|
-
- HY-B0602D
-
|
|
Drug Metabolite
|
Neurological Disease
|
|
(S)-(+)-O-Desmethyl Venlafaxine is a S-enantiomer of O-Desmethyl Venlafaxine. O-Desmethyl Venlafaxine is an active metabolite of Venlafaxine . Venlafaxine (HY-B0196) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class .
|
-
- HY-B0161ES
-
|
(Rac)-Duloxetine-d3 hydrochloride
|
Isotope-Labeled Compounds
Serotonin Transporter
|
Neurological Disease
|
|
(±)-Duloxetine-d3 (hydrochloride) is deuterium labeled (±)-Duloxetine (hydrochloride). (±)-Duloxetine ((Rac)-Duloxetine) hydrochloride is the racemate of Duloxetine hydrochloride. Duloxetine hydrochloride, a serotonin-norepinephrine reuptake inhibitor, can be used for diabetic neuropathic pain and fibromyalgia as well as major depressive disorder research .
|
-
- HY-181828
-
|
|
iGluR
Dopamine Receptor
|
Neurological Disease
|
|
SePP is a blood-brain barrier-permeable NMDAR antagonist and dopamine/norepinephrine reuptake inhibitor, with a Ki of 28.7 nM for rat NMDAR. SePP exerts anticonvulsant effects. SePP can be used in research related to fragile X syndrome .
|
-
- HY-131479A
-
|
|
Drug Metabolite
|
Neurological Disease
|
|
Threo-dihydrobupropion is a major metabolite of Bupropion, formed via oxidation and reduction exhibit pharmacological activity. Bupropion, a dual dopamine-norepinephrine uptake inhibitor and a nicotine receptor antagonist, is widely used in the management of depression and as a smoking cessation aid .
|
-
- HY-129682
-
-
- HY-W722796
-
|
|
Adrenergic Receptor
|
Others
|
|
Tuaminoheptane sulfate is an alpha-adrenergic receptor agonist. Tuaminoheptane sulfate exerts its decongestant and irritant effects by inhibiting norepinephrine reuptake and promoting its release. Tuaminoheptane sulfate can be used in research on nasal diseases such as decongestion .
|
-
- HY-120017
-
|
MD-370503
|
Monoamine Oxidase
|
Neurological Disease
|
|
Befloxatone (MD-370503) is an orally active, selective and reversible inhibitor of Monoamine Oxidase A (MAO-A) (IC50=4 nM). Befloxatone increases the tissue level of monoamine, striatal dopamine and cortical norepinephrine. Befloxatone has antidepressant potential .
|
-
- HY-Y0123S2
-
|
|
Isotope-Labeled Compounds
|
Neurological Disease
|
|
DL-Tyrosine-d2 is the deuterium labeled DL-Tyrosine. DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine) .
|
-
- HY-B0161S
-
-
- HY-Y0123S3
-
|
|
Isotope-Labeled Compounds
|
Neurological Disease
|
|
DL-Tyrosine-d3 is the deuterium labeled DL-Tyrosine. DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine) .
|
-
- HY-W411193
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
Pincainide is a calcium channel inhibitor. Pincainide inhibits voltage-gated calcium channel-mediated calcium influx in smooth muscle. Pincainide inhibits norepinephrine- and high potassium-induced contractile responses. Pincainide can be used in the research of heart diseases .
|
-
- HY-Y0123S1
-
|
|
Isotope-Labeled Compounds
|
Neurological Disease
|
|
DL-Tyrosine-d7 is the deuterium labeled DL-Tyrosine. DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine) .
|
-
- HY-A0091
-
|
|
Monoamine Oxidase
|
Cardiovascular Disease
Cancer
|
|
Pargyline hydrochloride is an irreversible monoamine oxidase (MAO) inhibitor with Kis of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively. Pargyline hydrochloride has antihypertensive and anticancer activities . Pargyline (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-101355
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
CGP 20712 is a highly selective β1-adrenoceptor antagonist (Ki=0.3 nmol/L). CGP 20712’s primary mechanism of action is through competitively binding to β1-receptors, thereby blocking the positive chronotropic effects of adrenaline and noradrenaline .
|
-
- HY-14542A
-
|
CP-88059 hydrochloride
|
5-HT Receptor
Dopamine Receptor
|
Neurological Disease
|
|
Ziprasidone (CP-88059) hydrochloride is an orally active combined 5-HT and dopamine receptor antagonist . Ziprasidone hydrochloride has affinities for Rat D2 (Ki=4.8 nM), 5-HT2A (Ki=0.42 nM) and 5-HT1A (Ki=3.4 nM) .
|
-
- HY-A0091A
-
|
|
Monoamine Oxidase
|
Cardiovascular Disease
Cancer
|
|
Pargyline is an irreversible monoamine oxidase (MAO) inhibitor with Kis of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively. Pargyline has antihypertensive and anticancer activities . Pargyline is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-A0091AR
-
|
|
Reference Standards
Monoamine Oxidase
|
Cardiovascular Disease
Cancer
|
|
Pargyline (Standard) is the analytical standard of Pargyline. This product is intended for research and analytical applications. Pargyline is an irreversible monoamine oxidase (MAO) inhibitor with Kis of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively. Pargyline has antihypertensive and anticancer activities . Pargyline is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-A0091R
-
|
|
Reference Standards
Monoamine Oxidase
|
Cardiovascular Disease
Cancer
|
|
Pargyline (hydrochloride) (Standard) is the analytical standard of Pargyline (hydrochloride). This product is intended for research and analytical applications. Pargyline hydrochloride is an irreversible monoamine oxidase (MAO) inhibitor with Kis of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively. Pargyline hydrochloride has antihypertensive and anticancer activities . Pargyline (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-B1272AS
-
-
- HY-W052508R
-
|
N-Desalkylquetiapine (Standard)
|
5-HT Receptor
Reference Standards
|
Neurological Disease
|
|
Norquetiapine is an antidepressant and neuroprotective agent and is the active metabolic component of Quetiapine (HY-14544). Norquetiapine is also a partial 5-HT1A receptor agonist, and a presynaptic α2, 5-HT2C and 5-HT7 b> Receptor antagonist. Norquetiapine can also selectively inhibit norepinephrine transporter (NET), inhibit norepinephrine reuptake, and has potential inhibitory effects on bipolar depression, major depressive disorder, and generalized anxiety disorder. Norquetiapine demonstrated in vivo activity in forced swimming in mice and learned helplessness tests in rats .
|
-
- HY-B1272AS1
-
-
- HY-B0168S
-
|
|
Isotope-Labeled Compounds
Serotonin Transporter
PERK
|
Neurological Disease
|
|
Milnacipran-d10 (hydrochloride) is the deuterium labeled Milnacipran hydrochloride (HY-B0168A). Milnacipran hydrochloride is an orally active Serotonin (HY-B1473A) and Norepinephrine (HY-13715) reuptake inhibitor. Milnacipran hydrochloride inhibits monoamine transporters, especially the norepinephrine transporter and the serotonin transporter (Ki values of 31 and 8.5 nM, respectively). Milnacipran hydrochloride inhibits pERK1/2 activation. Milnacipran hydrochloride has antidepressant, anxiolytic and analgesic properties. Milnacipran hydrochloride inhibits biting behavior in mice. Milnacipran hydrochloride can be used in the study of major depressive disorder, anxiety disorders, and neuropathic pain (e.g., fibromyalgia) .
|
-
- HY-B0168AS
-
|
|
Isotope-Labeled Compounds
Serotonin Transporter
PERK
|
Neurological Disease
|
|
Milnacipran-d5 hydrochloride is deuterium labeled Milnacipran hydrochloride (HY-B0168A). Milnacipran hydrochloride is an orally active Serotonin (HY-B1473A) and Norepinephrine (HY-13715) reuptake inhibitor. Milnacipran hydrochloride inhibits monoamine transporters, especially the norepinephrine transporter and the serotonin transporter (Ki values of 31 and 8.5 nM, respectively). Milnacipran hydrochloride inhibits pERK1/2 activation. Milnacipran hydrochloride has antidepressant, anxiolytic and analgesic properties. Milnacipran hydrochloride inhibits biting behavior in mice. Milnacipran hydrochloride can be used in the study of major depressive disorder, anxiety disorders, and neuropathic pain (e.g., fibromyalgia) .
|
-
- HY-113121S1
-
|
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Vanillylmandelic acid-d is the deuterium labeled Vanillylmandelic acid. Vanillylmandelic acid is the endproduct of epinephrine and norepinephrine metabolism. Vanillylmandelic acid can be used as an indication of the disorder in neurotransmitter metabolism as well. Vanillylmandelic acid has antioxidant activity towards DPPH radical with an IC50 value of 33 μM .
|
-
- HY-175873
-
|
|
mAChR
Adrenergic Receptor
|
Inflammation/Immunology
|
|
AD109 is a combination of the selective norepinephrine reuptake inhibitor Atomoxetine (HY-107370) and the antimuscarinic agent Aroxybutynin (HY-B0267C). AD109 shows orally active significantly and reduces the apnea-hypopnea index .
|
-
- HY-B0196S3
-
-
- HY-B2074
-
|
|
SARS-CoV
|
Neurological Disease
|
|
Demexiptiline is a tricyclic antidepressant. Demexiptiline is a norepinephrine reuptake inhibitor. Demexiptiline has a binding affinity with SARS-CoV-2 3CL protease of 8.14 kcal/mol. Demexiptiline can also be studied in research on melancholic states .
|
-
- HY-B0161AR
-
|
(S)-Duloxetine hydrochloride (Standard); LY-248686 hydrochloride (Standard)
|
Reference Standards
Serotonin Transporter
|
Neurological Disease
Cancer
|
|
Duloxetine (hydrochloride) (Standard) is the analytical standard of Duloxetine (hydrochloride). This product is intended for research and analytical applications. Duloxetine hydrochloride ((S)-Duloxetine hydrochloride) is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .
|
-
- HY-131254
-
|
|
Drug Metabolite
|
Neurological Disease
|
|
(S)-O-Desmethyl Venlafaxine N-Oxide is a N-oxyde of (S)-O-Desmethyl Venlafaxine. O-Desmethyl Venlafaxine is an active metabolite of Venlafaxine . Venlafaxine (HY-B0196) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class .
|
-
- HY-105975
-
|
WY-23409
|
Adrenergic Receptor
|
Neurological Disease
Metabolic Disease
Endocrinology
|
|
Ciclazindol (WY-23409) is an orally active antidepressant. Ciclazindol can inhibit the reuptake of norepinephrine. Ciclazindol also exhibits effects of lowering blood glucose, suppressing appetite and reducing weight. Ciclazindol can be used in the research of diseases such as depression and obesity .
|
-
- HY-B0196S2
-
-
- HY-164009
-
|
|
Adrenergic Receptor
Dopamine Receptor
5-HT Receptor
|
Neurological Disease
|
|
Teniloxazine is an inhibitor for norepinephrine neuronal reuptake and an weak inhibitor for reuptake of Serotonin (HY-B1473A) and Dopamine (HY-B0451). Teniloxazine exhibits antidepressant, antihypoxic and anti-amnestic properties without anticholinergic, sedative, and cardiovascular adverse effects .
|
-
- HY-B0161S3
-
|
(S)-Duloxetine-d5 oxalate; LY248686-d5 oxalate
|
Isotope-Labeled Compounds
Serotonin Transporter
|
Neurological Disease
Cancer
|
|
Duloxetine-d5 (oxalate) ((S)-Duloxetine-d5 (oxalate)) is deuterium labeled Duloxetine. Duloxetine is a serotonin-norepinephrine reuptake inhibitor with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .
|
-
- HY-B1272R
-
|
|
Reference Standards
Adrenergic Receptor
ERK
JNK
p38 MAPK
NF-κB
AP-1
Apoptosis
Reactive Oxygen Species (ROS)
Mitochondrial Metabolism
TNF Receptor
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Desipramine hydrochloride (Standard) is the analytical standard of Desipramine hydrochloride (HY-B1272). This product is intended for research and analytical applications. Desipramine hydrochloride is a first-generation tricyclic antidepressant. Desipramine hydrochloride selectively binds to norepinephrine transporter and blocks neuronal norepinephrine reuptake. Desipramine hydrochloride activates MAPK signaling via ERK1/2, JNK, and p38, represses NF-κB and AP-1 activity, and induces apoptosis via ROS elevation, mitochondrial membrane potential reduction, and intracellular calcium increase. Desipramine hydrochloride also shows anyi-inflammatory activity, inhibiting TNF-α production. Desipramine hydrochloride can be used for the research of hepatocellular cancer, inflammation, and neurological diseases .
|
-
- HY-14794AS
-
|
(1S,2R)-Milnacipran-d10 hydrochloride; F2695-d10 hydrochloride
|
Isotope-Labeled Compounds
Serotonin Transporter
Trk Receptor
PI3K
mTOR
P-glycoprotein
Akt
|
Neurological Disease
Inflammation/Immunology
|
|
Levomilnacipran-d10 ((1S,2R)-Milnacipran-d10) hydrochloride is deuterium labeled Levomilnacipran hydrochloride (HY-B0168B). Levomilnacipran ((1S,2R)-Milnacipran) hydrochloride is the enantiomer of Milnacipran (HY-B0168) and a strong substrate of P-gp that can cross the blood-brain barrier. Levomilnacipran hydrochloride is a serotonin and norepinephrine reuptake inhibitor, with IC50 values of 10.5 nM and 19.0 nM, and Ki values of 92.2 nM and 1.2 nM for human norepinephrine transporter (NET) and serotonin transporter (SERT), respectively. Levomilnacipran hydrochloride has antidepressant and anxiolytic activities. Levomilnacipran hydrochloride can be used for the research of depression .
|
-
- HY-B0168BS
-
|
(1S,2R)-Milnacipran-d5 hydrochloride; F-2695-d5 hydrochloride
|
Isotope-Labeled Compounds
Serotonin Transporter
Trk Receptor
PI3K
Akt
mTOR
P-glycoprotein
|
Neurological Disease
Inflammation/Immunology
|
|
Levomilnacipran-d5 ((1S,2R)-Milnacipran-d5) hydrochloride is deuterium labeled Levomilnacipran hydrochloride (HY-B0168B). Levomilnacipran ((1S,2R)-Milnacipran) hydrochloride is the enantiomer of Milnacipran (HY-B0168) and a strong substrate of P-gp that can cross the blood-brain barrier. Levomilnacipran hydrochloride is a serotonin and norepinephrine reuptake inhibitor, with IC50 values of 10.5 nM and 19.0 nM, and Ki values of 92.2 nM and 1.2 nM for human norepinephrine transporter (NET) and serotonin transporter (SERT), respectively. Levomilnacipran hydrochloride has antidepressant and anxiolytic activities. Levomilnacipran hydrochloride can be used for the research of depression .
|
-
- HY-131527R
-
|
N-Desmethyl Venlafaxine hydrochloride (Standard); Wy 45494 (Standard)
|
Serotonin Transporter
Reference Standards
|
Metabolic Disease
|
|
Wy-45494 (hydrochloride) (Standard) is the analytical standard of Wy-45494 (hydrochloride). This product is intended for research and analytical applications. Wy-45494 hydrochloride (N-Desmethyl Venlafaxine hydrochloride; Wy 45494) is a minor active metabolite of the selective norepinephrine and serotonin reuptake inhibitor (SNRI) venlafaxine. It is formed from venlafaxine via the cytochrome P450 (CYP) isomer CYP3A4.2. Wy-45494 hydrochloride inhibits norepinephrine and serotonin reuptake in rat synaptosomal preparations (IC50s of 4.7 and 1.6 μM, respectively). In vivo, Wy-45494 hydrochloride reversed reserpine-induced hypothermia in mice at a minimum effective dose (MED) of 10 mg/kg.
|
-
- HY-B0168AR
-
|
|
Reference Standards
Serotonin Transporter
PERK
|
Neurological Disease
|
|
Milnacipran (hydrochloride) (Standard) is the analytical standard of Milnacipran hydrochloride (HY-B0168A). This product is intended for research and analytical applications. Milnacipran hydrochloride is an orally active Serotonin (HY-B1473A) and Norepinephrine (HY-13715) reuptake inhibitor. Milnacipran hydrochloride inhibits monoamine transporters, especially the norepinephrine transporter and the serotonin transporter (Ki values of 31 and 8.5 nM, respectively). Milnacipran hydrochloride inhibits pERK1/2 activation. Milnacipran hydrochloride has antidepressant, anxiolytic and analgesic properties. Milnacipran hydrochloride inhibits biting behavior in mice. Milnacipran hydrochloride can be used in the study of major depressive disorder, anxiety disorders, and neuropathic pain (e.g., fibromyalgia) .
|
-
- HY-N0913R
-
|
|
Reference Standards
Antifolate
Thymidylate Synthase
|
Others
|
|
Wy-45494 (hydrochloride) (Standard) is the analytical standard of Wy-45494 (hydrochloride). This product is intended for research and analytical applications. Wy-45494 hydrochloride (N-Desmethyl Venlafaxine hydrochloride; Wy 45494) is a minor active metabolite of the selective norepinephrine and serotonin reuptake inhibitor (SNRI) venlafaxine. It is formed from venlafaxine via the cytochrome P450 (CYP) isomer CYP3A4.2. Wy-45494 hydrochloride inhibits norepinephrine and serotonin reuptake in rat synaptosomal preparations (IC50s of 4.7 and 1.6 μM, respectively). In vivo, Wy-45494 hydrochloride reversed reserpine-induced hypothermia in mice at a minimum effective dose (MED) of 10 mg/kg.
|
-
- HY-Y0123S4
-
|
|
Isotope-Labeled Compounds
Drug Derivative
|
Infection
Neurological Disease
|
|
DL-Tyrosine-d4 is the deuterium labeled DL-Tyrosine (HY-Y0123). DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine) .
|
-
- HY-B0602S
-
|
|
Isotope-Labeled Compounds
Drug Metabolite
|
Neurological Disease
|
|
(R)-(-)-O-Desmethyl Venlafaxine-d6 is the deuterium labeled (R)-(-)-O-Desmethyl Venlafaxine. O-Desmethyl Venlafaxine is an active metabolite of Venlafaxine . Venlafaxine (HY-B0196) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class .
|
-
- HY-113121S
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Vanillylmandelic acid-d3 is the deuterium labeled Vanillylmandelic acid. Vanillylmandelic acid is the endproduct of epinephrine and norepinephrine metabolism. Vanillylmandelic acid can be used as an indication of the disorder in neurotransmitter metabolism as well. Vanillylmandelic acid has antioxidant activity towards DPPH radical with an IC50 value of 33 μM .
|
-
- HY-B0562
-
|
|
Carbonic Anhydrase
|
Cardiovascular Disease
Metabolic Disease
|
|
Methyclothiazide is an orally active antihypertensive agent and a diuretic agent. Methyclothiazide leads to a reduction of the vascular response to the action of endogenous vasoconstricting stimuli, such as Norepinephrine (HY-13715). Methyclothiazide is against voltage-dependent Ca-channel (VDCC) activity in vitro .
|
-
- HY-P10435
-
|
|
Dopamine Receptor
|
Neurological Disease
|
|
KEMPFPKYPVEP is a 12-amino acids neuropeptide, which upregulates levels of dopamine (DA) and norepinephrine (NE) in the prefrontal cortex, exhibits spatial and object recognition memory promoting ability in Scopolamine (HY-N0296)-induced amnesia mouse model .
|
-
- HY-B0602S1
-
|
|
Drug Metabolite
|
Neurological Disease
|
|
(S)-(+)-O-Desmethyl Venlafaxine-d6 is the deuterium labeled (S)-(+)-O-Desmethyl Venlafaxine. O-Desmethyl Venlafaxine is an active metabolite of Venlafaxine . Venlafaxine (HY-B0196) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class .
|
-
- HY-122272S2
-
-
- HY-Y0123S5
-
|
|
Isotope-Labeled Compounds
Drug Derivative
|
Infection
Neurological Disease
|
|
DL-Tyrosine- 13C is the 13C-labeled DL-Tyrosine (HY-Y0123). DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine) .
|
-
- HY-108256S
-
|
|
Isotope-Labeled Compounds
5-HT Receptor
|
Neurological Disease
|
|
Melitracen-d6 (hydrochloride) is the deuterium labeled Melitracen hydrochloride. Melitracen hydrochloride is an orally active biphasic antidepressant and antianxiety agent. Melitracen hydrochloride can inhibit the uptake of Norepinephrine and 5-HT (serotonin) through the presynaptic membrane inducing the increase of monoamine transmitters in synaptic space .
|
-
- HY-107031
-
|
19560 RP
|
iGluR
|
Others
|
|
Metapramine (19560 RP) is an antidepressant agent, belonging to the class of tricyclic compounds . Metapramine inhibits norepinephrine reuptake, without affecting the reuptake of serotonin or dopamine . Metapramine is a low-affinity antagonist of the N-methyl-D-aspartic acid (NMDA) receptor complex channel .
|
-
- HY-Y0123S
-
|
|
Isotope-Labeled Compounds
|
Neurological Disease
|
|
L-Tyrosine- 13C9, 15N is the 13C- and 15N-labeled L-Tyrosine. L-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. L-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine) .
|
-
- HY-113121R
-
|
|
Drug Metabolite
Reference Standards
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Vanillylmandelic acid (Standard) is the analytical standard of Vanillylmandelic acid. This product is intended for research and analytical applications. Vanillylmandelic acid is the endproduct of epinephrine and norepinephrine metabolism. Vanillylmandelic acid can be used as an indication of the disorder in neurotransmitter metabolism as well. Vanillylmandelic acid has antioxidant activity towards DPPH radical with an IC50 value of 33 μM .
|
-
- HY-B0196S4
-
-
- HY-14450
-
|
|
Neuropeptide Y Receptor
|
Neurological Disease
Endocrinology
|
|
JNJ-31020028 is a selective and brain penetrant antagonist of neuropeptide Y Y2 receptor with pIC50 values of 8.07 and 8.22 for human and rat Y2 receptor, respectively. JNJ-31020028 can be used for the research of nervous disease .
|
-
- HY-W922811
-
|
|
iGluR
|
Neurological Disease
|
|
DL-Willardiine is an AMPA antagonist with an IC50 of 2 μM. DL-Willardiine can be utilized in psychotropic cccccc research .
|
-
- HY-B1308R
-
|
|
Reference Standards
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Adrenalone (hydrochloride) (Standard) is the analytical standard of Adrenalone (hydrochloride). This product is intended for research and analytical applications. Adrenalone hydrochloride is an adrenergic agonist used as a topical vasoconstrictor and hemostatic. Adrenalone hydrochloride is an inhibitor of dopamine β oxidase. Adrenalone hydrochloride is chemically similar to known norepinephrine transporter (NET) ligands with an IC50 of 36.9 μM .
|
-
- HY-B0725A
-
|
|
mTOR
PI3K
Akt
|
Neurological Disease
Cancer
|
|
Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant. Doxepin has therapeutic effects in atopic dermatitis,chronic urticarial,can improve cognitive processes, protect central nervous system. Doxepin has also been proposed as a protective factor against oxidative stress .
|
-
- HY-79722
-
|
trans-4-Aminocyclohexan-1-ol
|
Drug Intermediate
|
Neurological Disease
|
|
4-trans-Hydroxycyclohexylamine (trans-4-Aminocyclohexan-1-ol) is an intermediate. 4-trans-Hydroxycyclohexylamine can be used in the synthesis of norepinephrine transporter inhibitors. 4-trans-Hydroxycyclohexylamine can be used in the research of mood and behavior-related diseases .
|
-
- HY-12766S
-
|
|
Isotope-Labeled Compounds
nAChR
Dopamine Transporter
|
Neurological Disease
|
|
Bupropion morpholinol-d6 is the deuterated form of Bupropion morpholinol. Bupropion morpholinol is a major metabolite of Bupropion. Bupropion morpholinol inhibits Dopamine, Norepinephrine transporters and the α4β2 nicotinic receptor in vitro. Bupropion morpholinol contributes to antidepressant and smoking cessation activities .
|
-
- HY-120405
-
|
|
Dopamine Receptor
|
Others
|
|
RS-12254 is a compound with hypotensive, diuretic and sympathostatic effects, and has the activity of regulating blood pressure, water and salt metabolism and sympathetic nerve activity. RS-12254 can lower blood pressure, reduce plasma norepinephrine levels, has diuretic and natriuretic effects, and has sympathostatic properties.
|
-
- HY-Y0123R
-
|
|
Drug Derivative
Reference Standards
|
Infection
Neurological Disease
|
|
DL-Tyrosine (Standard) is the analytical standard of DL-Tyrosine (HY-Y0123). This product is intended for research and analytical applications. DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine) .
|
-
- HY-B0932R
-
|
L-Propionylcarnitine chloride (Standard); ST-261 (Standard)
|
Integrin
NADPH Oxidase
Reference Standards
Others
|
Others
|
|
Adrenalone (hydrochloride) (Standard) is the analytical standard of Adrenalone (hydrochloride). This product is intended for research and analytical applications. Adrenalone hydrochloride is an adrenergic agonist used as a topical vasoconstrictor and hemostatic. Adrenalone hydrochloride is an inhibitor of dopamine β oxidase. Adrenalone hydrochloride is chemically similar to known norepinephrine transporter (NET) ligands with an IC50 of 36.9 μM .
|
-
- HY-12718
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
(±)-WB 4101 is a highly selective α1-adrenergic receptor antagonist. (±)-WB 4101 blocks norepinephrine-induced vascular smooth muscle contraction to exert antihypertensive and benign prostatic hyperplasia (BPH)-relieving effects. (±)-WB 4101 is promising for research of hypertension and BPH .
|
-
- HY-B0161AS1
-
|
(S)-Duloxetine-d7 hydrochloride; LY248686-d7 hydrochloride
|
Isotope-Labeled Compounds
Serotonin Transporter
|
Neurological Disease
Cancer
|
|
Duloxetine-d7 hydrochloride ((S)-Duloxetine-d7 hydrochloride) is the deuterium labeled Duloxetine hydrochloride (HY-B0161A). Duloxetine hydrochloride ((S)-Duloxetine hydrochloride) is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .
|
-
- HY-17385
-
|
Tomoxetine hydrochloride; (R)-Tomoxetine hydrochloride; LY 139603
|
Adrenergic Receptor
Serotonin Transporter
Sodium Channel
|
Neurological Disease
Cancer
|
|
Atomoxetine (Tomoxetine) hydrochloride is a selective noradrenaline reuptake inhibitor with Ki values of 5 nM, 77 nM and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine hydrochloride is a potent Na + channels (VGSCs) blocker. Atomoxetine hydrochloride can be used for attention-deficit hyperactivity disorder (ADHD) research .
|
-
- HY-172763
-
|
|
Drug Derivative
Serotonin Transporter
Dopamine Transporter
5-HT Receptor
|
Neurological Disease
|
|
EDMA hydrochloride is a derivative of MDMA. EDMA hydrochloride is a substrate for multiple neurotransmitter transporters, including serotonin transporter (SERT), dopamine transporter (DAT), and norepinephrine transporter (NET). EDMA hydrochloride has 5-HT releasing activity at SERT (EC50 = 117 nM) and MPP + releasing activity at DAT (EC50 = 597 nM) and NET (EC50 = 325 nM) .
|
-
- HY-13458A
-
|
L-DOPS hydrochloride; DOPS hydrochloride; SM5688 hydrochloride
|
Adrenergic Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Droxidopa (L-DOPS) hydrochloride is a potent, orally active norepinephrine precursor. Droxidopa hydrochloride increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa hydrochloride has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder) .
|
-
- HY-135615AR
-
|
N-Desmethylsibutramine hydrochloride (Standard)
|
Reference Standards
Serotonin Transporter
|
Neurological Disease
Metabolic Disease
|
|
Desmethyl Sibutramine (hydrochloride) (Standard) is the analytical standard of Desmethyl Sibutramine (hydrochloride). This product is intended for research and analytical applications. Desmethyl Sibutramine hydrochloride, the secondary metabolite of Sibutramine, is an orally active norepinephrine transporter (NET) and serotonin transporter (SERT) inhibitor. Desmethyl Sibutramine hydrochloride can be used in the research of obesity and appetite suppressant .
|
-
- HY-129040A
-
|
MIBG sulfate; Iobenguane sulfate
|
Adrenergic Receptor
|
Cancer
|
|
m-Iodobenzylguanidine sulfate (MIBG sulfate) is an analogue of the neurotransmitter norepinephrine with antitumor activity. Radioiodinated m-Iodobenzylguanidine sulfate is clinically used as a tumor-targeted radiopharmaceutical in the diagnosis and treatment of adrenergic tumors. m-Iodobenzylguanidine sulfate is a high-affinity substrate for cholera toxin that interferes with cellular mono(ADP-ribosylation) .
|
-
- HY-N4115R
-
|
Su 3118 (Standard)
|
Reference Standards
Monocarboxylate Transporter
|
Cardiovascular Disease
Cancer
|
|
Syrosingopine (Su 3118) is an orally active lactate transporters (MCT1/MCT4) dual inhibitor, which can reduce glycolysis and induce synthetic lethality in cancer cells when combine with metformin. Syrosingopine shows anti-hypertensive activity by depleting peripheral stores of norepinephrine .
|
-
- HY-N4115
-
|
Su 3118
|
Monocarboxylate Transporter
|
Cardiovascular Disease
Cancer
|
|
Syrosingopine (Su 3118) is an orally active lactate transporters (MCT1/MCT4) dual inhibitor, which can reduce glycolysis and induce synthetic lethality in cancer cells when combine with metformin. Syrosingopine shows anti-hypertensive activity by depleting peripheral stores of norepinephrine .
|
-
- HY-13458
-
|
L-DOPS; DOPS; SM5688
|
Adrenergic Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Droxidopa (L-DOPS; SM5688) is a potent, orally active norepinephrine precursor. Droxidopa increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder) .
|
-
- HY-13458S1
-
|
L-DOPS-13C2,15N hydrochloride; DOPS-13C2,15N hydrochloride; SM5688-13C2,15N hydrochloride
|
Adrenergic Receptor
Isotope-Labeled Compounds
|
Neurological Disease
|
|
Droxidopa- 13C2, 15N (hydrochloride) is deuterium labeled Droxidopa. Droxidopa(L-DOPS), the mixture of Droxidopa (w/w80%) and Pharmaceutical starch (w/w20%), acts as a proagent to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline); Droxidopa(L-DOPS) is capable of crossing the protective blood-brain barrier .
|
-
- HY-19013
-
|
|
Drug Derivative
|
Cardiovascular Disease
|
|
L44-0 is a nicotinic acid derivative. L44-0 reduces atherosclerotic lesions and decreases vascular norepinephrine levels in the renal arteries, femoral arteries, and veins in a New Zealand white rabbit model of atherosclerosis. L44-0 can be used in research on cardiovascular and cerebrovascular diseases such as atherosclerosis .
|
-
- HY-W438378
-
|
HMPG piperazine
|
Biochemical Assay Reagents
|
Others
|
|
4-Hydroxy-3-methoxyphenylglycol piperazine (HMPG piperazine) is a salt of HMPG combined with piperazine. HMPG is a metabolite of adrenaline and norepinephrine and is an important marker of catecholamine hormone metabolism in the body. 4-Hydroxy-3-methoxyphenylglycol piperazine is used as a standard in clinical laboratories to accurately measure the HMPG content in urine .
|
-
- HY-123044
-
-
- HY-N16748
-
|
|
Others
|
Cardiovascular Disease
|
|
Heptazoline is a carbazole alkaloid that can be isolated from the stem bark of Clausena excavata. Heptazoline exhibits significant antiplatelet aggregation activity (inhibiting platelet aggregation induced by arachidonic acid, collagen, etc.) and certain vasodilatory activity (inhibiting norepinephrine-induced contraction of rat aorta). Heptazoline can be used in antithrombotic research in the cardiovascular field .
|
-
- HY-14258
-
|
(S)-Citalopram; (S)-(+)-Citalopram
|
Serotonin Transporter
|
Neurological Disease
|
|
Escitalopram ((S)-Citalopram), the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram is an antidepressant for the research of major depression .
|
-
- HY-174833
-
|
|
Monoamine Oxidase
|
Neurological Disease
|
|
MAO-A-IN-2 (Compound 4l) is a selective monoamine oxidase A (MAO-A) inhibitor with an IC50 value of 0.4 μM. MAO-A-IN-2 reduces the degradation of monoamine neurotransmitters (e.g., serotonin, norepinephrine). MAO-A-IN-2 is promising for research of neurological diseases related to monoamine neurotransmitter imbalance such as depression and anxiety disorders .
|
-
- HY-101435
-
|
CNPZ
|
5-HT Receptor
Adrenergic Receptor
|
Neurological Disease
|
|
Centpropazine (CNPZ) is a brain-penetrant and non-selective antagonist of serotonin (5-HT1/5-HT2) and adrenergic (α1) receptors. Centpropazine functions by modulating monoamine neurotransmission, particularly reducing serotonin and norepinephrine reuptake, to exert antidepressant effects. Centpropazine is promising for research of depression .
|
-
- HY-159106
-
-
- HY-N7647
-
|
Brevifolincarboxylic acid methyl ester
|
Influenza Virus
|
Infection
Cardiovascular Disease
Inflammation/Immunology
|
|
Methyl brevifolincarboxylate (Brevifolincarboxylic acid methyl ester) is a potent influenza virus PB2 cap-binding inhibitor. Methyl brevifolincarboxylate has anti-oxidant activity. Methyl brevifolincarboxylate also inhibits platelet aggregation, lipid metabolism and inflammation .
|
-
- HY-116062A
-
|
|
Histone Methyltransferase
|
Neurological Disease
|
|
JNJ-7925476 is a triple reuptake inhibitor that selectively and potently inhibits the activity of the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT). JNJ-7925476 is rapidly absorbed into the blood and its concentration in the brain is 7-fold higher than that in plasma. The occupancy ED(50) values of JNJ-7925476 for SERT, NET, and DAT in the rat brain are 0.18, 0.09, and 2.4 mg/kg, respectively. JNJ-7925476 rapidly induces a significant increase in the levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex in a dose-dependent manner. JNJ-7925476 exhibits potent antidepressant-like activity in the mouse tail suspension test. These results suggest that JNJ-7925476 has in vivo efficacy in biochemical and behavioral models of depression .
|
-
- HY-B1237A
-
|
|
Calcium Channel
Fungal
|
Cardiovascular Disease
Infection
|
|
Suloctidil hydrochloride is an orally active calcium channel blocker and antifungal agent. Suloctidil hydrochloride antagonizes vasoconstriction induced by norepinephrine, angiotensin and serotonin. Suloctidil hydrochloride inhibits platelet function and exhibits neuroprotective effects. Suloctidil hydrochloride exerts inhibitory effects on Candida albicans biofilm and virulence. Suloctidil hydrochloride can be used in research on vasospasm relief, antithrombosis and superficial candidiasis .
|
-
- HY-B0562R
-
|
|
Reference Standards
Carbonic Anhydrase
|
Cardiovascular Disease
Metabolic Disease
|
|
Methyclothiazide (Standard) is the analytical standard of Methyclothiazide. This product is intended for research and analytical applications. Methyclothiazide is an orally active antihypertensive agent and a diuretic agent. Methyclothiazide leads to a reduction of the vascular response to the action of endogenous vasoconstricting stimuli, such as Norepinephrine (HY-13715). Methyclothiazide is against voltage-dependent Ca-channel (VDCC) activity in vitro .
|
-
- HY-P1685
-
|
|
Bombesin Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Ranatensin is a undecapeptide and a Bombesin Receptor angonist, can be isolated from amphibian skin, such as the frog, Rana pipiens. Ranatensin could maintain the dynamic balance of animal blood pressure, without cross-tachyphylaxis with Angiotensin amide (HY-P2212),Bradykinin (HY-P0206), or Norepinephrine (HY-13715) .
|
-
- HY-W700149
-
|
|
Isotope-Labeled Compounds
Drug Metabolite
|
Cancer
|
|
N,O-Didesmethylvenlafaxine-d3 is the deuterium labeled N,O-Didesmethylvenlafaxine (HY-138818). N,O-Didesmethylvenlafaxine (NODVFX) is a metabolite of Venlafaxine (VFX; HY-B0196). Venlafaxine (Wy 45030) is an orally active, potent serotonin (5-HT)/norepinephrine (NE) reuptake dual inhibitor .
|
-
- HY-126158
-
|
|
Dopamine Transporter
Serotonin Transporter
|
Neurological Disease
|
|
SRI-29574 is an allosteric modulator of the dopamine transporter (DAT). SRI-29574 partially inhibits the uptake of the DAT (IC50=2.3 nM) and also partially inhibits the uptake of the serotonin transporter (SERT) and norepinephrine transporter (NET). SRI-29574 may serve as a useful probe to study the function and regulatory mechanisms of DAT .
|
-
- HY-101755
-
-
- HY-14258A
-
|
(S)-Citalopram oxalate; (S)-(+)-Citalopram oxalate
|
Serotonin Transporter
|
Neurological Disease
Cancer
|
|
Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .
|
-
- HY-N15737
-
|
|
Calcium Channel
Enterovirus
|
Infection
Cardiovascular Disease
|
|
Fukinolic acid is a benzyltartaric acid ester, is a vasodilator with antiviral activity against enterovirus A71 (EV-A71) replication. Fukinolic acid is a receptor-operated Ca 2+ channels (ROC) inhibitor, suppressing extracellular Ca 2+ influx through ROC activated by Norepinephrine (HY-13715) without affecting voltage-dependent Ca 2+ channels .
|
-
- HY-108513
-
|
|
Sigma Receptor
|
Neurological Disease
|
|
σ1 Receptor antagonist 4 (compound TC1) is a selective sigma1 (σ1) receptor antagonist with a Ki of 10 nM. σ1 Receptor antagonist 4 is weakly active at σ2 receptor (Ki of 370 nM) and has no activity at dopamine (DAT), serotonin (SERT), and norepinephrine (NET) transporters .
|
-
- HY-N0749
-
|
|
Cholinesterase (ChE)
5-HT Receptor
Bacterial
|
Neurological Disease
|
|
Jatrorrhizine is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine is a potent and orally active inhibitor of AChE (IC50=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .
|
-
- HY-B1199A
-
|
|
Monoamine Oxidase
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
Nialamide hydrochloride is a non-selective monoamine oxidase (MAO) inhibitor. Nialamide hydrochloride inhibits MAO and regulates ROS production. Nialamide hydrochloride induces hyperkinesis in animals, enhances the anticonvulsant effect of Diphenylhydantoin in mice, increases rectal temperature, and enhances the pressor effect of Norepinephrine. Nialamide hydrochloride can be used in the research of depression, inflammatory diseases, neurodegenerative diseases, and hypertension .
|
-
- HY-B1199
-
-
- HY-N0740
-
|
|
Cholinesterase (ChE)
5-HT Receptor
Bacterial
|
Neurological Disease
Inflammation/Immunology
|
|
Jatrorrhizine chloride is an alkaloid isolated from?Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine chloride is a potent and orally active inhibitor of?AChE?(IC50=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine chloride reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .
|
-
- HY-116062
-
|
|
Monoamine Transporter
Dopamine Transporter
Adrenergic Receptor
|
Others
|
|
JNJ-7925476 (hydrochloride) is a triple monoamine uptake inhibitor with the ability to regulate neurotransmitter levels and antidepressant activity. JNJ-7925476 (hydrochloride) can be rapidly absorbed into the plasma in rats, with a higher concentration in the brain than in plasma. It can induce an increase in the levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex, and exhibits antidepressant activity in the mouse tail suspension test.
|
-
- HY-B0991
-
-
- HY-B0602
-
|
O-Desmethylvenlafaxine
|
Environmental Pollutants
Serotonin Transporter
|
Neurological Disease
|
|
Desvenlafaxine, the succinate salt form of the isolated major active metabolite of Venlafaxine (HY-B0196), is an orally active and BBB penetrated 5-HT and norepinephrine reuptake inhibitor, with IC50 values of 47.3 nM and 531.3 nM for hSERT and hNET, respectively. Desvenlafaxine shows weak binding affinity (62% inhibition at 100 μM) at the human dopamine (DA) transporter .
|
-
- HY-12554
-
|
|
Vasopressin Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
|
Terlipressin is a vasopressin analogue with potent vasoactive properties. Terlipressin is a highly selective vasopressin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin exerts anti-inflammatory and anti-oxidative effects. Terlipressin has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research .
|
-
- HY-12554A
-
|
|
Vasopressin Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
|
Terlipressin diacetate is a vasopressin analogue with potent vasoactive properties. Terlipressin diacetate is a highly selective vasopressin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin diacetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin diacetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research .
|
-
- HY-135242
-
|
|
Adrenergic Receptor
|
Endocrinology
|
|
LY87130 free base is an octopamine-N-methyltransferase inhibitor with epinephrine-inhibiting activity. LY87130 free base can significantly reduce the basal level of epinephrine in the hypothalamus after administration. LY87130 free base has no significant effect on the basal levels of norepinephrine, 3,4-dihydroxyphenylacetic acid (DOPAC) and 5-hydroxyindoleacetic acid (5-HIAA) in the hypothalamus .
|
-
- HY-145487A
-
|
|
5-HT Receptor
Adrenergic Receptor
|
Neurological Disease
|
|
5-Hydroxy-6-methoxy (S)-duloxetine maleate is an orally active and brain-penetrant serotonin (5-HT) and norepinephrine (NE) reuptake inhibitor with antidepressant and analgesic activities. 5-Hydroxy-6-methoxy (S)-duloxetine maleate is promising for research of psychiatric and neurological disorders such as depression, diabetic neuropathic pain, generalized anxiety disorder, and fibromyalgia .
|
-
- HY-12554B
-
|
|
Vasopressin Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
|
Terlipressin acetate is a vasopressin analogue with potent vasoactive properties. Terlipressin acetate is a highly selective vasopressin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin acetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin acetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research .
|
-
- HY-107370
-
|
Tomoxetine; (R)-Tomoxetine
|
Serotonin Transporter
Sodium Channel
|
Neurological Disease
Cancer
|
|
Atomoxetine (Tomoxetine) is a selective noradrenaline reuptake inhibitor with Ki values of 5, 77 and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine (Tomoxetine) increases of DAEX and NEEX in the PFC and enhances catecholaminergic neurotransmission. Atomoxetine (Tomoxetine) is a potent Na + channels (VGSCs) blocker. Atomoxetine (Tomoxetine) can be used for attention-deficit hyperactivity disorder (ADHD) research .
|
-
- HY-E70007
-
|
COMT
|
Endogenous Metabolite
|
Neurological Disease
|
|
Catechol O-methyltransferase, porcine liver (COMT), the magnesium-dependent transfer of methyl groups from S-adenosyl methionine to a hydroxyl group on dopamine, converting it to 3-methoxytyramine. Catechol O-methyltransferase has two forms in tissues, a soluble form (S-COMT) and a membrane-bound form (MB-COMT). Catechol O-methyltransferase is to regulate epinephrine, norepinephrine, and dopamine levels in the brain .
|
-
- HY-B0602A
-
|
O-Desmethylvenlafaxine succinate hydrate
|
Serotonin Transporter
|
Neurological Disease
|
|
Desvenlafaxine succinate hydrate, the succinate salt form of the isolated major active metabolite of Venlafaxine (HY-B0196), is an orally active and BBB penetrated 5-HT and norepinephrine reuptake inhibitor, with IC50 values of 47.3 nM and 531.3 nM for hSERT and hNET, respectively. Desvenlafaxine succinate hydrate shows weak binding affinity (62% inhibition at 100 μM) at the human dopamine (DA) transporter .
|
-
- HY-111066
-
|
|
Dopamine Receptor
|
Others
|
|
JNJ-37822681 is a fast dissociating D2 antagonist with activity in inhibiting schizophrenia. JNJ-37822681 has high specificity for D2 receptors and is effective in animal models, inducing increased levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex, and exhibiting antidepressant activity in the mouse tail suspension test, while having a good brain distribution and lower prolactin release.
|
-
- HY-W699990
-
|
|
Isotope-Labeled Compounds
|
Others
|
|
4-(1,2-Dihydroxyethyl)benzene-1,2-diol-d5 is the deuterium labeled 4-(1,2-Dihydroxyethyl)benzene-1,2-diol (HY-W010066). 4-(1,2-Dihydroxyethyl)benzene-1,2-diol, a normal norepinephrine metabolite, is found to be associated with Menkes syndrome.
|
-
- HY-N0749A
-
|
|
Cholinesterase (ChE)
5-HT Receptor
Bacterial
|
Neurological Disease
Inflammation/Immunology
|
|
Jatrorrhizine hydroxide is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine hydroxide is a potent and orally active inhibitor of AChE (IC50=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine hydroxide reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .
|
-
- HY-17385R
-
|
Tomoxetine hydrochloride (Standard); (R)-Tomoxetine hydrochloride (Standard); LY 139603 (Standard)
|
Reference Standards
Adrenergic Receptor
Serotonin Transporter
Sodium Channel
|
Neurological Disease
Cancer
|
|
Atomoxetine (hydrochloride) (Standard) is the analytical standard of Atomoxetine (hydrochloride). This product is intended for research and analytical applications. Atomoxetine (Tomoxetine) hydrochloride is a selective noradrenaline reuptake inhibitor with Ki values of 5 nM, 77 nM and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine hydrochloride is a potent Na+ channels (VGSCs) blocker. Atomoxetine hydrochloride can be used for attention-deficit hyperactivity disorder (ADHD) research .
|
-
- HY-16170
-
|
O-Desmethylvenlafaxine succinate; Wy-45233 succinate
|
Serotonin Transporter
|
Neurological Disease
Metabolic Disease
|
|
Desvenlafaxine succinate, the succinate salt form of the isolated major active metabolite of Venlafaxine (HY-B0196), is an orally active and BBB penetrated 5-HT and norepinephrine reuptake inhibitor, with IC50 values of 47.3 nM and 531.3 nM for hSERT and hNET, respectively. Desvenlafaxine succinate (DVS) shows weak binding affinity (62% inhibition at 100 μM) at the human dopamine (DA) transporter .
|
-
- HY-133858
-
|
|
5-HT Receptor
|
Neurological Disease
|
|
25N-NBOMe hydrochloride, a 2C-N derivative, is a 5-HT2A and 5-HT2C receptors agonist with Ki values of 0.144 nM and 1.06 nM, respectively. 25N-NBOMe hydrochloride has little to no efficacy at inducing release of preloaded neurotransmitter from recombinant dopamine, serotonin and norepinephrine transporters .
|
-
- HY-P11313
-
|
Rat chromogranin A367–387
|
nAChR
Akt
|
Cardiovascular Disease
|
|
Catestatin (rat) (Rat chromogranin A367–387) is a potent, reversible, noncompetitive, and noncooperative nicotinic cholinergic antagonist derived from chromogranin A (A367-387). Catestatin (rat) inhibits norepinephrine release in rat PC12 pheochromocytoma cells (IC50 = 1.2 μM), and blocks desensitization of norepinephrine release (IC50 = 0.62 μM). Catestatin (rat) exerts antiadrenergic effects through the endothelial PI3K-AKT-eNOS pathway in rat papillary muscles and isolated cardiomyocytes. Catestatin (rat) maintains mitochondrial membrane potential in I/R cardiomyocytes and increases phosphorylation of AKT at S473, GSK3β at S9, PLB at T17, and eNOS at S1179. Catestatin (rat) reverses desensitization of 22Na + uptake. Catestatin (rat) can be used for the study of nicotinic cholinergic receptor regulation and catecholamine release control mechanisms .
|
-
- HY-W017113
-
|
|
Environmental Pollutants
Endogenous Metabolite
|
Metabolic Disease
|
|
2-Mercaptobenzothiazole is an activator of the aryl hydrocarbon receptor (AhR) , inhibiting thyroid hormone synthesis and dopamine beta-hydroxylase activity . 2-Mercaptobenzothiazole promotes bladder cancer cell invasion by altering the conformation of the AhR ligand binding domain (LBD), activating AhR transcription, and upregulating the mRNA and protein expression of target genes CYP1A1 and CYP1B1 . 2-Mercaptobenzothiazole inhibits thyroid peroxidase (TPO) with an IC50 value of 11.5 μM, induces histological changes such as follicular cell hypertrophy in Xenopus laevis tadpoles, delaying metamorphosis . 2-Mercaptobenzothiazole increases chromosomal aberrations and sister chromatid exchanges (SCEs) in Chinese hamster ovary (CHO) cells, and enhances carcinogenicity in F344/N rats . 2-Mercaptobenzothiazole inhibits norepinephrine synthesis in mice and completely blocks the conversion of exogenous dopamine to norepinephrine in rat cardiomyocytes .
|
-
- HY-N0126
-
|
|
Environmental Pollutants
Calcium Channel
Monoamine Oxidase
|
Cardiovascular Disease
Neurological Disease
|
|
Xanthone is a monoamine oxidase A (MAO-A) inhibitor with an IC50 of 0.84 µM. Xanthon inhibits Norepinephrine (HY-13715) and high-K +-induced vasoconstriction with IC50 values of 60.26 μM and 82.9 μM, respectively. Xanthon increases intracellular cyclic adenosine 3′,5′-monophosphate (cAMP) content and blocks Ca 2+ channels. Xanthone is the scaffold of several pharmacologically active compounds .
|
-
- HY-B1435R
-
|
Thymoxamine hydrochloride (Standard)
|
Adrenergic Receptor
Reference Standards
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
|
|
Moxisylyte (Thymoxamine) hydrochloride Standard is the analytical standard of Moxisylyte hydrochloride (HY-B1435). This product is intended for research and analytical applications. Moxisylyte (Thymoxamine) hydrochloride is a selective α1A-adrenergic receptor antagonist. Moxisylyte hydrochloride competitively antagonizes the activation mediated by norepinephrine. Moxisylyte hydrochloride relaxes penile cavernous smooth muscle and aids erectile function. Moxisylyte hydrochloride is applicable to research related to erectile dysfunction and multiple system atrophy.
|
-
- HY-118997
-
|
|
Dopamine Receptor
|
Neurological Disease
|
|
PD-89211 is a selective dopamine D4 receptor antagonist with a Ki value of 3.7 nM. PD-89211 reverses Quinpirole (HY-B1752A)-induced [3H]thymidine uptake in CHOpro5 cells (IC50 = 2.1 nM). PD-89211 regulates dopamine/norepinephrine metabolism in the hippocampus and can be used for research on central nervous system disorders such as schizophrenia .
|
-
- HY-W417914
-
|
4-MA hydrochloride
|
5-HT Receptor
Monoamine Transporter
Dopamine Receptor
|
Neurological Disease
|
|
4-Methylamphetamine hydrochloride is a 5-HT1A receptor agonist that induces hypothermia in rats by binding to the 5-HT1A receptor. Additionally, 4-Methylamphetamine hydrochloride acts on norepinephrine (NE), dopamine (DA), and serotonin (5-HT) transporters to increase the extracellular levels of these neurotransmitters. 4-Methylamphetamine hydrochloride can be used in the study of neurological disorders .
|
-
- HY-14258R
-
|
(S)-Citalopram (Standard); (S)-(+)-Citalopram (Standard)
|
Serotonin Transporter
Reference Standards
|
Neurological Disease
Cancer
|
|
Escitalopram (Standard) is the analytical standard of Escitalopram. This product is intended for research and analytical applications. Escitalopram ((S)-Citalopram), the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram has ~30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram is an antidepressant for the research of major depression .
|
-
- HY-13458R
-
|
L-DOPS (Standard); DOPS (Standard); SM5688 (Standard)
|
Reference Standards
Adrenergic Receptor
|
Neurological Disease
|
|
Droxidopa (Standard) is the analytical standard of Droxidopa. This product is intended for research and analytical applications. Droxidopa (L-DOPS; SM5688) is a potent, orally active norepinephrine precursor. Droxidopa increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder) .
|
-
- HY-P1080A
-
|
|
Calcium Channel
|
Neurological Disease
|
|
ω-Agatoxin IVA TFA is a potent, selective P/Q type Ca 2+ (Cav2.1) channel blocker with IC50 values of 2 nM and 90 nM. ω-Agatoxin IVA TFA inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA TFA inhibits Capsaicin (HY-10448)-induced CGRP release and vasodilation. ω-Agatoxin IVA TFA can be used for the research of neurological and cardiovascular disease .
|
-
- HY-B0991S
-
-
- HY-B1110
-
|
(±)-Nomifensine; Nomifensin
|
Dopamine Receptor
Adrenergic Receptor
|
Neurological Disease
|
|
Nomifensine ((±)-Nomifensine) is a potent norepinephrine (NE) and dopamine (DA) reuptake inhibitor. Nomifensine inhibits uptake of NE, DA and 5-HT in rat brain synaptosomes, with IC50 values of 6.6 nM, 48 nM and 830 nM, and Ki values of 4.7 nM, 26 nM and 4000 nM, respectively. Nomifensine has antidepressant and analgesic effects. Nomifensine is used in neurodegenerative diseases, compound addiction, and pain research .
|
-
- HY-129040AR
-
|
MIBG sulfate (Standard); Iobenguane sulfate (Standard)
|
Adrenergic Receptor
Reference Standards
|
Cancer
|
|
m-Iodobenzylguanidine (sulfate) (Standard) is the analytical standard of m-Iodobenzylguanidine (sulfate). This product is intended for research and analytical applications. m-Iodobenzylguanidine sulfate (MIBG sulfate) is an analogue of the neurotransmitter norepinephrine with antitumor activity. Radioiodinated m-Iodobenzylguanidine sulfate is clinically used as a tumor-targeted radiopharmaceutical in the diagnosis and treatment of adrenergic tumors. m-Iodobenzylguanidine sulfate is a high-affinity substrate for cholera toxin that interferes with cellular mono(ADP-ribosylation) .
|
-
- HY-N15735
-
|
2-Caffeoylpiscidic acid
|
Calcium Channel
|
Cardiovascular Disease
|
|
Cimicifugic acid D (2-Caffeoylpiscidic acid) is a benzyltartaric acid ester that induces vasodilation of precontracted rat aortic strips and endothelium-independent relaxation mechanism. Cimicifugic acid D inhibits extracellular Ca 2+ influx through receptor-operated Ca 2+ channels (ROC) in Norepinephrine (HY-13715)-induced contraction of rat aortic strips, without affecting voltage-dependent Ca 2+ channels (VDC) or K +-induced contractions .
|
-
- HY-14258AS
-
|
|
Serotonin Transporter
|
Neurological Disease
|
|
Escitalopram-d6 (oxalate) is the deuterium labeled Escitalopram oxalate. Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ~30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .
|
-
- HY-17385S1
-
|
Tomoxetine-d7 hydrochloride; (R)-Tomoxetine-d7 hydrochloride
|
Isotope-Labeled Compounds
Serotonin Transporter
Adrenergic Receptor
Sodium Channel
|
Neurological Disease
Cancer
|
|
Atomoxetine-d7 hydrochloride (Tomoxetine-d7 hydrochloride) is the deuterium labeled Atomoxetine hydrochloride (HY-17385). Atomoxetine (Tomoxetine) hydrochloride is a selective noradrenaline reuptake inhibitor with Ki values of 5 nM, 77 nM and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine hydrochloride is a potent Na+ channels (VGSCs) blocker. Atomoxetine hydrochloride can be used for attention-deficit hyperactivity disorder (ADHD) research .
|
-
- HY-B0602S3
-
|
|
Isotope-Labeled Compounds
Serotonin Transporter
|
Neurological Disease
|
|
Desvenlafaxine-d10 is deuterium labeled Desvenlafaxine. Desvenlafaxine, the succinate salt form of the isolated major active metabolite of Venlafaxine (HY-B0196), is an orally active and BBB penetrated 5-HT and norepinephrine reuptake inhibitor, with IC50 values of 47.3 nM and 531.3 nM for hSERT and hNET, respectively. Desvenlafaxine shows weak binding affinity (62% inhibition at 100 μM) at the human dopamine (DA) transporter .
|
-
- HY-180358
-
|
|
mAChR
Cholinesterase (ChE)
|
Inflammation/Immunology
|
|
Gallamine is an allosteric, selective muscarinic M2 acetylcholine receptor antagonist (EC50: 130 nM for [ 3H]NMS dissociation from porcine muscarinic M2 receptors). Gallamine is also an acetylcholinesterase inhibitor (IC50s : 1070 μM, 1480 μM, 235 μM for EeAChE, hAChE, hBChE, respectively (in the absence of MeCN)). Gallamine increases free norepinephrine levels. Gallamine can be used as a muscle relaxant .
|
-
- HY-B0602S2
-
|
|
Isotope-Labeled Compounds
Serotonin Transporter
|
Neurological Disease
|
|
Desvenlafaxine-d6 is deuterium labeled Desvenlafaxine. Desvenlafaxine, the succinate salt form of the isolated major active metabolite of Venlafaxine (HY-B0196), is an orally active and BBB penetrated 5-HT and norepinephrine reuptake inhibitor, with IC50 values of 47.3 nM and 531.3 nM for hSERT and hNET, respectively. Desvenlafaxine shows weak binding affinity (62% inhibition at 100 μM) at the human dopamine (DA) transporter .
|
-
- HY-14258AS1
-
|
(S)-Citalopram-d4 oxalate; (S)-(+)-Citalopram-d4 oxalate
|
Isotope-Labeled Compounds
Serotonin Transporter
|
Neurological Disease
|
|
Escitalopram-d4 (oxalate) is deuterium labeled Escitalopram (oxalate). Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ~30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .
|
-
- HY-13458S2
-
|
L-DOPS-13C6; DOPS-13C6; SM5688-13C6
|
Isotope-Labeled Compounds
Adrenergic Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Droxidopa- 13C6 (L-DOPS- 13C6) is 13C labeled Droxidopa. Droxidopa (L-DOPS; SM5688) is a potent, orally active norepinephrine precursor. Droxidopa increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder) .
|
-
- HY-B1110A
-
|
(±)-Nomifensine maleate; Nomifensin maleate
|
Dopamine Receptor
Adrenergic Receptor
|
Neurological Disease
|
|
Nomifensine ((±)-Nomifensine) maleate is a potent norepinephrine (NE) and dopamine (DA) reuptake inhibitor. Nomifensine maleate inhibits uptake of NE, DA and 5-HT in rat brain synaptosomes, with IC50 values of 6.6 nM, 48 nM and 830 nM, and Ki values of 4.7 nM, 26 nM and 4000 nM, respectively. Nomifensine maleate has antidepressant and analgesic effects. Nomifensine maleate is used in neurodegenerative diseases, compound addiction, and pain research .
|
-
- HY-106865
-
|
|
Dopamine Receptor
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Mivazerol is a selective α2-adrenoceptor agonist. Mivazerol decreases the spontaneous release of serotonin (5-HT) and significantly inhibits the immobilization stress-induced enhancement of norepinephrine (NE), dopamine (DA) and dihydroxyphenylacetic acid (DOPAC). Mivazerol inhibits intrathecal release of glutamate evoked by halothane withdrawal in rats, and exerts neuroprotective effects in forebrain ischemia rats. Mivazerol can be used for myocardial ischemia research .
|
-
- HY-N0740R
-
|
|
Reference Standards
Cholinesterase (ChE)
5-HT Receptor
Bacterial
|
Neurological Disease
Inflammation/Immunology
|
|
Jatrorrhizine (chloride) (Standard) is the analytical standard of Jatrorrhizine (chloride). This product is intended for research and analytical applications. Jatrorrhizine chloride is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine chloride is a potent and orally active inhibitor of AChE (IC50=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine chloride reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .
|
-
- HY-14258AR
-
|
(S)-Citalopram oxalate (Standard); (S)-(+)-Citalopram oxalate (Standard)
|
Reference Standards
Serotonin Transporter
|
Neurological Disease
Cancer
|
|
Escitalopram (oxalate) (Standard) is the analytical standard of Escitalopram (oxalate). This product is intended for research and analytical applications. Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .
|
-
- HY-P1544A
-
|
|
Calcium Channel
PKA
Endogenous Metabolite
Adenylate Cyclase
|
Neurological Disease
Metabolic Disease
|
|
Cerebellin TFA is a neuromodulatory hexadecapeptide that serves as a marker for Purkinje cell maturation. Cerebellin TFA stimulates norepinephrine release via the adenylate cyclase/PKA-dependent signaling pathway. Cerebellin TFA reduces insulin secretion from pancreatic islets under high-glucose conditions. Cerebellin TFA also regulates synaptic structure formation and controls catecholamine secretion in peripheral tissues. Cerebellin TFA can be used in neurological research .
|
-
- HY-B0991R
-
|
CL-67772 (Standard)
|
Reference Standards
Autophagy
Bacterial
|
Infection
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
Amoxapine (Standard) is the analytical standard of Amoxapine. This product is intended for research and analytical applications. Amoxapine (CL-67772) is a norepinephrine reuptake blocker and a 5-HT2/5-HT3 antagonist. Amoxapine can be used for the research of depression. Amoxapine has antibacterial activity. Amoxapine can enhance the killing effect of macrophages on mycobacterium by inducing autophagy, while protecting the cells from death .
|
-
- HY-107370A
-
|
(Rac)-Tomoxetine hydrochloride; (Rac)-LY 139603
|
Serotonin Transporter
Sodium Channel
|
Metabolic Disease
Cancer
|
|
(Rac)-Atomoxetine hydrochloride ((Rac)-Tomoxetine (hydrochloride); (Rac)-LY 139603) is the racemic mixture of Atomoxetine hydrochloride (HY-17385). Atomoxetine hydrochloride is a selective noradrenaline reuptake inhibitor with Ki values of 5, 77 and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine hydrochloride increases of DAEX and NEEX in the PFC and enhances catecholaminergic neurotransmission. Atomoxetine hydrochloride is a potent Na + channels (VGSCs) blocker. Atomoxetine hydrochloride can be used for attention-deficit hyperactivity disorder (ADHD) research .
|
-
- HY-W116433
-
|
|
Dopamine Receptor
|
Neurological Disease
|
|
SK609 is a selective dopamine D3 receptor agonist with activity that improves dopamine and norepinephrine levels in the cerebral cortex. SK609 has been successfully used to suppress dyskinesias in Parkinson's disease models and alleviated muscle twitches induced by L-dopa. SK609 improved performance in sustained attention tasks by significantly reducing misses and false alarms. SK609 may provide an inhibitory option for suppressing movement and cognitive impairment in patients with Parkinson's disease .
|
-
- HY-B0602R
-
|
O-Desmethylvenlafaxine (Standard)
|
Reference Standards
Serotonin Transporter
|
Neurological Disease
|
|
Desvenlafaxine (Standard) is the analytical standard of Desvenlafaxine. This product is intended for research and analytical applications. Desvenlafaxine, the succinate salt form of the isolated major active metabolite of Venlafaxine (HY-B0196), is an orally active and BBB penetrated 5-HT and norepinephrine reuptake inhibitor, with IC50 values of 47.3 nM and 531.3 nM for hSERT and hNET, respectively. Desvenlafaxine shows weak binding affinity (62% inhibition at 100 μM) at the human dopamine (DA) transporter .
|
-
- HY-N2426R
-
|
|
Reference Standards
Interleukin Related
|
Inflammation/Immunology
|
|
Desvenlafaxine (Standard) is the analytical standard of Desvenlafaxine. This product is intended for research and analytical applications. Desvenlafaxine, the succinate salt form of the isolated major active metabolite of Venlafaxine (HY-B0196), is an orally active and BBB penetrated 5-HT and norepinephrine reuptake inhibitor, with IC50 values of 47.3 nM and 531.3 nM for hSERT and hNET, respectively. Desvenlafaxine shows weak binding affinity (62% inhibition at 100 μM) at the human dopamine (DA) transporter .
|
-
- HY-101607A
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
KT-362 free acid is an intracellular calcium antagonist with antiarrhythmic and vasodilatory effects. KT-362 free acid shows an antagonistic effect against norepinephrine (NE) induced vasoconstriction response, achieved by reducing inositol phospholipid hydrolysis, thereby reducing intracellular calcium mobilization. KT-362 free acid can be used to study the contraction and relaxation mechanisms of vascular smooth muscle, especially in exploring the role of intracellular calcium mobilization and inositol phospholipid hydrolysis in vascular contraction .
|
-
- HY-12554AR
-
|
|
Vasopressin Receptor
Reference Standards
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
|
Terlipressin (diacetate) (Standard) is the analytical standard of Terlipressin (diacetate). This product is intended for research and analytical applications. Terlipressin diacetate is a vasopressin analogue with potent vasoactive properties. Terlipressin diacetate is a highly selective vasopressin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin diacetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin diacetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research .
|
-
- HY-117542
-
|
|
Histone Methyltransferase
|
Neurological Disease
|
|
D595 is a phenylethylamine calcium channel blocker with potent negative inotropic activity. D595 has shown significant efficacy in its corresponding pharmacological studies, especially in inhibiting the uptake of monoamine neurotransmitters. D595 has high affinity in binding to the dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET). Structural adjustments of D595, especially changes in the hydroxyl stereochemistry, significantly affect its interaction with the transporters, showing a specific preference for stereoisomers .
|
-
- HY-111283
-
|
(+)-AJ 76; (1S,2R)-AJ 76
|
Dopamine Receptor
|
Neurological Disease
|
|
AJ-76 ((+)-AJ 76; (1S,2R)-AJ 76) is a dopamine autoreceptor antagonist. AJ-76 can increase the synthesis and turnover of dopamine in the rat brain, while having little effect on the synthesis and turnover of serotonin (5-HT) and norepinephrine. AJ-76 can also antagonize the sedative effects of low-dose apomorphine and has a weak antagonistic effect on postsynaptic dopamine receptor .
|
-
- HY-10121B
-
-
- HY-32329
-
|
Org-8282
|
5-HT Receptor
Adrenergic Receptor
|
Neurological Disease
|
|
Setiptiline (Org-8282) is a serotonin receptor antagonist. Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). Setiptiline acts as a norepinephrine reuptake inhibitor, α2-adrenergic receptor antagonist, and serotonin receptor antagonist, likely at the 5-HT2A, 5-HT2C, and/or 5-HT3 subtypes, as well as an H1 receptor inverse agonist/antihistamine.
|
-
- HY-121670
-
|
|
Others
|
Neurological Disease
|
|
Ambenoxan is a central nervous system-acting skeletal muscle relaxant that is effective in mice, rats, rabbits, dogs, and monkeys without loss of the righting reflex. It has no peripheral neuromuscular blocking effects and significantly reduces or eliminates decerebrate rigidity in rabbits, but does not antagonize the effects of strychnine, leptazol, or tremorine. Like other central nervous system depressants, ambenoxan prolongs sleep duration with hexobarbitone, but it has no local anesthetic effects. In anesthetized cats, the agent lowers blood pressure and reduces the pressor response to epinephrine, but has no effect on norepinephrine.
|
-
- HY-107370S
-
|
Tomoxetine-d7; (R)-Tomoxetine-d7
|
Isotope-Labeled Compounds
Serotonin Transporter
Sodium Channel
|
Neurological Disease
Cancer
|
|
Atomoxetine-d7 (Tomoxetine-d7) is deuterium labeled Atomoxetine. Atomoxetine (Tomoxetine) is a selective noradrenaline reuptake inhibitor with Ki values of 5, 77 and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine (Tomoxetine) increases of DAEX and NEEX in the PFC and enhances catecholaminergic neurotransmission. Atomoxetine (Tomoxetine) is a potent Na + channels (VGSCs) blocker. Atomoxetine (Tomoxetine) can be used for attention-deficit hyperactivity disorder (ADHD) research .
|
-
- HY-101755R
-
|
Lu AA24530 hydrobromide (Standard)
|
Reference Standards
5-HT Receptor
Adrenergic Receptor
|
Neurological Disease
Endocrinology
|
|
Tedatioxetine hydrobromide (Standard) (Lu AA24530 hydrobromide (Standard)) is the analytical standard of Tedatioxetine hydrobromide (HY-101755). This product is intended for research and analytical applications. Tedatioxetine (Lu AA24530) hydrobromide acts as a serotonin and norepinephrine (NE)-preferring triple reuptake inhibitor (TRI) and 5-HT2A, 5-HT2C, 5-HT3 and α1A-adrenergic receptor antagonist .
,
|
-
- HY-12798
-
|
AR-13324
|
Monoamine Transporter
ROCK
|
Cardiovascular Disease
Neurological Disease
|
|
Netarsudil (AR-13324) is a competitive inhibitor of Rho-associated protein kinases (ROCK I and ROCK II) and a reversible inhibitor of the norepinephrine transporter (NET). Netarsudil reduces intraocular pressure by inhibiting ROCK, causing relaxation of trabecular meshwork cells and dilation of episcleral veins, thereby increasing the ease of aqueous humor outflow, while inhibiting NET to reduce aqueous humor production. Netarsudil is mainly used in the study of ocular hypertension and primary open-angle glaucoma .
|
-
- HY-121670A
-
|
|
Adrenergic Receptor
|
Neurological Disease
|
|
Ambenoxan hydrochloride is a central nervous system-acting skeletal muscle relaxant that is effective in mice, rats, rabbits, dogs, and monkeys without loss of the righting reflex. It has no peripheral neuromuscular blocking effects and significantly reduces or eliminates decerebrate rigidity in rabbits, but does not antagonize the effects of strychnine, leptazol, or tremorine. Like other central nervous system depressants, ambenoxan prolongs sleep duration with hexobarbitone, but it has no local anesthetic effects. In anesthetized cats, the agent lowers blood pressure and reduces the pressor response to epinephrine, but has no effect on norepinephrine.
|
-
- HY-B1110AR
-
|
(±)-Nomifensine maleate (Standard); Nomifensin maleate (Standard)
|
Dopamine Receptor
Adrenergic Receptor
Reference Standards
|
Neurological Disease
|
|
Nomifensine (maleate) (Standard) is the analytical standard of Nomifensine (maleate). This product is intended for research and analytical applications. Nomifensine ((±)-Nomifensine) maleate is a potent norepinephrine (NE) and dopamine (DA) reuptake inhibitor. Nomifensine maleate inhibits uptake of NE, DA and 5-HT in rat brain synaptosomes, with IC50 values of 6.6 nM, 48 nM and 830 nM, and Ki values of 4.7 nM, 26 nM and 4000 nM, respectively. Nomifensine maleate has antidepressant and analgesic effects. Nomifensine maleate is used in neurodegenerative diseases, compound addiction, and pain research .
|
-
- HY-14196
-
|
MD 69276
|
Monoamine Oxidase
|
Neurological Disease
|
|
Toloxatone (MD 69276) is a reversible, selective MAO-A inhibitor that can cross the blood-brain barrier. Toloxatone increases the levels of serotonin (5-HT) and norepinephrine in the brain. Toloxatone reduces the immobility time in the forced swimming test in mice, inhibits killing behavior in rats without causing sedation, and shows a correlation between its free plasma concentration and cerebrospinal fluid concentration. Toloxatone is widely used in research related to depression, depressive disorders and Parkinson's disease .
|
-
- HY-107370S1
-
|
Tomoxetine-d5; (R)-Tomoxetine-d5
|
Isotope-Labeled Compounds
|
Neurological Disease
Cancer
|
|
Atomoxetine-d5 (Tomoxetine-d5) is deuterium labeled Atomoxetine. Atomoxetine (Tomoxetine) is a selective noradrenaline reuptake inhibitor with Ki values of 5, 77 and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine (Tomoxetine) increases of DAEX and NEEX in the PFC and enhances catecholaminergic neurotransmission. Atomoxetine (Tomoxetine) is a potent Na + channels (VGSCs) blocker. Atomoxetine (Tomoxetine) can be used for attention-deficit hyperactivity disorder (ADHD) research .
|
-
- HY-B1110R
-
|
(±)-Nomifensine (Standard); Nomifensin (Standard)
|
Dopamine Receptor
Adrenergic Receptor
Reference Standards
|
Neurological Disease
|
|
Nomifensine (Standard) is the analytical standard of Nomifensine. This product is intended for research and analytical applications. Nomifensine ((±)-Nomifensine) is a potent norepinephrine (NE) and dopamine (DA) reuptake inhibitor. Nomifensine inhibits uptake of NE, DA and 5-HT in rat brain synaptosomes, with IC50 values of 6.6 nM, 48 nM and 830 nM, and Ki values of 4.7 nM, 26 nM and 4000 nM, respectively. Nomifensine has antidepressant and analgesic effects. Nomifensine is used in neurodegenerative diseases, compound addiction, and pain research .
|
-
- HY-10121R
-
-
- HY-B0725
-
|
|
Histamine Receptor
Cytochrome P450
|
Neurological Disease
Cancer
|
|
Doxepin hydrochloride is an orally active tricyclic antidepressant agent. Doxepin hydrochloride is a potent and selective histamine receptor H1 antagonist. Doxepin hydrochloride is also a potent CYP450 inhibitor and significantly inhibits CYP450 2C19 and 1A2 . Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant .. Doxepin has therapeutic effects in atopic dermatitis,chronic urticarial,can improve cognitive processes, protect central nervous system .. Doxepin has also been proposed as a protective factor against oxidative stress ..
|
-
- HY-122300B
-
|
Levoprotiline
|
Adrenergic Receptor
|
Neurological Disease
|
|
R-(-)-Oxaprotiline (Levoprotiline) is an antidepressant with anticholinergic and sympathostimulatory activities. R-(-)-Oxaprotiline exhibits different abilities to block norepinephrine uptake and anticholinergic activity compared to its enantiomer C 49802 B-Ba. R-(-)-Oxaprotiline in human studies shows physiological effects consistent with those in animals. Administration of R-(-)-Oxaprotiline results in a modest increase in heart rate and arterial blood pressure. Salivation is inhibited with R-(-)-Oxaprotiline, consistent with its anticholinergic properties. R-(-)-Oxaprotiline has similar effects to the established antidepressant compound Levoprotiline and has a shorter onset of action .
|
-
- HY-18610
-
|
Ro 8-4650 hydrochloride
|
Dopamine Transporter
Adrenergic Receptor
5-HT Receptor
|
Neurological Disease
|
|
Diclofensine (Ro 8-46500) hydrochloride is an orally active neuronal monoamine uptake inhibitor. Diclofensine hydrochloride blocks the uptake of dopamine, noradrenaline, and serotonin by rat brain synaptosomes with IC50 values of 0.74, 2.3 and 3.7 nM, respectively. Diclofensine hydrochloride potentiates norepinephrine-induced hypertension and attenuates Tyramine (HY-W007606)-induced hypertension. Diclofensine hydrochloride produces psychostimulant and mood-elevating effects without causing sudden disappearance or withdrawal reactions. Diclofensine hydrochloride can be used in the research of moderate to severe depression .
|
-
- HY-118387
-
|
|
Potassium Channel
|
Cardiovascular Disease
|
|
AVE-0118 is a Kv1.5 potassium channel blocker and antiarrhythmic agent. AVE-0118 blocks neuronal Kv1.5 potassium channels, thereby enhancing the release of norepinephrine. AVE-0118 enhances field stimulation-induced neurogenic contraction, an effect sensitive to α1-adrenergic receptor blockade. AVE-0118 terminates persistent atrial fibrillation in some dogs. AVE-0118 is applicable to research related to atrial fibrillation and persistent atrial fibrillation .
|
-
- HY-B0193AR
-
|
|
Reference Standards
Adrenergic Receptor
Autophagy
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Prazosin (hydrochloride) (Standard) is the analytical standard of Prazosin (hydrochloride). This product is intended for research and analytical applications. Prazosin hydrochloride is a well-tolerated, CNS-active α1-adrenergic receptor antagonist for the research of high blood pressure and alcohol use disorders . Prazosin hydrochloride potently inhibits Norepinephrine (NE)-stimulated 45Ca efflux with an IC50 of 0.15 nM .Prazosin hydrochloride inhibits organic cation transporters OCT-1 and OCT-3 with IC50s of 1.8, and 13 μM, respectively .
|
-
- HY-14472S
-
|
NS-2330-d5
|
Isotope-Labeled Compounds
Serotonin Transporter
Dopamine Transporter
|
Metabolic Disease
|
|
Tesofensine-d5 (NS-2330-d5) is the deuterium labeled Tesofensine (HY-14472). Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent. Tesofensine is a CNS acting anti-obesity agent.
|
-
- HY-12798A
-
|
AR-13324 dimesylate
|
ROCK
|
Cardiovascular Disease
Neurological Disease
|
|
Netarsudil (AR-13324) dimesylate is a competitive inhibitor of Rho-associated protein kinases (ROCK I and ROCK II) and a reversible inhibitor of the norepinephrine transporter (NET). Netarsudil dimesylate reduces intraocular pressure by inhibiting ROCK, causing relaxation of trabecular meshwork cells and dilation of episcleral veins, thereby increasing the ease of aqueous humor outflow, while inhibiting NET to reduce aqueous humor production. Netarsudil dimesylate is mainly used in the study of ocular hypertension and primary open-angle glaucoma .
|
-
- HY-B1110S
-
|
(±)-Nomifensine-d3 maleate; Nomifensin-d3 maleate
|
Isotope-Labeled Compounds
Dopamine Receptor
Adrenergic Receptor
|
Neurological Disease
|
|
Nomifensine-d3 ((±)-Nomifensine-d3) maleate is the deuterium labeled Nomifensine maleate (HY-B1110A). Nomifensine ((±)-Nomifensine) maleate is a potent norepinephrine (NE) and dopamine (DA) reuptake inhibitor. Nomifensine maleate inhibits uptake of NE, DA and 5-HT in rat brain synaptosomes, with IC50 values of 6.6 nM, 48 nM and 830 nM, and Ki values of 4.7 nM, 26 nM and 4000 nM, respectively. Nomifensine maleate has antidepressant and analgesic effects. Nomifensine maleate is used in neurodegenerative diseases, compound addiction, and pain research .
|
-
- HY-113323S
-
|
HMPG-d3; MHPG-d3; MOPEG-d3
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Neurological Disease
|
|
3-Methoxy-4-hydroxyphenylglycol-d3 (HMPG-d3) is the deuterium labeled 3-Methoxy-4-hydroxyphenylglycol. 3-Methoxy-4-hydroxyphenylglycol is a metabolite of norepinephrine degradation in the brain. 3-Methoxy-4-hydroxyphenylglycol (HMPG) serves as an indicator of noradrenergic activity in the central nervous system. 3-Methoxy-4-hydroxyphenylglycol (HMPG) can be used for research on diseases such as depression and chronic schizophrenia.
|
-
- HY-B1202R
-
|
AY-22284 (Standard)
|
Reference Standards
Aldose Reductase
|
Metabolic Disease
|
|
Alrestatin (AY-22284) Standard is the analytical standard of Alrestatin (HY-B1202). This product is intended for research and analytical applications. Alrestatin (AY-22284) is an aldose reductase inhibitor. Alrestatin reduces fructose levels in the uterine fluid of mice. Alrestatin interferes with sperm capacitation and impairs fertilization function in mice. Alrestatin decreases basal and tyramine-induced norepinephrine release in rat pancreatic specimens in vitro. Alrestatin enhances glucose- and arginine-stimulated insulin secretion in vivo. Alrestatin can be used in studies related to diabetes and reproductive diseases.
|
-
- HY-N0126R
-
|
|
Reference Standards
Monoamine Oxidase
Calcium Channel
|
Cardiovascular Disease
Neurological Disease
|
|
Xanthone (Standard) is the analytical standard of Xanthone (HY-N0126). This product is intended for research and analytical applications. Xanthone is a monoamine oxidase A (MAO-A) inhibitor with an IC50 of 0.84 µM. Xanthon inhibits Norepinephrine (HY-13715) and high-K +-induced vasoconstriction with IC50 values of 60.26 μM and 82.9 μM, respectively. Xanthon increases intracellular cyclic adenosine 3′,5′-monophosphate (cAMP) content and blocks Ca 2+ channels. Xanthone is the scaffold of several pharmacologically active compounds .
|
-
- HY-32329A
-
|
MO-8282
|
5-HT Receptor
|
Neurological Disease
|
|
Setiptiline maleate (MO-8282 maleate) is a serotonin receptor antagonist. Setiptiline maleate is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). Setiptiline maleate acts as a norepinephrine reuptake inhibitor, α2-adrenergic receptor antagonist, and serotonin receptor antagonist, likely at the 5-HT2A, 5-HT2C, and/or 5-HT3 subtypes, as well as an H1 receptor inverse agonist/antihistamine .
|
-
- HY-16567
-
-
- HY-10121S2
-
-
- HY-10121
-
-
- HY-103213
-
|
|
Adrenergic Receptor
|
Neurological Disease
Endocrinology
|
|
JP1302 dihydrochloride is a potent, selective, high affinity antagonist of the α2C-adrenoceptor, with a Kb of 16 nM and a Ki of 28 nM for the human α2C-receptor. JP1302 dihydrochloride shows antidepressant and antipsychotic-like effects. JP1302 dihydrochloride can be used for neuropsychiatric disorders and renal dysfunction research .
|
-
- HY-103213A
-
JP1302
2 Publications Verification
|
Adrenergic Receptor
|
Neurological Disease
|
|
JP1302 is a potent, selective, high affinity antagonist of the α2C-adrenoceptor, with a Kb of 16 nM and a Ki of 28 nM for the human α2C-receptor. JP1302 shows antidepressant and antipsychotic-like effects. JP1302 can be used for neuropsychiatric disorders and renal dysfunction research .
|
-
- HY-U00021
-
|
Clotixamide
|
Dopamine Receptor
|
Neurological Disease
|
|
Clothixamide (Clotixamide) is an orally active and brain-penetrant dopamine antagonist. Clothixamide can be used for the research of psychiatric disorders .
|
-
- HY-W769200
-
|
Org 5222-13C,d3 maleate
|
Isotope-Labeled Compounds
5-HT Receptor
Adrenergic Receptor
Dopamine Receptor
Histamine Receptor
|
Others
|
|
Asenapine- 13C,d3 Maleate is the deuterium labeled and 13C-Asenapine Maleate (HY-11100). Asenapine (Org 5222) Maleate, an atypical antipsychotic, is an antagonist of serotonin receptors (pKi: 8.4-10.5), adrenoceptors (pKi: 8.9-9.5), dopamine receptors (pKi: 8.9-9.4) and histamine receptors (pKi: 8.2-9.0). Asenapine Maleate can be used in the research of schizophrenia and bipolar disorder .
|
-
- HY-11100
-
|
Org 5222 maleate
|
5-HT Receptor
|
Neurological Disease
|
|
Asenapine (Org 5222) maleate, a brain-penetrant atypical antipsychotic, is an antagonist of serotonin receptors (pKi: 8.4-10.5), adrenoceptors (pKi: 8.9-9.5), dopamine receptors (pKi: 8.9-9.4) and histamine receptors (pKi: 8.2-9.0). Asenapine maleate can be used in the research of schizophrenia and bipolar disorder .
|
-
- HY-103213R
-
|
|
Reference Standards
Adrenergic Receptor
|
Neurological Disease
Endocrinology
|
|
JP1302 dihydrochloride (Standard) is the analytical standard of JP1302 dihydrochloride. This product is intended for research and analytical applications. JP1302 dihydrochloride is a potent, selective, high affinity antagonist of the α2C-adrenoceptor, with a Kb of 16 nM and a Ki of 28 nM for the human α2C-receptor. JP1302 dihydrochloride shows antidepressant and antipsychotic-like effects. JP1302 dihydrochloride can be used for neuropsychiatric disorders and renal dysfunction research .
|
-
- HY-18610R
-
|
Ro 8-4650 hydrochloride (Standard)
|
Reference Standards
Dopamine Transporter
Adrenergic Receptor
5-HT Receptor
|
Neurological Disease
|
|
Diclofensine (Ro 8-4650) hydrochloride (Standard) is the analytical standard of Diclofensine hydrochloride. This product is intended for research and analytical applications. Diclofensine hydrochloride is an orally active neuronal monoamine uptake inhibitor. Diclofensine hydrochloride blocks the uptake of dopamine, noradrenaline, and serotonin by rat brain synaptosomes with IC50 values of 0.74, 2.3 and 3.7 nM, respectively. Diclofensine hydrochloride potentiates norepinephrine-induced hypertension and attenuates Tyramine (HY-W007606)-induced hypertension. Diclofensine hydrochloride produces psychostimulant and mood-elevating effects without causing sudden disappearance or withdrawal reactions. Diclofensine hydrochloride can be used in the research of moderate to severe depression.
|
-
- HY-111124
-
|
BRL29060-d2
|
Isotope-Labeled Compounds
Serotonin Transporter
Adrenergic Receptor
P2X Receptor
Apoptosis
|
Neurological Disease
Cancer
|
|
Paroxetine-d2 (CTP 347) is a deuterium labeled Paroxetine (HY-122272). Paroxetine is an oral inhibitor that falls under the category of selective serotonin reuptake inhibitors (SSRIs). Paroxetine is also a very weak norepinephrine (NE) reuptake inhibitor, capable of inducing cell apoptosis and having anti-tumor activity. Paroxetine has antidepressant, anti-anxiety, and pain-relieving effects, and it can help improve conditions like obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual anxiety, and chronic headaches .
|
-
- HY-19732
-
|
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
BIBS 39 is a non-peptide angiotensin II receptor antagonist with antihypertensive activity, with higher affinity for the AT1 receptor than for the AT2 receptor. BIBS 39 competitively blocks AT1-mediated vasoconstriction and pressor responses, and effectively inhibits the activity of the renin-angiotensin-aldosterone system. BIBS 39 reduces diastolic blood pressure and induces mild, transient reflex tachycardia, with no off-target functional activity on the norepinephrine, K +/Cl − or vasopressin pathways. BIBS 39 can be used in research related to hypertension and renal hypertension [1][2 ][3].
|
-
- HY-12716A
-
|
|
Adrenergic Receptor
ERK
p38 MAPK
Dopamine Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
BRL-44408 maleate is a selective, blood-brain barrier-permeable α2A-adrenergic receptor antagonist with a Ki value of 8.56 nM against human targets. BRL-44408 maleate exhibits activities such as antidepressant, analgesic effects and attenuation of sepsis-induced acute lung injury by regulating the release of neurotransmitters such as norepinephrine and dopamine, or inhibiting signaling pathways including ERK1/2, p38MAPK and p65. BRL-44408 maleate can be used in studies related to acute respiratory distress syndrome, depression and visceral pain .
|
-
- HY-12716
-
|
|
Adrenergic Receptor
p38 MAPK
Dopamine Receptor
ERK
|
Cardiovascular Disease
Neurological Disease
|
|
BRL-44408 is a selective, blood-brain barrier-permeable α2A-adrenergic receptor antagonist with a Ki value of 8.56 nM against human targets. BRL-44408 exhibits activities such as antidepressant, analgesic effects and attenuation of sepsis-induced acute lung injury by regulating the release of neurotransmitters such as norepinephrine and dopamine, or inhibiting signaling pathways including ERK1/2, p38MAPK and p65. BRL-44408 can be used in studies related to acute respiratory distress syndrome, depression and visceral pain .
|
-
- HY-122272S
-
|
BRL29060-d4
|
Isotope-Labeled Compounds
Serotonin Transporter
Adrenergic Receptor
Apoptosis
P2X Receptor
|
Neurological Disease
Cancer
|
|
Paroxetine-d4 (BRL29060-d4) is deuterium labeled Paroxetine. Paroxetine is an oral inhibitor that falls under the category of selective serotonin reuptake inhibitors (SSRIs). Paroxetine is also a very weak norepinephrine (NE) reuptake inhibitor, capable of inducing cell apoptosis and having anti-tumor activity. Paroxetine has antidepressant, anti-anxiety, and pain-relieving effects, and it can help improve conditions like obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual anxiety, and chronic headaches .
|
-
- HY-14472S1
-
|
NS-2330-13C,d3
|
Isotope-Labeled Compounds
Serotonin Transporter
Dopamine Transporter
|
Metabolic Disease
|
|
Tesofensine- 13C,d3 (NS-2330- 13C,d3) is the deuterium and 13C-labeled Tesofensine (HY-14472). Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent . Tesofensine is a CNS acting anti-obesity agent .
|
-
- HY-18610S
-
|
|
Isotope-Labeled Compounds
Dopamine Transporter
Adrenergic Receptor
5-HT Receptor
|
Neurological Disease
|
|
Diclofensine-d3 (Ro-8-4650-d3) hydrochloride is the deuterium labeled Diclofensine hydrochloride. Diclofensine hydrochloride is an orally active neuronal monoamine uptake inhibitor. Diclofensine hydrochloride blocks the uptake of dopamine, noradrenaline, and serotonin by rat brain synaptosomes with IC50 values of 0.74, 2.3 and 3.7 nM, respectively. Diclofensine hydrochloride potentiates norepinephrine-induced hypertension and attenuates Tyramine (HY-W007606)-induced hypertension. Diclofensine hydrochloride produces psychostimulant and mood-elevating effects without causing sudden disappearance or withdrawal reactions. Diclofensine hydrochloride can be used in the research of moderate to severe depression.
|
-
- HY-32329S
-
|
|
Isotope-Labeled Compounds
5-HT Receptor
Adrenergic Receptor
|
Neurological Disease
|
|
Setiptiline-d3 is the deuterium labeled Setiptiline. Setiptiline (Org-8282) is a serotonin receptor antagonist. Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). Setiptiline acts as a norepinephrine reuptake inhibitor, α2-adrenergic receptor antagonist, and serotonin receptor antagonist, likely at the 5-HT2A, 5-HT2C, and/or 5-HT3 subtypes, as well as an H1 receptor inverse agonist/antihistamine .
|
-
- HY-125784B
-
|
(S)-Viloxazin hydrochloride; (S)-Emovit hydrochloride
|
Drug Isomer
Adrenergic Receptor
|
Neurological Disease
|
|
(S)-Viloxazine hydrochloride is the isomer of Viloxazine hydrochloride (HY-125784). Viloxazine hydrochloride is the hydrochloride salt form of Viloxazine (HY-W380450). Viloxazine (Viloxazin) hydrochloride is a norepinephrine reuptake inhibitor and a potent 5-HT2C agonist agent and 5-HT2B antagonist,EC50 for 5-HT2C b> is 32 μM,and the IC50 for 5-HT2B is 27 μM. Viloxazine hydrochloride's mechanism of action primarily involves serotonergic and noradrenergic pathways. Viloxazine hydrochloride is used in antidepressant research .
|
-
- HY-32329R
-
|
Org-8282 (Standard)
|
5-HT Receptor
Adrenergic Receptor
Reference Standards
|
Neurological Disease
|
|
Setiptiline (Standard) is the analytical standard of Setiptiline. This product is intended for research and analytical applications. Setiptiline (Org-8282) is a serotonin receptor antagonist. Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). Setiptiline acts as a norepinephrine reuptake inhibitor, α2-adrenergic receptor antagonist, and serotonin receptor antagonist, likely at the 5-HT2A, 5-HT2C, and/or 5-HT3 subtypes, as well as an H1 receptor inverse agonist/antihistamine.
|
-
- HY-135004
-
|
|
Adrenergic Receptor
|
Endocrinology
|
|
Su-4029 is an agent that interacts with alpha receptors. It negates the blockade of norepinephrine by the reversible adrenergic blocker phentolamine but not by the irreversible blocker Dibenamine, suggesting Su-4029 acts at the same site as these blockers. Su-4029 pretreatment results in three categories of responses to pressor phenylalkylamines: irreversible blockade of amines with no or only p-hydroxylation, reversible blockade of amines with beta-carbon hydroxylation, and no blockade or augmentation of amines with m and p-hydroxylation or m or p plus beta-hydroxylation. Su-4029 may deform the alpha receptor site affected by adrenergic blocking agents .
|
-
- HY-12392A
-
|
|
Opioid Receptor
|
Neurological Disease
|
|
Iprindole hydrochloride, an opioid receptor agonist, is a tricyclic antidepressant. Iprindole hydrochloride shortens the immobility time in mice forced swimming test, which can be reversed by the opiate antagonist Naloxone (HY-17417A). Iprindole hydrochloride induces lamellar body formation but devoid of lamellar bodies. Iprindole hydrochloride can be used for the research of depression .
|
-
- HY-12392R
-
|
|
Reference Standards
Opioid Receptor
|
Neurological Disease
|
|
Iprindole (Standard) is the analytical standard of Iprindole. This product is intended for research and analytical applications. Iprindole, an opioid receptor agonist, is a tricyclic antidepressant. Iprindole shortens the immobility time in mice forced swimming test, which can be reversed by the opiate antagonist Naloxone (HY-17417A). Iprindole induces lamellar body formation but devoid of lamellar bodies. Iprindole hydrochloride can be used for the research of depression .
|
-
- HY-137683A
-
|
GDPβS trisodium
|
Adenylate Cyclase
|
Cardiovascular Disease
|
|
Guanosine 5'-O-(2-thiodiphosphate) trisodium (GDPβS trisodium) is a non-hydrolyzable derivative of GDP. Guanosine 5'-O-(2-thiodiphosphate) trisodium acts as an inhibitor of adenylyl cyclase (AC) with a Ki value of 600 nM. In the absence of glutamic-pyruvic transaminase (GPT) in cerebral cortex membranes of rodent models, Guanosine 5'-O-(2-thiodiphosphate) trisodium partially activates AC with an EC50 of 400 nM. Guanosine 5'-O-(2-thiodiphosphate) trisodium prevents norepinephrine-induced nitric oxide release in ventricular myocytes .
|
-
- HY-B0725R
-
|
|
Reference Standards
Histamine Receptor
Cytochrome P450
|
Neurological Disease
Cancer
|
|
Doxepin (Hydrochloride) (Standard) is the analytical standard of Doxepin (Hydrochloride). This product is intended for research and analytical applications. Doxepin hydrochloride is an orally active tricyclic antidepressant agent. Doxepin hydrochloride is a potent and selective histamine receptor H1 antagonist. Doxepin hydrochloride is also a potent CYP450 inhibitor and significantly inhibits CYP450 2C19 and 1A2 . Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant .. Doxepin has therapeutic effects in atopic dermatitis,chronic urticarial,can improve cognitive processes, protect central nervous system .. Doxepin has also been proposed as a protective factor against oxidative stress ..
|
-
- HY-32329AR
-
|
MO-8282 (Standard)
|
5-HT Receptor
Reference Standards
|
Neurological Disease
|
|
Setiptiline (maleate) (Standard) is the analytical standard of Setiptiline (maleate). This product is intended for research and analytical applications. Setiptiline maleate (MO-8282 maleate) is a serotonin receptor antagonist. Setiptiline maleate is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). Setiptiline maleate acts as a norepinephrine reuptake inhibitor, α2-adrenergic receptor antagonist, and serotonin receptor antagonist, likely at the 5-HT2A, 5-HT2C, and/or 5-HT3 subtypes, as well as an H1 receptor inverse agonist/antihistamine .
|
-
- HY-179568
-
|
|
Monoamine Transporter
|
Neurological Disease
|
|
F3288-0031 is a brain-penetrant norepinephrine transporter (NET) allosteric inhibitor with inhibitory rates of 73.5% at 20 μM. F3288-0031 binds within the inner vestibule of NET, stabilizing the inward-open state and has a preferential NET/SERT inhibition with pIC50 = 5.9. F3288-0031 shows no detectable off-target functional activity in vitro. F3288-0031 demonstrates robust antidepressant-like efficacy in vivo without confounding locomotor effects, F3288-0031 can be used for depressive disorder and related neuropsychiatric conditions .
|
-
- HY-B1018A
-
|
|
Monoamine Oxidase
GABA Receptor
Histone Demethylase
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Phenelzine sulfate, an antidepressant agent, is an irreversible and orally active monoamine oxidase (MAO-A and MAO-B) inhibitor. Phenelzine sulfate inhibits GABA transaminase and primary amine oxidase (PrAO), and sequester reactive aldehydes. Phenelzine sulfate also inhibits LSD1 (Ki: 5.6 μM) and suppresses oxidative stress and lipogenesis. Phenelzine sulfate elevates neurotransmitters (serotonin, norepinephrine, dopamine). Phenelzine sulfate is studied in neurological, metabolic and cancer diseases for depression and anxiety disorders, stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, inflammatory pain, obesity and prostate cancer .
|
-
- HY-16728
-
|
GLYX-13
|
iGluR
ERK
mTOR
|
Neurological Disease
Cancer
|
|
Rapastinel (GLYX-13) is a potent NMDAR modulator capable of crossing the blood-brain barrier, and it exhibits extremely high affinity for human NMDAR (EC50=0.0017-9.9 nM). Rapastinel enhances ERK signaling and activates the mTOR pathway, thereby upregulating the expression of BDNF and VGF, and inducing significant neuroplastic changes such as enhanced LTP and increased mature dendritic spine density in the hippocampus. Rapastinel moderately elevates the efflux of dopamine, norepinephrine and 5-HT in the prefrontal cortex, and uniquely avoids side effects of traditional antidepressants such as dissociation, addiction or sedation. Rapastinel is applicable to the research of major depressive disorder and hepatocellular carcinoma .
|
-
- HY-U00237B
-
|
|
Adrenergic Receptor
|
Others
|
|
L-771688 hydrochloride is a potent and highly selective α1A-adrenoceptor antagonist (Kd=43-90 pM). L-771688 hydrochloride is effective against cloned human, rat and dog α1A-adrenergic receptors. L-771688 exhibits high affinity (Ki ≤ 1 nM) and over 500-fold selectivity over the α1B and α1D isoforms. L-771688 potently antagonizes norepinephrine-induced responses at these receptors. Inhibits contractions induced by phenylephrine or A-61603 in rat, dog, human and monkey models .
|
-
- HY-16728B
-
|
GLYX-13 Trifluoroacetate
|
iGluR
mTOR
ERK
|
Neurological Disease
|
|
Rapastinel (GLYX-13) Trifluoroacetate is a potent NMDAR modulator capable of crossing the blood-brain barrier, and it exhibits extremely high affinity for human NMDAR (EC50=0.0017-9.9 nM). Rapastinel Trifluoroacetate enhances ERK signaling and activates the mTOR pathway, thereby upregulating the expression of BDNF and VGF, and inducing significant neuroplastic changes such as enhanced LTP and increased mature dendritic spine density in the hippocampus. Rapastinel Trifluoroacetate moderately elevates the efflux of dopamine, norepinephrine and 5-HT in the prefrontal cortex, and uniquely avoids side effects of traditional antidepressants such as dissociation, addiction or sedation. Rapastinel Trifluoroacetate is applicable to the research of major depressive disorder and hepatocellular carcinoma .
|
-
- HY-16728A
-
|
GLYX-13 acetate
|
iGluR
mTOR
ERK
|
Neurological Disease
|
|
Rapastinel (GLYX-13) acetate is a potent NMDAR modulator capable of crossing the blood-brain barrier, and it exhibits extremely high affinity for human NMDAR (EC50=0.0017-9.9 nM). Rapastinel acetate enhances ERK signaling and activates the mTOR pathway, thereby upregulating the expression of BDNF and VGF, and inducing significant neuroplastic changes such as enhanced LTP and increased mature dendritic spine density in the hippocampus. Rapastinel acetate moderately elevates the efflux of dopamine, norepinephrine and 5-HT in the prefrontal cortex, and uniquely avoids side effects of traditional antidepressants such as dissociation, addiction or sedation. Rapastinel acetate is applicable to the research of major depressive disorder and hepatocellular carcinoma .
|
-
- HY-W380450
-
|
Viloxazin; Emovit
|
5-HT Receptor
|
Neurological Disease
|
|
Viloxazine is a non-brain-penetrant, selective norepinephrine transporter (NET) inhibitor (IC50= 0.26 μM) and 5-HT receptor modulator. Viloxazine antagonizes 5-HT2B receptors (Ki=4.2 μM) and agonizes 5-HT2C receptors (EC50= 32 μM), respectively, and enhances 5-HT neurotransmission by modulating 5-HT2B/C receptors. Viloxazine also competitively inhibits NET from increasing NE and DA levels in the synaptic cleft, and can be used in the study of attention deficit hyperactivity disorder (ADHD) .
|
-
- HY-117063
-
|
|
5-HT Receptor
|
Endocrinology
|
|
LEK 8841 methanesulfonate is a gastrointestinal calming agent with strong selective 5-HT2 receptor antagonist activity. The antipsychotic potential of LEK 8841 has made it the focus of research into alternative medicines. LEK 8841 behaves as a pure competitive antagonist in response to 5-HT and norepinephrine, with pA2 values of 7.93 and 6.45, respectively. The selectivity of LEK 8841 is better than that of the comparative drug ketanserin, making it an important reference value in corresponding receptor research. Studies related to structural modifications have shown that LEK 8841 exhibits high affinity for 5-HT2 receptors and low alpha-adrenergic receptor activity .
|
-
- HY-W380450R
-
|
Viloxazin (Standard); Emovit (Standard)
|
Reference Standards
5-HT Receptor
|
Neurological Disease
|
|
Viloxazine is a non-brain-penetrant, selective norepinephrine transporter (NET) inhibitor (IC50= 0.26 μM) and 5-HT receptor modulator. Viloxazine antagonizes 5-HT2B receptors (Ki=4.2 μM) and agonizes 5-HT2C receptors (EC50= 32 μM), respectively, and enhances 5-HT neurotransmission by modulating 5-HT2B/C receptors. Viloxazine also competitively inhibits NET from increasing NE and DA levels in the synaptic cleft, and can be used in the study of attention deficit hyperactivity disorder (ADHD) .
|
-
- HY-U00244
-
|
P2647; BZQ; Benzoquinamide
|
Adrenergic Receptor
Dopamine Receptor
|
Metabolic Disease
|
|
Benzquinamide (P2647; BZQ; Benzoquinamide) is an orally active binder of dopamine receptors and adrenergic receptors. Benzquinamide specifically targets dopamine D2, D3, D4 receptors and α-2A, α-2B, α-2C adrenergic receptors. Benzquinamide regulates blood pressure and heart rate, attenuates the pressor effect of adrenaline, and exhibits activities such as antiemesis, anxiolysis, and reduction of histamine-induced bronchoconstriction. Benzquinamide has good safety and does not deplete serotonin or norepinephrine in the brain. Benzquinamide can be used in studies related to nausea/vomiting, mental disorders, anxiety states, neurosis, and psychosis .
|
-
- HY-U00244A
-
|
P2647 hydrochloride; BZQ hydrochloride; Benzoquinamide hydrochloride
|
Adrenergic Receptor
Dopamine Receptor
|
Neurological Disease
|
|
Benzquinamide (P2647; BZQ; Benzoquinamide) hydrochloride is an orally active binder of dopamine receptors and adrenergic receptors. Benzquinamide hydrochloride specifically targets dopamine D2, D3, D4 receptors and α-2A, α-2B, α-2C adrenergic receptors. Benzquinamide hydrochloride regulates blood pressure and heart rate, attenuates the pressor effect of adrenaline, and exhibits activities such as antiemesis, anxiolysis, and reduction of histamine-induced bronchoconstriction. Benzquinamide hydrochloride has good safety and does not deplete serotonin or norepinephrine in the brain. Benzquinamide hydrochloride can be used in studies related to nausea/vomiting, mental disorders, anxiety states, neurosis, and psychosis .
|
-
- HY-125784
-
|
Viloxazin hydrochloride; Emovit hydrochloride
|
5-HT Receptor
|
Neurological Disease
|
|
Viloxazine hydrochloride is a non-brain-penetrant, selective norepinephrine transporter (NET) inhibitor (IC50=0.26 μM) and 5-HT receptor modulator. Viloxazine antagonizes 5-HT2B receptors (Ki=4.2 μM) and agonizes 5-HT2C receptors (EC50=32 μM), respectively, and enhances 5-HT neurotransmission by modulating 5-HT2B/C receptors. Viloxazine also competitively inhibits NET from increasing NE and DA levels in the synaptic cleft, and can be used in the study of attention deficit hyperactivity disorder (ADHD) .
|
-
- HY-B1018AS
-
|
|
Isotope-Labeled Compounds
Monoamine Oxidase
GABA Receptor
Histone Demethylase
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Phenelzine-d5 sulfate is the deuterium labeled Phenelzine sulfate (HY-B1018A). Phenelzine sulfate, an antidepressant agent, is an irreversible and orally active monoamine oxidase (MAO-A and MAO-B) inhibitor. Phenelzine sulfate inhibits GABA transaminase and primary amine oxidase (PrAO), and sequester reactive aldehydes. Phenelzine sulfate also inhibits LSD1 (Ki: 5.6 μM) and suppresses oxidative stress and lipogenesis. Phenelzine sulfate elevates neurotransmitters (serotonin, norepinephrine, dopamine). Phenelzine sulfate is studied in neurological, metabolic and cancer diseases for depression and anxiety disorders, stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, inflammatory pain, obesity and prostate cancer .
|
-
- HY-U00134A
-
|
Bencyclane fumarate; Benzcyclan fumarate
|
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Benzcyclane fumarate (Bencyclane fumarate; Benzcyclan fumarate) is a serotonin receptor antagonist and a cerebral/peripheral vasodilator. Benzcyclane fumarate exerts atypical serotonin antagonistic effects in rabbit superior mesenteric arteries. Benzcyclane fumarate relaxes high K +-induced contractions in rabbit basilar arteries and superior mesenteric arteries, and selectively inhibits sympathetic nerve stimulation-induced contractions in rabbit pulmonary arteries. Benzcyclane fumarate exerts non-competitive norepinephrine antagonistic effects in rabbit superior mesenteric arteries, and slightly reduces the maximum contractile response induced by histamine. Benzcyclane fumarate relaxes smooth muscles, induces transient hypotension, inhibits thrombosis, and accelerates blood fibrinolytic activity. Benzcyclane fumarate increases cerebral glucose content/uptake, enhances hypoxia tolerance in mice, and increases cerebral blood supply in dogs. Benzcyclane fumarate is applicable to studies related to cerebral vascular circulation .
|
-
- HY-W047432
-
|
DL0805
|
ROCK
|
Cardiovascular Disease
|
|
5-Nitro-1H-indazole-3-carbonitrile (DL0805) is a Rho kinase(ROCK) inhibitor with an IC50 of 6.67 μM for ROCK-I. 5-Nitro-1H-indazole-3-carbonitrile reduces Norepinephrine (HY-13715)-induced transient contraction and inhibits contraction induced by increasing external calcium in the endothelium-denuded rings of rat models. 5-Nitro-1H-indazole-3-carbonitrile has a vasorelaxant activity but high toxicity. 5-Nitro-1H-indazole-3-carbonitrile can be used for cardiovascular diseases, especially hypertension research .
|
-
- HY-U00134
-
|
Bencyclane; Benzcyclan
|
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Benzcyclane (Bencyclane; Benzcyclan) is a serotonin receptor antagonist and a cerebral/peripheral vasodilator. Benzcyclane exerts atypical serotonin antagonistic effects in rabbit superior mesenteric arteries. Benzcyclane relaxes high K +-induced contractions in rabbit basilar arteries and superior mesenteric arteries, and selectively inhibits sympathetic nerve stimulation-induced contractions in rabbit pulmonary arteries. Benzcyclane exerts non-competitive norepinephrine antagonistic effects in rabbit superior mesenteric arteries, and slightly reduces the maximum contractile response induced by histamine. Benzcyclane relaxes smooth muscles, induces transient hypotension, inhibits thrombosis, and accelerates blood fibrinolytic activity. Benzcyclane increases cerebral glucose content/uptake, enhances hypoxia tolerance in mice, and increases cerebral blood supply in dogs. Benzcyclane is applicable to studies related to cerebral vascular circulation .
|
-
- HY-16525
-
|
|
Monoamine Transporter
Adrenergic Receptor
|
Neurological Disease
|
|
XEN-2174 is a noradrenaline transporter (NET) inhibitor. XEN-2174 inhibits the reuptake of noradrenaline through non-competitive inhibition, increasing the concentration of noradrenaline in the synaptic cleft, thereby activating α2-adrenergic receptor at the spinal level and exerting analgesic effects. XEN-2174 exhibits long-lasting analgesic effects in models of neuropathic pain and postoperative pain in rats. XEN-2174 can be used in pain research .
|
-
- HY-136693
-
|
|
Adrenergic Receptor
|
Neurological Disease
|
|
L-654284 is an α2-adrenergic receptor antagonist with significant selectivity. L-654284 competes with the binding of 3H-clonidine and 3H-rauwolscine in vitro and shows Ki values of 0.8 nM and 1.1 nM, respectively. L-654284 can block the protrusion effect of clonidine in isolated vas deferens in rats, with a pA2 value of 9.1. L-654284 exhibits remarkable selectivity for α2 and α1 adrenergic receptors, and exhibits a Ki of 110 nM in inhibiting 3H-prazosin binding. L-654284 can significantly increase the turnover rate of norepinephrine in rat cerebral cortex in vivo, showing α2-adrenergic receptor blocking activity in the central nervous system .
|
-
- HY-135115
-
|
3,4-DHPEA-EA
|
α-synuclein
HDAC
Adrenergic Receptor
|
Inflammation/Immunology
|
|
Oleuropein Aglycone (3,4-DHPEA-EA) is a polyphenol and the aglycone form of oleuropein (HY-N0292), formed by enzymatic, acidic or acetylated hydrolysis of oleuropein. Dietary intake of oleuropein Aglycone (50 mg/kg diet) increases the number of neuronal autophagic vesicles, reverses cognitive deficits in the TgCRND8 transgenic mouse model of Alzheimer's disease, and reduces the levels of histone deacetylase 2 (HDAC2) in the cortex and hippocampus. Oleuropein Aglycone increases urinary norepinephrine, interscapular brown adipose tissue epinephrine, and UCP1 protein levels, and reduced plasma leptin levels and total abdominal adipose tissue weight in a rat model of high-fat diet-induced obesity. Oleuropein Aglycone also reduced lung neutrophil infiltration, lipid peroxidation, and IL-1β levels in a mouse model of carrageenan-induced pleurisy.
|
-
- HY-128483
-
|
|
TGF-beta/Smad
PI3K
NF-κB
Akt
Apoptosis
Dopamine β-hydroxylase
mTOR
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Fusaric acid is an orally active multi-pathway inhibitor with the activity of inducing oxidative stress and apoptosis. Fusaric acid can chelate divalent metal cations, damage mitochondrial membrane structure, and activate apoptosis-related proteases such as Caspase-3/7, -8, and -9. Fusaric acid also regulates Bax/Bcl-2 protein, inhibits fibrosis-related signaling pathways such as NF-κB, TGF-β1/SMADs, and PI3K/AKT/mTOR, and reduces collagen deposition. Fusaric acid is also a dopamine β-hydroxylase inhibitor, which reduces endogenous levels of norepinephrine and epinephrine in the brain, heart, spleen, and adrenal glands. Fusaric acid can play a role in myocardial fibrosis and improve cardiac hypertrophy in heart disease, and can also be used in the study of esophageal cancer and liver cancer .
|
-
- HY-A0139
-
|
NSC 108165; Navan; Navane
|
Sigma Receptor
mAChR
Histamine Receptor
Dopamine Receptor
Adrenergic Receptor
|
Others
|
|
Thiothixene is a typical antipsychotic. It selectively binds to dopamine D2 over D1, D3, and D4 receptors (Kis=0.417, 338, 186.2, and 363.1 nM, respectively). Thiothixene also binds to various serotonin (5-HT), histamine H1, α1- and α2-adrenergic, muscarinic acetylcholine, and sigma receptors (Kis=15-5,754 nM) as well as the dopamine, norepinephrine, and serotonin transporters (Kis=3.16-30 μM). In vivo, thiothixene reduces spontaneous and amphetamine-induced locomotor activity in rats. It enhances latent inhibition, as measured by a decreased lick latency in response to light and foot shock stimuli, which is a measure of selective attention in rats.3 Thiothixene also increases competitive behavior in submissive mice, indicating antidepressant-like behavior.
|
-
- HY-U00134R
-
|
Bencyclane (Standard); Benzcyclan (Standard)
|
Reference Standards
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Benzcyclane (Standard) is the analytical standard of Benzcyclane (HY-U00134). This product is intended for research and analytical applications. Benzcyclane (Bencyclane; Benzcyclan) is a serotonin receptor antagonist and a cerebral/peripheral vasodilator. Benzcyclane exerts atypical serotonin antagonistic effects in rabbit superior mesenteric arteries. Benzcyclane relaxes high K +-induced contractions in rabbit basilar arteries and superior mesenteric arteries, and selectively inhibits sympathetic nerve stimulation-induced contractions in rabbit pulmonary arteries. Benzcyclane exerts non-competitive norepinephrine antagonistic effects in rabbit superior mesenteric arteries, and slightly reduces the maximum contractile response induced by histamine. Benzcyclane relaxes smooth muscles, induces transient hypotension, inhibits thrombosis, and accelerates blood fibrinolytic activity. Benzcyclane increases cerebral glucose content/uptake, enhances hypoxia tolerance in mice, and increases cerebral blood supply in dogs. Benzcyclane is applicable to studies related to cerebral vascular circulation .
|
-
- HY-N0724R
-
|
|
Reference Standards
NO Synthase
|
Neurological Disease
|
|
Mesaconitine (Standard) is the analytical standard of Mesaconitine. This product is intended for research and analytical applications. Mesaconitine is a nitric oxide synthase activator. Mesaconitine drives extracellular Na + and Ca 2+ influx into endothelial cells, increases intracellular Na + and Ca 2+ concentrations, and triggers nitric oxide release. Mesaconitine is applicable for pain-related research .
|
-
- HY-N0724
-
|
|
NO Synthase
|
Neurological Disease
|
|
Mesaconitine is a nitric oxide synthase activator. Mesaconitine drives extracellular Na + and Ca 2+ influx into endothelial cells, increases intracellular Na + and Ca 2+ concentrations, and triggers nitric oxide release. Mesaconitine is applicable for pain-related research .
|
-
- HY-N17738
-
|
|
Calcium Channel
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Acetyljujuboside B is a saponin. Acetyljujuboside B can be isolated from seeds of Zizyphus jujuba Mill. var. spinosa. Acetyljujuboside B inhibits Ca 2+ influx. Acetyljujuboside B shows only sustained vasorelaxant effects, with no transient effect on NE-induced vasoconstrictions. Acetyljujuboside B inhibits histamine release from rat peritoneal exudate cells induced by the antigen-antibody reaction .
|
-
- HY-156807
-
|
|
Serotonin Transporter
5-HT Receptor
|
Neurological Disease
|
LY 367265 is a 5-hydroxytryptamine transporter (SERT) inhibitor (IC₅₀ = 3.1 nM) and a 5-HT₂A receptor antagonist (Kᵢ = 0.81 nM). LY 367265 has the inhibitory activity on the norepinephrine transporter (NET) of extremely weak (IC₅₀ > 1000 nM); it has low affinity for subtypes such as 5-HT₁B (Kᵢ = 490 nM) and 5-HT₁D (Kᵢ = 81 nM), showing high selectivity. LY 367265 concentration-dependently enhances of [³H]5-HT efflux (EC₅₀ = 250 nM). LY 367265 antagonizes the contraction response of Sumatriptan (HY-B0121B), indicating its functional antagonistic activity on 5-HT₁D-like receptors. LY 367265 can be used for the study of diseases such as anxiety disorders and post-traumatic stress disorder .
|
-
- HY-W680886
-
|
|
Monoamine Transporter
Serotonin Transporter
Dopamine Transporter
5-HT Receptor
|
Neurological Disease
|
|
6-APDB is a class of monoamine neurotransmitter releaser and Monoamine Transporter modulator that exerts selective effects on human monoamine transporters and acts as a partial agonist at 5-HT2 family receptors. For NET, 6-APDB has an IC50 of 0.56 μM and a Ki of 18 μM; for SERT, it has an IC50 of 2.3 μM and a Ki of 23 μM; for DAT, it has an IC50 of 33 μM and a Ki of >30 μM, and affinity for rat and mouse TAAR1, with Ki values of 1.0 μM and 0.21 μM, respectively. 6-APDB inhibits norepinephrine and 5-HT reuptake, mediates the release of three types of monoamine neurotransmitters, shows a dose-dependent biphasic locomotor effect in mice, and fully substitutes the discriminative stimulus effect of MDMA. 6-APDB shows no significant cytotoxicity at high concentrations, and possesses empathogenic psychoactivity, potential hallucinogenic effects, and behavioral effects associated with intermittent abuse .
|
-
- HY-128483R
-
|
|
TGF-beta/Smad
PI3K
NF-κB
Akt
Apoptosis
Dopamine β-hydroxylase
mTOR
Adrenergic Receptor
Reference Standards
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Fusaric acid (Standard) is the analytical standard of Fusaric acid (HY-128483). This product is intended for research and analytical applications. Fusaric acid is an orally active multi-pathway inhibitor with the activity of inducing oxidative stress and apoptosis. Fusaric acid can chelate divalent metal cations, damage mitochondrial membrane structure, and activate apoptosis-related proteases such as Caspase-3/7, -8, and -9. Fusaric acid also regulates Bax/Bcl-2 protein, inhibits fibrosis-related signaling pathways such as NF-κB, TGF-β1/SMADs, and PI3K/AKT/mTOR, and reduces collagen deposition. Fusaric acid is also a dopamine β-hydroxylase inhibitor, which reduces endogenous levels of norepinephrine and epinephrine in the brain, heart, spleen, and adrenal glands. Fusaric acid can play a role in myocardial fibrosis and improve cardiac hypertrophy in heart disease, and can also be used in the study of esophageal cancer and liver cancer .
|
-
- HY-103247
-
|
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
EMD 66684 is an antagonist of Angiotensin II Type 1 (AT1) receptor. EMD 66684 shows potent binding affinities for the AT1 subtype Ang II receptor with an IC50 value of 0.7 nM. EMD 66684 also serves as an antiischemic cytoprotectant - .
|
-
- HY-B0527A
-
|
|
Serotonin Transporter
5-HT Receptor
mAChR
Histamine Receptor
Adrenergic Receptor
Trk Receptor
Sodium Channel
Potassium Channel
Dopamine Transporter
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Endocrinology
|
|
Amitriptyline hydrochloride is an orally active tricyclic antidepressant (TCA). Amitriptyline hydrochloride mainly exerts its antidepressant effect by blocking SERT (Ki = 3.45 nM) and NET (Ki = 13.3 nM), thereby increasing the concentrations of 5-hydroxytryptamine (5-HT) and norepinephrine (NE) in the synaptic cleft. Amitriptyline hydrochloride is also an agonist at α2A and TrkA/TrkB receptors, thereby exerting analgesic and neurotrophic activities (inhibiting cell apoptosis). Amitriptyline hydrochloride can reduce inflammation, angiogenesis and fibrosis. Amitriptyline hydrochloride binds to DAT (with Ki = 2.58 μM). Amitriptyline hydrochloride has high affinity for a series of receptors and can antagonize muscarinic cholinergic receptors (M1/M2/M3/M4/M5 receptors) (Ki = 11-24 nM), H1 receptors (Ki = 0.5-1.1 nM), adrenergic α1 receptors (Ki = 4.4 nM), etc., resulting in a series of side effects. Amitriptyline hydrochloride can block sodium channels and hERG potassium channel (IC50 = 4.78 μM) and it has cardiotoxicity .
|
-
- HY-W748758
-
|
NSC 108165-d8; Navan-d8; Navane-d8
|
Isotope-Labeled Compounds
Dopamine Receptor
Histamine Receptor
mAChR
Adrenergic Receptor
Sigma Receptor
|
Others
|
|
(Z)-Thiothixene-d8 (NSC 108165-d8; Navan-d8; Navane-d8) is the deuterium labeled Thiothixene (HY-A0139). Thiothixene is a typical antipsychotic. It selectively binds to dopamine D2 over D1, D3, and D4 receptors (Kis=0.417, 338, 186.2, and 363.1 nM, respectively). Thiothixene also binds to various serotonin (5-HT), histamine H1, α1- and α2-adrenergic, muscarinic acetylcholine, and sigma receptors (Kis=15-5,754 nM) as well as the dopamine, norepinephrine, and serotonin transporters (Kis=3.16-30 μM). In vivo, thiothixene reduces spontaneous and amphetamine-induced locomotor activity in rats. It enhances latent inhibition, as measured by a decreased lick latency in response to light and foot shock stimuli, which is a measure of selective attention in rats.3 Thiothixene also increases competitive behavior in submissive mice, indicating antidepressant-like behavior.
|
-
- HY-B0527
-
|
|
Serotonin Transporter
Trk Receptor
Sodium Channel
5-HT Receptor
Histamine Receptor
Adrenergic Receptor
mAChR
Potassium Channel
Dopamine Transporter
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Endocrinology
|
|
Amitriptyline is an orally active tricyclic antidepressant (TCA). Amitriptyline mainly exerts its antidepressant effect by blocking SERT (Ki = 3.45 nM) and NET (Ki = 13.3 nM), thereby increasing the concentrations of 5-hydroxytryptamine (5-HT) and norepinephrine (NE) in the synaptic cleft. Amitriptyline is also an agonist at α2A and TrkA/TrkB receptors, thereby exerting analgesic and neurotrophic activities (inhibiting cell apoptosis). Amitriptyline can reduce inflammation, angiogenesis and fibrosis. Amitriptyline binds to DAT (with Ki = 2.58 μM). Amitriptyline has high affinity for a series of receptors and can antagonize muscarinic cholinergic receptors (M1/M2/M3/M4/M5 receptors) (Ki = 11-24 nM), H1 receptors (Ki = 0.5-1.1 nM), adrenergic α1 receptors (Ki = 4.4 nM), etc., resulting in a series of side effects. Amitriptyline can block sodium channels and hERG potassium channel (IC50 = 4.78 μM) and it has cardiotoxicity .
|
-
- HY-B0527AS
-
|
|
Isotope-Labeled Compounds
Serotonin Transporter
5-HT Receptor
Histamine Receptor
mAChR
Adrenergic Receptor
Trk Receptor
Sodium Channel
Potassium Channel
Dopamine Transporter
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Endocrinology
|
|
Amitriptyline-d6 hydrochloride is the deuterium labeled Amitriptyline hydrochloride (HY-B0527A). Amitriptyline hydrochloride is an orally active tricyclic antidepressant (TCA). Amitriptyline hydrochloride mainly exerts its antidepressant effect by blocking SERT (Ki = 3.45 nM) and NET (Ki = 13.3 nM), thereby increasing the concentrations of 5-hydroxytryptamine (5-HT) and norepinephrine (NE) in the synaptic cleft. Amitriptyline hydrochloride is also an agonist at α2A and TrkA/TrkB receptors, thereby exerting analgesic and neurotrophic activities (inhibiting cell apoptosis). Amitriptyline hydrochloride can reduce inflammation, angiogenesis and fibrosis. Amitriptyline hydrochloride binds to DAT (with Ki = 2.58 μM). Amitriptyline hydrochloride has high affinity for a series of receptors and can antagonize muscarinic cholinergic receptors (M1/M2/M3/M4/M5 receptors) (Ki = 11-24 nM), H1 receptors (Ki = 0.5-1.1 nM), adrenergic α1 receptors (Ki = 4.4 nM), etc., resulting in a series of side effects. Amitriptyline hydrochloride can block sodium channels and hERG potassium channel (IC50 = 4.78 μM) and it has cardiotoxicity.
|
-
- HY-B0527AR
-
|
|
Reference Standards
Serotonin Transporter
5-HT Receptor
Histamine Receptor
mAChR
Adrenergic Receptor
Trk Receptor
Sodium Channel
Potassium Channel
Dopamine Transporter
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Endocrinology
|
|
Amitriptyline hydrochloride (Standard) is the analytical standard of Amitriptyline hydrochloride (HY-B0527A). This product is intended for research and analytical applications. Amitriptyline hydrochloride is an orally active tricyclic antidepressant (TCA). Amitriptyline hydrochloride mainly exerts its antidepressant effect by blocking SERT (Ki = 3.45 nM) and NET (Ki = 13.3 nM), thereby increasing the concentrations of 5-hydroxytryptamine (5-HT) and norepinephrine (NE) in the synaptic cleft. Amitriptyline hydrochloride is also an agonist at α2A and TrkA/TrkB receptors, thereby exerting analgesic and neurotrophic activities (inhibiting cell apoptosis). Amitriptyline hydrochloride can reduce inflammation, angiogenesis and fibrosis. Amitriptyline hydrochloride binds to DAT (with Ki = 2.58 μM). Amitriptyline hydrochloride has high affinity for a series of receptors and can antagonize muscarinic cholinergic receptors (M1/M2/M3/M4/M5 receptors) (Ki = 11-24 nM), H1 receptors (Ki = 0.5-1.1 nM), adrenergic α1 receptors (Ki = 4.4 nM), etc., resulting in a series of side effects. Amitriptyline hydrochloride can block sodium channels and hERG potassium channel (IC50 = 4.78 μM) and it has cardiotoxicity.
|
-
- HY-N18471
-
|
5,7-DHP
|
Monoamine Oxidase
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
5,7-Dihydroxytryptamine (5,7-DHP) is an autofluorescent (λex≈365 nm), selective neurotoxin and a transport substrate for MAO-A and 5-HT. 5,7-Dihydroxytryptamine can specifically target and damage central and peripheral 5-HTergic neurons, while affecting 5-HT-related pathways and neurotransmitter balance. 5,7-Dihydroxytryptamine can be used to establish 5-HTergic neuron injury models for studies on neural development, neurodegenerative diseases, as well as mechanisms related to platelet function and retinal neurons .
|
-
- HY-W982195
-
|
|
Adrenergic Receptor
5-HT Receptor
|
Neurological Disease
|
|
Napamezole hydrochloride is an orally active α-2 adrenergic receptor antagonist and serotonin (5-HT Receptor) reuptake inhibitor, with Ki values of 28 nM and 93 nM for rat α-2 and α-1 adrenergic receptors, respectively. Napamezole hydrochloride can be used for the research of depression .
|
-
-
-
HY-L906
-
|
|
647 compounds
|
|
On May 15, 2024, "Dimerization and antidepressant recognition at noradrenaline transporter" was published online by Nature. The research findings were an effort from Shanghai Institute of Materia Medica, Chinese Academy of Sciences. This study unraveled the important neural system target - the noradrenaline transporter (NET), obtaining the binding modes of human NET homodimers with the natural substrate norepinephrine (NE) and six selective antidepressants. It laid an important theoretical foundation for understanding the physiological regulation mechanisms of NET and other monoamine transporters.
The Norepinephrine Transporter (NET) Compound Library is obtained by computer-aided virtual screening based on the HY-L901 compound library . The specific screening process includes molecular docking screening, key pharmacophore screening, and CNS-MPO screening, which can be used for new drug discovery targeting the noradrenaline transporter.
|
| Cat. No. |
상품명 |
Target |
Research Area |
-
- HY-12554A
-
|
|
Vasopressin Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
|
Terlipressin diacetate is a vasopressin analogue with potent vasoactive properties. Terlipressin diacetate is a highly selective vasopressin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin diacetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin diacetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research .
|
-
- HY-P1080A
-
|
|
Calcium Channel
|
Neurological Disease
|
|
ω-Agatoxin IVA TFA is a potent, selective P/Q type Ca 2+ (Cav2.1) channel blocker with IC50 values of 2 nM and 90 nM. ω-Agatoxin IVA TFA inhibits glutamate exocytosis and calcium influx elicited by high potassium. ω-Agatoxin IVA TFA inhibits Capsaicin (HY-10448)-induced CGRP release and vasodilation. ω-Agatoxin IVA TFA can be used for the research of neurological and cardiovascular disease .
|
-
- HY-P4641
-
|
Trp-Phe
|
Angiotensin-converting Enzyme (ACE)
Endothelin Receptor
|
Cardiovascular Disease
|
|
H-Trp-Phe-OH (Trp-Phe) is an ACE inhibitor and endothelial function regulator, with an ACE IC50 of 0.318 mg/mL. H-Trp-Phe-OH increases nitric oxide concentration, reduces endothelin-1 (ET-1) levels, and reverses norepinephrine-mediated endothelial cell dysfunction. H-Trp-Phe-OH exhibits antihypertensive activity. H-Trp-Phe-OH can be used in studies related to hypertension and atherosclerosis .
|
-
- HY-P1685
-
|
|
Bombesin Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Ranatensin is a undecapeptide and a Bombesin Receptor angonist, can be isolated from amphibian skin, such as the frog, Rana pipiens. Ranatensin could maintain the dynamic balance of animal blood pressure, without cross-tachyphylaxis with Angiotensin amide (HY-P2212),Bradykinin (HY-P0206), or Norepinephrine (HY-13715) .
|
-
- HY-12554B
-
|
|
Vasopressin Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
|
Terlipressin acetate is a vasopressin analogue with potent vasoactive properties. Terlipressin acetate is a highly selective vasopressin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin acetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin acetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research .
|
-
- HY-P11313
-
|
Rat chromogranin A367–387
|
nAChR
Akt
|
Cardiovascular Disease
|
|
Catestatin (rat) (Rat chromogranin A367–387) is a potent, reversible, noncompetitive, and noncooperative nicotinic cholinergic antagonist derived from chromogranin A (A367-387). Catestatin (rat) inhibits norepinephrine release in rat PC12 pheochromocytoma cells (IC50 = 1.2 μM), and blocks desensitization of norepinephrine release (IC50 = 0.62 μM). Catestatin (rat) exerts antiadrenergic effects through the endothelial PI3K-AKT-eNOS pathway in rat papillary muscles and isolated cardiomyocytes. Catestatin (rat) maintains mitochondrial membrane potential in I/R cardiomyocytes and increases phosphorylation of AKT at S473, GSK3β at S9, PLB at T17, and eNOS at S1179. Catestatin (rat) reverses desensitization of 22Na + uptake. Catestatin (rat) can be used for the study of nicotinic cholinergic receptor regulation and catecholamine release control mechanisms .
|
-
- HY-16525
-
|
|
Monoamine Transporter
Adrenergic Receptor
|
Neurological Disease
|
|
XEN-2174 is a noradrenaline transporter (NET) inhibitor. XEN-2174 inhibits the reuptake of noradrenaline through non-competitive inhibition, increasing the concentration of noradrenaline in the synaptic cleft, thereby activating α2-adrenergic receptor at the spinal level and exerting analgesic effects. XEN-2174 exhibits long-lasting analgesic effects in models of neuropathic pain and postoperative pain in rats. XEN-2174 can be used in pain research .
|
-
- HY-P3064
-
|
Leiurotoxin I
|
Potassium Channel
|
Neurological Disease
|
|
Scyllatoxin (Leiurotoxin I) is a peptide toxin, it can be isolated from the venom of the scorpion (Leiurus quinquestriatus hebraeus). Scyllatoxin is a blocker of small-conductance KCa (SK) channel. Scyllatoxin enhances both norepinephrine (NE) and epinephrine (Epi) release in vivo .
|
-
- HY-P1544
-
|
|
Endogenous Metabolite
Adenylate Cyclase
PKA
Calcium Channel
|
Neurological Disease
Metabolic Disease
|
|
Cerebellin is a neuromodulatory hexadecapeptide that serves as a marker for Purkinje cell maturation. Cerebellin stimulates norepinephrine release via the adenylate cyclase/PKA-dependent signaling pathway. Cerebellin reduces insulin secretion from pancreatic islets under high-glucose conditions. Cerebellin also regulates synaptic structure formation and controls catecholamine secretion in peripheral tissues. Cerebellin can be used in neurological research .
|
-
- HY-P10435
-
|
|
Dopamine Receptor
|
Neurological Disease
|
|
KEMPFPKYPVEP is a 12-amino acids neuropeptide, which upregulates levels of dopamine (DA) and norepinephrine (NE) in the prefrontal cortex, exhibits spatial and object recognition memory promoting ability in Scopolamine (HY-N0296)-induced amnesia mouse model .
|
-
- HY-12554AR
-
|
|
Vasopressin Receptor
Reference Standards
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
|
Terlipressin (diacetate) (Standard) is the analytical standard of Terlipressin (diacetate). This product is intended for research and analytical applications. Terlipressin diacetate is a vasopressin analogue with potent vasoactive properties. Terlipressin diacetate is a highly selective vasopressin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin diacetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin diacetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research .
|
-
- HY-P1544A
-
|
|
Calcium Channel
PKA
Endogenous Metabolite
Adenylate Cyclase
|
Neurological Disease
Metabolic Disease
|
|
Cerebellin TFA is a neuromodulatory hexadecapeptide that serves as a marker for Purkinje cell maturation. Cerebellin TFA stimulates norepinephrine release via the adenylate cyclase/PKA-dependent signaling pathway. Cerebellin TFA reduces insulin secretion from pancreatic islets under high-glucose conditions. Cerebellin TFA also regulates synaptic structure formation and controls catecholamine secretion in peripheral tissues. Cerebellin TFA can be used in neurological research .
|
| Cat. No. |
상품명 |
Category |
Target |
Chemical Structure |
-
- HY-13715
-
-
-
- HY-13715A
-
-
-
- HY-13715B
-
-
-
- HY-14258
-
|
(S)-Citalopram; (S)-(+)-Citalopram
|
Natural Products
Endogenous metabolite
Source Classification
|
Serotonin Transporter
|
|
Escitalopram ((S)-Citalopram), the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram is an antidepressant for the research of major depression .
|
-
-
- HY-113121
-
-
-
- HY-N0740
-
-
-
- HY-W017113
-
|
|
Structural Classification
Natural Products
Classification of Application Fields
Metabolic Disease
Endogenous metabolite
Disease Research Fields
Source Classification
|
Environmental Pollutants
Endogenous Metabolite
|
|
2-Mercaptobenzothiazole is an activator of the aryl hydrocarbon receptor (AhR) , inhibiting thyroid hormone synthesis and dopamine beta-hydroxylase activity . 2-Mercaptobenzothiazole promotes bladder cancer cell invasion by altering the conformation of the AhR ligand binding domain (LBD), activating AhR transcription, and upregulating the mRNA and protein expression of target genes CYP1A1 and CYP1B1 . 2-Mercaptobenzothiazole inhibits thyroid peroxidase (TPO) with an IC50 value of 11.5 μM, induces histological changes such as follicular cell hypertrophy in Xenopus laevis tadpoles, delaying metamorphosis . 2-Mercaptobenzothiazole increases chromosomal aberrations and sister chromatid exchanges (SCEs) in Chinese hamster ovary (CHO) cells, and enhances carcinogenicity in F344/N rats . 2-Mercaptobenzothiazole inhibits norepinephrine synthesis in mice and completely blocks the conversion of exogenous dopamine to norepinephrine in rat cardiomyocytes .
|
-
-
- HY-128483
-
|
|
Infection
Microorganisms
Classification of Application Fields
Ketones, Aldehydes, Acids
Disease Research Fields
Source Classification
|
TGF-beta/Smad
PI3K
NF-κB
Akt
Apoptosis
Dopamine β-hydroxylase
mTOR
Adrenergic Receptor
|
|
Fusaric acid is an orally active multi-pathway inhibitor with the activity of inducing oxidative stress and apoptosis. Fusaric acid can chelate divalent metal cations, damage mitochondrial membrane structure, and activate apoptosis-related proteases such as Caspase-3/7, -8, and -9. Fusaric acid also regulates Bax/Bcl-2 protein, inhibits fibrosis-related signaling pathways such as NF-κB, TGF-β1/SMADs, and PI3K/AKT/mTOR, and reduces collagen deposition. Fusaric acid is also a dopamine β-hydroxylase inhibitor, which reduces endogenous levels of norepinephrine and epinephrine in the brain, heart, spleen, and adrenal glands. Fusaric acid can play a role in myocardial fibrosis and improve cardiac hypertrophy in heart disease, and can also be used in the study of esophageal cancer and liver cancer .
|
-
-
- HY-13715C
-
-
-
- HY-113323
-
-
-
- HY-N7142
-
-
-
- HY-N0749
-
-
-
- HY-N0126
-
-
-
- HY-N0724
-
-
-
- HY-113474
-
-
-
- HY-N0749A
-
-
-
- HY-13715R
-
-
-
- HY-W008794
-
-
-
- HY-Y0123
-
-
-
- HY-N7506
-
|
Delta3,2-Hydroxylbakuchiol
|
Structural Classification
Monophenols
Leguminosae
Phenols
Psoralea corylifolia L.
Plants
Source Classification
|
Monoamine Transporter
Dopamine Transporter
|
|
13-Hydroxyisobakuchiol (Delta3,2-Hydroxylbakuchiol), an analog of Bakuchiol (HY-N0235) that can be isolated from Psoralea corylifolia (L.), is a potent selective monoamine transporter inhibitor. 13-Hydroxyisobakuchiol is more selective for the dopamine transporter (DAT) (IC50 = 0.58 μM) and norepinephrine transporter (NET) (IC50 = 0.69 μM) than for the serotonin transporter (SERT) (IC50 = 312.02 μM). 13-Hydroxyisobakuchiol increases the activity of intact mice and improves the decreased activity of reserpinized mice in vivo. 13-Hydroxyisobakuchiol can be used for the research of disorders such as Parkinson's disease and depression .
|
-
-
- HY-13715AR
-
-
-
- HY-N3198A
-
-
-
- HY-113121R
-
-
-
- HY-E70007
-
-
-
- HY-13715BR
-
-
-
- HY-N7647
-
-
-
- HY-N15737
-
-
-
- HY-N0126R
-
-
-
- HY-115762
-
-
-
- HY-W008794R
-
|
(±)-Normetanephrine hydrochloride (Standard); DL-Normetanephrine hydrochloride (Standard); (Rac)-Normetanephrine hydrochloride (Standard)
|
Phenols
Endogenous metabolite
Source Classification
|
Reference Standards
Endogenous Metabolite
|
|
Normetanephrine (hydrochloride) (Standard) is the analytical standard of Normetanephrine (hydrochloride). This product is intended for research and analytical applications. Normetanephrine ((±)-Normetanephrine) hydrochloride is the O-methylated metabolite of norepinephrine (NE) .
|
-
-
- HY-113474R
-
-
-
- HY-59132R
-
-
-
- HY-N0913R
-
|
|
Structural Classification
Polysaccharides
Microorganisms
other families
Plants
Saccharides
Source Classification
|
Reference Standards
Antifolate
Thymidylate Synthase
|
|
Wy-45494 (hydrochloride) (Standard) is the analytical standard of Wy-45494 (hydrochloride). This product is intended for research and analytical applications. Wy-45494 hydrochloride (N-Desmethyl Venlafaxine hydrochloride; Wy 45494) is a minor active metabolite of the selective norepinephrine and serotonin reuptake inhibitor (SNRI) venlafaxine. It is formed from venlafaxine via the cytochrome P450 (CYP) isomer CYP3A4.2. Wy-45494 hydrochloride inhibits norepinephrine and serotonin reuptake in rat synaptosomal preparations (IC50s of 4.7 and 1.6 μM, respectively). In vivo, Wy-45494 hydrochloride reversed reserpine-induced hypothermia in mice at a minimum effective dose (MED) of 10 mg/kg.
|
-
-
- HY-14258R
-
|
(S)-Citalopram (Standard); (S)-(+)-Citalopram (Standard)
|
Structural Classification
Natural Products
Endogenous metabolite
Source Classification
|
Serotonin Transporter
Reference Standards
|
|
Escitalopram (Standard) is the analytical standard of Escitalopram. This product is intended for research and analytical applications. Escitalopram ((S)-Citalopram), the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram has ~30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram is an antidepressant for the research of major depression .
|
-
-
- HY-N15735
-
|
2-Caffeoylpiscidic acid
|
Ranunculaceae
Phenols
Polyphenols
Plants
Cimicifuga racemosa (L.) Nutt.
Source Classification
|
Calcium Channel
|
|
Cimicifugic acid D (2-Caffeoylpiscidic acid) is a benzyltartaric acid ester that induces vasodilation of precontracted rat aortic strips and endothelium-independent relaxation mechanism. Cimicifugic acid D inhibits extracellular Ca 2+ influx through receptor-operated Ca 2+ channels (ROC) in Norepinephrine (HY-13715)-induced contraction of rat aortic strips, without affecting voltage-dependent Ca 2+ channels (VDC) or K +-induced contractions .
|
-
-
- HY-N0740R
-
-
-
- HY-N2426R
-
|
|
Clerodendrum trichotomum Thunb.
Flavonoids
Verbenaceae
Plants
Isoflavones
|
Reference Standards
Interleukin Related
|
|
Desvenlafaxine (Standard) is the analytical standard of Desvenlafaxine. This product is intended for research and analytical applications. Desvenlafaxine, the succinate salt form of the isolated major active metabolite of Venlafaxine (HY-B0196), is an orally active and BBB penetrated 5-HT and norepinephrine reuptake inhibitor, with IC50 values of 47.3 nM and 531.3 nM for hSERT and hNET, respectively. Desvenlafaxine shows weak binding affinity (62% inhibition at 100 μM) at the human dopamine (DA) transporter .
|
-
-
- HY-N0724R
-
-
-
- HY-128483R
-
|
|
Structural Classification
Microorganisms
Ketones, Aldehydes, Acids
Source Classification
|
TGF-beta/Smad
PI3K
NF-κB
Akt
Apoptosis
Dopamine β-hydroxylase
mTOR
Adrenergic Receptor
Reference Standards
|
|
Fusaric acid (Standard) is the analytical standard of Fusaric acid (HY-128483). This product is intended for research and analytical applications. Fusaric acid is an orally active multi-pathway inhibitor with the activity of inducing oxidative stress and apoptosis. Fusaric acid can chelate divalent metal cations, damage mitochondrial membrane structure, and activate apoptosis-related proteases such as Caspase-3/7, -8, and -9. Fusaric acid also regulates Bax/Bcl-2 protein, inhibits fibrosis-related signaling pathways such as NF-κB, TGF-β1/SMADs, and PI3K/AKT/mTOR, and reduces collagen deposition. Fusaric acid is also a dopamine β-hydroxylase inhibitor, which reduces endogenous levels of norepinephrine and epinephrine in the brain, heart, spleen, and adrenal glands. Fusaric acid can play a role in myocardial fibrosis and improve cardiac hypertrophy in heart disease, and can also be used in the study of esophageal cancer and liver cancer .
|
-
-
- HY-N9628
-
-
-
- HY-Y0123R
-
-
-
- HY-W438378
-
|
HMPG piperazine
|
Monophenols
Phenols
Endogenous metabolite
Source Classification
|
Biochemical Assay Reagents
|
|
4-Hydroxy-3-methoxyphenylglycol piperazine (HMPG piperazine) is a salt of HMPG combined with piperazine. HMPG is a metabolite of adrenaline and norepinephrine and is an important marker of catecholamine hormone metabolism in the body. 4-Hydroxy-3-methoxyphenylglycol piperazine is used as a standard in clinical laboratories to accurately measure the HMPG content in urine .
|
-
-
- HY-N16748
-
-
-
- HY-N17738
-
-
-
- HY-N18471
-
|
5,7-DHP
|
Structural Classification
Alkaloids
Animals
Indole Alkaloids
Source Classification
|
Monoamine Oxidase
5-HT Receptor
|
|
5,7-Dihydroxytryptamine (5,7-DHP) is an autofluorescent (λex≈365 nm), selective neurotoxin and a transport substrate for MAO-A and 5-HT. 5,7-Dihydroxytryptamine can specifically target and damage central and peripheral 5-HTergic neurons, while affecting 5-HT-related pathways and neurotransmitter balance. 5,7-Dihydroxytryptamine can be used to establish 5-HTergic neuron injury models for studies on neural development, neurodegenerative diseases, as well as mechanisms related to platelet function and retinal neurons .
|
-
| Cat. No. |
상품명 |
Chemical Structure |
-
- HY-N7142S
-
|
|
|
DL-Norepinephrine-d6 hydrochloride is the deuterium labeled DL-Norepinephrine hydrochloride. DL-Norepinephrine hydrochloride is an external racemic catecholamine neurotransmitter, which is an equal mixture of the left-handed (L-, with activity) and right-handed (D-, with very low or no activity) stereoisomers. DL-Norepinephrine hydrochloride after being labeled with tritium can be used as a tracer for the research on Parkinson's disease .
|
-
-
- HY-W008794S
-
|
|
|
Normetanephrine-d3 (hydrochloride) is the deuterium labeled Normetanephrine hydrochloride. Normetanephrine ((±)-Normetanephrine) hydrochloride is the O-methylated metabolite of norepinephrine (NE) .
|
-
-
- HY-B0196AS1
-
|
|
|
Venlafaxine-d6 (hydrochloride) is the deuterium labeled Venlafaxine hydrochloride. Venlafaxine hydrochloride (Wy 45030 hydrochloride) is an orally active, potent serotonin (5-HT)/norepinephrine (NE) reuptake dual inhibitor. Venlafaxine is an antidepressant .
|
-
-
- HY-12766S
-
|
|
|
Bupropion morpholinol-d6 is the deuterated form of Bupropion morpholinol. Bupropion morpholinol is a major metabolite of Bupropion. Bupropion morpholinol inhibits Dopamine, Norepinephrine transporters and the α4β2 nicotinic receptor in vitro. Bupropion morpholinol contributes to antidepressant and smoking cessation activities .
|
-
-
- HY-N7142S3
-
|
|
|
DL-Norepinephrine-d6 is the deuterium labeled DL-Norepinephrine. DL-Norepinephrine is an external racemic catecholamine neurotransmitter, which is an equal mixture of the left-handed (L-, with activity) and right-handed (D-, with very low or no activity) stereoisomers. DL-Norepinephrine after being labeled with tritium can be used as a tracer for the research on Parkinson's disease .
|
-
-
- HY-B0196S
-
|
|
|
Venlafaxine-d6 is the deuterium labeled Venlafaxine. Venlafaxine (Wy 45030) is an orally active, potent serotonin (5-HT)/norepinephrine (NE) reuptake dual inhibitor. Venlafaxine is an antidepressant .
|
-
-
- HY-113323S
-
|
|
|
3-Methoxy-4-hydroxyphenylglycol-d3 (HMPG-d3) is the deuterium labeled 3-Methoxy-4-hydroxyphenylglycol. 3-Methoxy-4-hydroxyphenylglycol is a metabolite of norepinephrine degradation in the brain. 3-Methoxy-4-hydroxyphenylglycol (HMPG) serves as an indicator of noradrenergic activity in the central nervous system. 3-Methoxy-4-hydroxyphenylglycol (HMPG) can be used for research on diseases such as depression and chronic schizophrenia.
|
-
-
- HY-B0161S
-
|
|
|
Duloxetine-d7 ((S)-Duloxetine-d7) is the deuterium labeled Duloxetine. Duloxetine is a serotonin-norepinephrine reuptake inhibitor with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .
|
-
-
- HY-113121S
-
|
|
|
Vanillylmandelic acid-d3 is the deuterium labeled Vanillylmandelic acid. Vanillylmandelic acid is the endproduct of epinephrine and norepinephrine metabolism. Vanillylmandelic acid can be used as an indication of the disorder in neurotransmitter metabolism as well. Vanillylmandelic acid has antioxidant activity towards DPPH radical with an IC50 value of 33 μM .
|
-
-
- HY-Y0123S
-
|
|
|
L-Tyrosine- 13C9, 15N is the 13C- and 15N-labeled L-Tyrosine. L-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. L-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine) .
|
-
-
- HY-B0527AS
-
|
|
|
Amitriptyline-d6 hydrochloride is the deuterium labeled Amitriptyline hydrochloride (HY-B0527A). Amitriptyline hydrochloride is an orally active tricyclic antidepressant (TCA). Amitriptyline hydrochloride mainly exerts its antidepressant effect by blocking SERT (Ki = 3.45 nM) and NET (Ki = 13.3 nM), thereby increasing the concentrations of 5-hydroxytryptamine (5-HT) and norepinephrine (NE) in the synaptic cleft. Amitriptyline hydrochloride is also an agonist at α2A and TrkA/TrkB receptors, thereby exerting analgesic and neurotrophic activities (inhibiting cell apoptosis). Amitriptyline hydrochloride can reduce inflammation, angiogenesis and fibrosis. Amitriptyline hydrochloride binds to DAT (with Ki = 2.58 μM). Amitriptyline hydrochloride has high affinity for a series of receptors and can antagonize muscarinic cholinergic receptors (M1/M2/M3/M4/M5 receptors) (Ki = 11-24 nM), H1 receptors (Ki = 0.5-1.1 nM), adrenergic α1 receptors (Ki = 4.4 nM), etc., resulting in a series of side effects. Amitriptyline hydrochloride can block sodium channels and hERG potassium channel (IC50 = 4.78 μM) and it has cardiotoxicity.
|
-
-
- HY-N7142S1
-
|
|
|
DL-Norepinephrine-d3 hydrochloride is the deuterium labeled DL-Norepinephrine hydrochloride. DL-Norepinephrine hydrochloride is an external racemic catecholamine neurotransmitter, which is an equal mixture of the left-handed (L-, with activity) and right-handed (D-, with very low or no activity) stereoisomers. DL-Norepinephrine hydrochloride after being labeled with tritium can be used as a tracer for the research on Parkinson's disease.
|
-
-
- HY-13715S
-
|
|
|
(Rac)-Norepinephrine-d3 (formate) is deuterium labeled Norepinephrine. Norepinephrine (Levarterenol; L-Noradrenaline) is a potent adrenergic receptor (AR) agonist. Norepinephrine activates α1, α2, β1 receptors .
|
-
-
- HY-13458S1
-
|
|
|
Droxidopa- 13C2, 15N (hydrochloride) is deuterium labeled Droxidopa. Droxidopa(L-DOPS), the mixture of Droxidopa (w/w80%) and Pharmaceutical starch (w/w20%), acts as a proagent to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline); Droxidopa(L-DOPS) is capable of crossing the protective blood-brain barrier .
|
-
-
- HY-14258AS
-
|
|
|
Escitalopram-d6 (oxalate) is the deuterium labeled Escitalopram oxalate. Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ~30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .
|
-
-
- HY-B1018AS
-
|
|
|
Phenelzine-d5 sulfate is the deuterium labeled Phenelzine sulfate (HY-B1018A). Phenelzine sulfate, an antidepressant agent, is an irreversible and orally active monoamine oxidase (MAO-A and MAO-B) inhibitor. Phenelzine sulfate inhibits GABA transaminase and primary amine oxidase (PrAO), and sequester reactive aldehydes. Phenelzine sulfate also inhibits LSD1 (Ki: 5.6 μM) and suppresses oxidative stress and lipogenesis. Phenelzine sulfate elevates neurotransmitters (serotonin, norepinephrine, dopamine). Phenelzine sulfate is studied in neurological, metabolic and cancer diseases for depression and anxiety disorders, stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, inflammatory pain, obesity and prostate cancer .
|
-
-
- HY-B0457S
-
|
|
|
Clomipramine-d3 (hydrochloride) is a deuterium labeled Clomipramine hydrochloride. Clomipramine hydrochloride is a serotonin transporter (SERT), norepinephrine transporter (NET) dopamine transporter (DAT) blocker with Ki of 0.14, 54 and 3 nM, respectively .
|
-
-
- HY-B0457AS
-
|
|
|
Clomipramine-d3 is the deuterium labeled Clomipramine. Clomipramine is a serotonin transporter (SERT), norepinephrine transporter (NET) dopamine transporter (DAT) blocker with Ki of 0.14, 54 and 3 nM, respectively .
|
-
-
- HY-B0196AS
-
|
|
|
Venlafaxine-d10 (hydrochloride) is the deuterium labeled Venlafaxine hydrochloride. Venlafaxine (Wy 45030) hydrochloride is an orally active, potent serotonin (5-HT)/norepinephrine (NE) reuptake dual inhibitor. Venlafaxine is an antidepressant .
|
-
-
- HY-B0168S
-
|
|
|
Milnacipran-d10 (hydrochloride) is the deuterium labeled Milnacipran hydrochloride (HY-B0168A). Milnacipran hydrochloride is an orally active Serotonin (HY-B1473A) and Norepinephrine (HY-13715) reuptake inhibitor. Milnacipran hydrochloride inhibits monoamine transporters, especially the norepinephrine transporter and the serotonin transporter (Ki values of 31 and 8.5 nM, respectively). Milnacipran hydrochloride inhibits pERK1/2 activation. Milnacipran hydrochloride has antidepressant, anxiolytic and analgesic properties. Milnacipran hydrochloride inhibits biting behavior in mice. Milnacipran hydrochloride can be used in the study of major depressive disorder, anxiety disorders, and neuropathic pain (e.g., fibromyalgia) .
|
-
-
- HY-B0602S2
-
|
|
|
Desvenlafaxine-d6 is deuterium labeled Desvenlafaxine. Desvenlafaxine, the succinate salt form of the isolated major active metabolite of Venlafaxine (HY-B0196), is an orally active and BBB penetrated 5-HT and norepinephrine reuptake inhibitor, with IC50 values of 47.3 nM and 531.3 nM for hSERT and hNET, respectively. Desvenlafaxine shows weak binding affinity (62% inhibition at 100 μM) at the human dopamine (DA) transporter .
|
-
-
- HY-14258AS1
-
|
|
|
Escitalopram-d4 (oxalate) is deuterium labeled Escitalopram (oxalate). Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ~30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .
|
-
-
- HY-W653885
-
|
|
|
rac 3,4-Dihydroxymandelic Acid-d3 is deuterium labeled 3,4-Dihydroxymandelic acid. 3,4-Dihydroxymandelic acid is a metabolite of norepinephrine .
|
-
-
- HY-B0196S1
-
|
|
|
Venlafaxine-d6-1 is deuterium labeled Venlafaxine. Venlafaxine (Wy 45030) is an orally active, potent serotonin (5-HT)/norepinephrine (NE) reuptake dual inhibitor. Venlafaxine is an antidepressant .
|
-
-
- HY-B0161AS
-
|
|
|
Duloxetine-d3 (hydrochloride) is a deuterium labeled Duloxetine hydrochloride. Duloxetine hydrochloride is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .
|
-
-
- HY-B0161ES
-
|
|
|
(±)-Duloxetine-d3 (hydrochloride) is deuterium labeled (±)-Duloxetine (hydrochloride). (±)-Duloxetine ((Rac)-Duloxetine) hydrochloride is the racemate of Duloxetine hydrochloride. Duloxetine hydrochloride, a serotonin-norepinephrine reuptake inhibitor, can be used for diabetic neuropathic pain and fibromyalgia as well as major depressive disorder research .
|
-
-
- HY-B1272AS
-
|
|
|
Desipramine-d4 is the deuterium labeled Desipramine (HY-B1272A). Desipramine is a first-generation tricyclic antidepressant. Desipramine selectively binds to norepinephrine transporter and blocks neuronal norepinephrine reuptake. Desipramine activates MAPK signaling via ERK1/2, JNK, and p38, represses NF-κB and AP-1 activity, and induces apoptosis via ROS elevation, mitochondrial membrane potential reduction, and intracellular calcium increase. Desipramine also shows anyi-inflammatory activity, inhibiting TNF-α production. Desipramine can be used for the research of hepatocellular cancer, inflammation, and neurological diseases .
|
-
-
- HY-B1272AS1
-
|
|
|
Desipramine-d3 is the deuterium labeled Desipramine (HY-B1272A). Desipramine is a first-generation tricyclic antidepressant. Desipramine selectively binds to norepinephrine transporter and blocks neuronal norepinephrine reuptake. Desipramine activates MAPK signaling via ERK1/2, JNK, and p38, represses NF-κB and AP-1 activity, and induces apoptosis via ROS elevation, mitochondrial membrane potential reduction, and intracellular calcium increase. Desipramine also shows anyi-inflammatory activity, inhibiting TNF-α production. Desipramine can be used for the research of hepatocellular cancer, inflammation, and neurological diseases .
|
-
-
- HY-B0168AS
-
|
|
|
Milnacipran-d5 hydrochloride is deuterium labeled Milnacipran hydrochloride (HY-B0168A). Milnacipran hydrochloride is an orally active Serotonin (HY-B1473A) and Norepinephrine (HY-13715) reuptake inhibitor. Milnacipran hydrochloride inhibits monoamine transporters, especially the norepinephrine transporter and the serotonin transporter (Ki values of 31 and 8.5 nM, respectively). Milnacipran hydrochloride inhibits pERK1/2 activation. Milnacipran hydrochloride has antidepressant, anxiolytic and analgesic properties. Milnacipran hydrochloride inhibits biting behavior in mice. Milnacipran hydrochloride can be used in the study of major depressive disorder, anxiety disorders, and neuropathic pain (e.g., fibromyalgia) .
|
-
-
- HY-B0196S3
-
|
|
|
Venlafaxine-d10 (Wy 45030-d10) is deuterium labeled Venlafaxine. Venlafaxine (Wy 45030) is an orally active, potent serotonin (5-HT)/norepinephrine (NE) reuptake dual inhibitor. Venlafaxine is an antidepressant .
|
-
-
- HY-B0196S2
-
|
|
|
Venlafaxine-d4 (Wy 45030-d4) is deuterium labeled Venlafaxine. Venlafaxine (Wy 45030) is an orally active, potent serotonin (5-HT)/norepinephrine (NE) reuptake dual inhibitor. Venlafaxine is an antidepressant .
|
-
-
- HY-B0161S3
-
|
|
|
Duloxetine-d5 (oxalate) ((S)-Duloxetine-d5 (oxalate)) is deuterium labeled Duloxetine. Duloxetine is a serotonin-norepinephrine reuptake inhibitor with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .
|
-
-
- HY-14794AS
-
|
|
|
Levomilnacipran-d10 ((1S,2R)-Milnacipran-d10) hydrochloride is deuterium labeled Levomilnacipran hydrochloride (HY-B0168B). Levomilnacipran ((1S,2R)-Milnacipran) hydrochloride is the enantiomer of Milnacipran (HY-B0168) and a strong substrate of P-gp that can cross the blood-brain barrier. Levomilnacipran hydrochloride is a serotonin and norepinephrine reuptake inhibitor, with IC50 values of 10.5 nM and 19.0 nM, and Ki values of 92.2 nM and 1.2 nM for human norepinephrine transporter (NET) and serotonin transporter (SERT), respectively. Levomilnacipran hydrochloride has antidepressant and anxiolytic activities. Levomilnacipran hydrochloride can be used for the research of depression .
|
-
-
- HY-B0168BS
-
|
|
|
Levomilnacipran-d5 ((1S,2R)-Milnacipran-d5) hydrochloride is deuterium labeled Levomilnacipran hydrochloride (HY-B0168B). Levomilnacipran ((1S,2R)-Milnacipran) hydrochloride is the enantiomer of Milnacipran (HY-B0168) and a strong substrate of P-gp that can cross the blood-brain barrier. Levomilnacipran hydrochloride is a serotonin and norepinephrine reuptake inhibitor, with IC50 values of 10.5 nM and 19.0 nM, and Ki values of 92.2 nM and 1.2 nM for human norepinephrine transporter (NET) and serotonin transporter (SERT), respectively. Levomilnacipran hydrochloride has antidepressant and anxiolytic activities. Levomilnacipran hydrochloride can be used for the research of depression .
|
-
-
- HY-B0602S1
-
|
|
|
(S)-(+)-O-Desmethyl Venlafaxine-d6 is the deuterium labeled (S)-(+)-O-Desmethyl Venlafaxine. O-Desmethyl Venlafaxine is an active metabolite of Venlafaxine . Venlafaxine (HY-B0196) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class .
|
-
-
- HY-B0602S
-
|
|
|
(R)-(-)-O-Desmethyl Venlafaxine-d6 is the deuterium labeled (R)-(-)-O-Desmethyl Venlafaxine. O-Desmethyl Venlafaxine is an active metabolite of Venlafaxine . Venlafaxine (HY-B0196) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class .
|
-
-
- HY-122272S2
-
|
|
|
Paroxetine-d6-1 is a deuterated labeled Paroxetine . Paroxetine, a phenylpiperidine derivative, is a potent and selective serotonin reuptake inhibitor (SSRI). Paroxetine is a very weak inhibitor of norepinephrine (NE) uptake but it is still more potent at this site than the other SSRIs .
|
-
-
- HY-108256S
-
|
|
|
Melitracen-d6 (hydrochloride) is the deuterium labeled Melitracen hydrochloride. Melitracen hydrochloride is an orally active biphasic antidepressant and antianxiety agent. Melitracen hydrochloride can inhibit the uptake of Norepinephrine and 5-HT (serotonin) through the presynaptic membrane inducing the increase of monoamine transmitters in synaptic space .
|
-
-
- HY-B0196S4
-
|
|
|
Venlafaxine-d9 (Wy 45030-d9) is a deuterium labeled Venlafaxine (HY-B0196). Venlafaxine (Wy 45030) is an orally active, potent serotonin (5-HT)/norepinephrine (NE) reuptake dual inhibitor. Venlafaxine is an antidepressant .
|
-
-
- HY-B0161AS1
-
|
|
|
Duloxetine-d7 hydrochloride ((S)-Duloxetine-d7 hydrochloride) is the deuterium labeled Duloxetine hydrochloride (HY-B0161A). Duloxetine hydrochloride ((S)-Duloxetine hydrochloride) is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .
|
-
-
- HY-W700149
-
|
|
|
N,O-Didesmethylvenlafaxine-d3 is the deuterium labeled N,O-Didesmethylvenlafaxine (HY-138818). N,O-Didesmethylvenlafaxine (NODVFX) is a metabolite of Venlafaxine (VFX; HY-B0196). Venlafaxine (Wy 45030) is an orally active, potent serotonin (5-HT)/norepinephrine (NE) reuptake dual inhibitor .
|
-
-
- HY-W699990
-
|
|
|
4-(1,2-Dihydroxyethyl)benzene-1,2-diol-d5 is the deuterium labeled 4-(1,2-Dihydroxyethyl)benzene-1,2-diol (HY-W010066). 4-(1,2-Dihydroxyethyl)benzene-1,2-diol, a normal norepinephrine metabolite, is found to be associated with Menkes syndrome.
|
-
-
- HY-B0991S
-
|
|
|
Amoxapine-d8 is the deuterium labeled Amoxapine. Amoxapine (CL-67772) is a norepinephrine reuptake blocker and a 5-HT2/5-HT3 antagonist. Amoxapine can be used for the research of depression. Amoxapine has antibacterial activity. Amoxapine can enhance the killing effect of macrophages on mycobacterium by inducing autophagy, while protecting the cells from death .
|
-
-
- HY-B0602S3
-
|
|
|
Desvenlafaxine-d10 is deuterium labeled Desvenlafaxine. Desvenlafaxine, the succinate salt form of the isolated major active metabolite of Venlafaxine (HY-B0196), is an orally active and BBB penetrated 5-HT and norepinephrine reuptake inhibitor, with IC50 values of 47.3 nM and 531.3 nM for hSERT and hNET, respectively. Desvenlafaxine shows weak binding affinity (62% inhibition at 100 μM) at the human dopamine (DA) transporter .
|
-
-
- HY-13458S2
-
|
|
|
Droxidopa- 13C6 (L-DOPS- 13C6) is 13C labeled Droxidopa. Droxidopa (L-DOPS; SM5688) is a potent, orally active norepinephrine precursor. Droxidopa increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder) .
|
-
-
- HY-107370S
-
|
|
|
Atomoxetine-d7 (Tomoxetine-d7) is deuterium labeled Atomoxetine. Atomoxetine (Tomoxetine) is a selective noradrenaline reuptake inhibitor with Ki values of 5, 77 and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine (Tomoxetine) increases of DAEX and NEEX in the PFC and enhances catecholaminergic neurotransmission. Atomoxetine (Tomoxetine) is a potent Na + channels (VGSCs) blocker. Atomoxetine (Tomoxetine) can be used for attention-deficit hyperactivity disorder (ADHD) research .
|
-
-
- HY-107370S1
-
|
|
|
Atomoxetine-d5 (Tomoxetine-d5) is deuterium labeled Atomoxetine. Atomoxetine (Tomoxetine) is a selective noradrenaline reuptake inhibitor with Ki values of 5, 77 and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine (Tomoxetine) increases of DAEX and NEEX in the PFC and enhances catecholaminergic neurotransmission. Atomoxetine (Tomoxetine) is a potent Na + channels (VGSCs) blocker. Atomoxetine (Tomoxetine) can be used for attention-deficit hyperactivity disorder (ADHD) research .
|
-
-
- HY-B1110S
-
|
|
|
Nomifensine-d3 ((±)-Nomifensine-d3) maleate is the deuterium labeled Nomifensine maleate (HY-B1110A). Nomifensine ((±)-Nomifensine) maleate is a potent norepinephrine (NE) and dopamine (DA) reuptake inhibitor. Nomifensine maleate inhibits uptake of NE, DA and 5-HT in rat brain synaptosomes, with IC50 values of 6.6 nM, 48 nM and 830 nM, and Ki values of 4.7 nM, 26 nM and 4000 nM, respectively. Nomifensine maleate has antidepressant and analgesic effects. Nomifensine maleate is used in neurodegenerative diseases, compound addiction, and pain research .
|
-
-
- HY-10121S2
-
|
|
|
Asenapine- 13C,d3 is 13C and deuterated labeled Asenapine (HY-10121). Asenapine (Org 5222), an atypical antipsychotic, is an antagonist of serotonin receptors (pKi: 8.4-10.5), adrenoceptors (pKi: 8.9-9.5), dopamine receptors (pKi: 8.9-9.4) and histamine receptors (pKi: 8.2-9.0). Asenapine can be used in the research of schizophrenia and bipolar disorder .
|
-
-
- HY-W769200
-
|
|
|
Asenapine- 13C,d3 Maleate is the deuterium labeled and 13C-Asenapine Maleate (HY-11100). Asenapine (Org 5222) Maleate, an atypical antipsychotic, is an antagonist of serotonin receptors (pKi: 8.4-10.5), adrenoceptors (pKi: 8.9-9.5), dopamine receptors (pKi: 8.9-9.4) and histamine receptors (pKi: 8.2-9.0). Asenapine Maleate can be used in the research of schizophrenia and bipolar disorder .
|
-
- HY-111124
-
|
|
|
Paroxetine-d2 (CTP 347) is a deuterium labeled Paroxetine (HY-122272). Paroxetine is an oral inhibitor that falls under the category of selective serotonin reuptake inhibitors (SSRIs). Paroxetine is also a very weak norepinephrine (NE) reuptake inhibitor, capable of inducing cell apoptosis and having anti-tumor activity. Paroxetine has antidepressant, anti-anxiety, and pain-relieving effects, and it can help improve conditions like obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual anxiety, and chronic headaches .
|
-
- HY-122272S
-
|
|
|
Paroxetine-d4 (BRL29060-d4) is deuterium labeled Paroxetine. Paroxetine is an oral inhibitor that falls under the category of selective serotonin reuptake inhibitors (SSRIs). Paroxetine is also a very weak norepinephrine (NE) reuptake inhibitor, capable of inducing cell apoptosis and having anti-tumor activity. Paroxetine has antidepressant, anti-anxiety, and pain-relieving effects, and it can help improve conditions like obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual anxiety, and chronic headaches .
|
-
- HY-18610S
-
|
|
|
Diclofensine-d3 (Ro-8-4650-d3) hydrochloride is the deuterium labeled Diclofensine hydrochloride. Diclofensine hydrochloride is an orally active neuronal monoamine uptake inhibitor. Diclofensine hydrochloride blocks the uptake of dopamine, noradrenaline, and serotonin by rat brain synaptosomes with IC50 values of 0.74, 2.3 and 3.7 nM, respectively. Diclofensine hydrochloride potentiates norepinephrine-induced hypertension and attenuates Tyramine (HY-W007606)-induced hypertension. Diclofensine hydrochloride produces psychostimulant and mood-elevating effects without causing sudden disappearance or withdrawal reactions. Diclofensine hydrochloride can be used in the research of moderate to severe depression.
|
-
- HY-32329S
-
|
|
|
Setiptiline-d3 is the deuterium labeled Setiptiline. Setiptiline (Org-8282) is a serotonin receptor antagonist. Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). Setiptiline acts as a norepinephrine reuptake inhibitor, α2-adrenergic receptor antagonist, and serotonin receptor antagonist, likely at the 5-HT2A, 5-HT2C, and/or 5-HT3 subtypes, as well as an H1 receptor inverse agonist/antihistamine .
|
-
- HY-W748758
-
|
|
|
(Z)-Thiothixene-d8 (NSC 108165-d8; Navan-d8; Navane-d8) is the deuterium labeled Thiothixene (HY-A0139). Thiothixene is a typical antipsychotic. It selectively binds to dopamine D2 over D1, D3, and D4 receptors (Kis=0.417, 338, 186.2, and 363.1 nM, respectively). Thiothixene also binds to various serotonin (5-HT), histamine H1, α1- and α2-adrenergic, muscarinic acetylcholine, and sigma receptors (Kis=15-5,754 nM) as well as the dopamine, norepinephrine, and serotonin transporters (Kis=3.16-30 μM). In vivo, thiothixene reduces spontaneous and amphetamine-induced locomotor activity in rats. It enhances latent inhibition, as measured by a decreased lick latency in response to light and foot shock stimuli, which is a measure of selective attention in rats.3 Thiothixene also increases competitive behavior in submissive mice, indicating antidepressant-like behavior.
|
-
- HY-Y0123S2
-
|
|
|
DL-Tyrosine-d2 is the deuterium labeled DL-Tyrosine. DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine) .
|
-
- HY-Y0123S3
-
|
|
|
DL-Tyrosine-d3 is the deuterium labeled DL-Tyrosine. DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine) .
|
-
- HY-Y0123S1
-
|
|
|
DL-Tyrosine-d7 is the deuterium labeled DL-Tyrosine. DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine) .
|
-
- HY-113121S1
-
|
|
|
Vanillylmandelic acid-d is the deuterium labeled Vanillylmandelic acid. Vanillylmandelic acid is the endproduct of epinephrine and norepinephrine metabolism. Vanillylmandelic acid can be used as an indication of the disorder in neurotransmitter metabolism as well. Vanillylmandelic acid has antioxidant activity towards DPPH radical with an IC50 value of 33 μM .
|
-
- HY-Y0123S4
-
|
|
|
DL-Tyrosine-d4 is the deuterium labeled DL-Tyrosine (HY-Y0123). DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine) .
|
-
- HY-Y0123S5
-
|
|
|
DL-Tyrosine- 13C is the 13C-labeled DL-Tyrosine (HY-Y0123). DL-Tyrosine is an aromatic nonessential amino acid synthesized from the essential amino acid phenylalanine. DL-Tyrosine is a precursor for several important neurotransmitters (epinephrine, norepinephrine, dopamine) .
|
-
- HY-17385S1
-
|
|
|
Atomoxetine-d7 hydrochloride (Tomoxetine-d7 hydrochloride) is the deuterium labeled Atomoxetine hydrochloride (HY-17385). Atomoxetine (Tomoxetine) hydrochloride is a selective noradrenaline reuptake inhibitor with Ki values of 5 nM, 77 nM and 1451 nM for norepinephrine (NE), serotonin (5-HT) and dopamine (DA) transporters, respectively. Atomoxetine hydrochloride is a potent Na+ channels (VGSCs) blocker. Atomoxetine hydrochloride can be used for attention-deficit hyperactivity disorder (ADHD) research .
|
-
- HY-14472S
-
|
|
|
Tesofensine-d5 (NS-2330-d5) is the deuterium labeled Tesofensine (HY-14472). Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent. Tesofensine is a CNS acting anti-obesity agent.
|
-
- HY-14472S1
-
|
|
|
Tesofensine- 13C,d3 (NS-2330- 13C,d3) is the deuterium and 13C-labeled Tesofensine (HY-14472). Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent . Tesofensine is a CNS acting anti-obesity agent .
|
-
| Cat. No. |
상품명 |
|
Classification |
-
- HY-A0091A
-
|
|
|
Alkynes
|
|
Pargyline is an irreversible monoamine oxidase (MAO) inhibitor with Kis of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively. Pargyline has antihypertensive and anticancer activities . Pargyline is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-A0091
-
|
|
|
Alkynes
|
|
Pargyline hydrochloride is an irreversible monoamine oxidase (MAO) inhibitor with Kis of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively. Pargyline hydrochloride has antihypertensive and anticancer activities . Pargyline (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- 상품명:
- Cat. No.:
- 수량:
- MCE Japan Authorized Agent: